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"He remembered that he always had one minute just before the 
epileptic fit when suddenly in the midst of sadness, spiritual 
darkness and oppression, there seemed at moments a flash of light 
in his brain, and with extraordinary impetus all his vital forces 
suddenly began working at their highest tension. The sense of life, 
the consciousness of self,  were multiplied ten times at these 
moments which passed like a flash of lightning. His mind and heart 
were flooded with extraordinary light... But these moments, these 
flashes, were only the prelude of that final second in which the fit 
began." 
From ‘The Idiot’ by F. Dostoevsky 
 
 
 
 
 
 
 
 
 
voor Daan en Arno 
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 General Introduction  
1. Canine epilepsy 
 
1.1 Terminology and classification 
Epilepsy is a disease characterized by recurrent seizures originating from the brain. It is 
the most common chronic neurologic disorder both in humans (Sander and Shorvon, 
1996; Brodie et al., 1997) and dogs (Chandler, 2006). The prevalence of epilepsy in dogs 
is estimated between 0.5 and 5.7% (Bielfelt et al., 1971; Schwartz-Porsche, 1994; 
Knowles, 1998; Patterson et al., 2005a; Chandler, 2006). Epilepsy is a general term 
covering different disorders that can be classified according to cause. The classification 
scheme for human epilepsy has recently been updated by the International League 
Against Epilepsy (Berg et al., 2010). In veterinary medicine, a universally accepted 
epilepsy terminology and species specific classification does not exist, and a classification 
system, based upon its human counterpart, is most often followed. This classification 
includes three categories: idiopathic, symptomatic and probable symptomatic epilepsy 
(see Table 1) (Berendt, 2008; Muñana, 2013a). The majority of dogs with recurrent 
seizures are classified as having idiopathic epilepsy which implies that no underlying 
cause for the seizures can be identified and a familial or genetic predisposition for the 
development of epilepsy is presumed(Schwartz-Porsche, 1994; Berendt, 2008). Recently, 
an update of descriptive terminology and of the diagnostic classification scheme for the 
use in veterinary patients has been proposed (Mariani, 2013), and one of its suggestions is 
to replace the term idiopathic by genetic epilepsy. Since this has just recently been 
proposed and definitive conclusions of veterinary neurologists have not yet been 
published, we still use the term idiopathic epilepsy in this thesis. 
Table 1: Commonly used epilepsy classification in veterinary medicine 
Epilepsy Type Definition Synonyms 
Idiopathic epilepsy Chronic seizures with no underlying cause 
other than a presumed genetic predisposition  
Primary epilepsy 
Genetic epilepsy 
Symptomatic epilepsy Identifiable lesion in the brain associated 
with an increased risk of developing seizures 
Structural epilepsy  
Secondary epilepsy 
Probable symptomatic 
epilepsy 
Suspected underlying cause of the seizures 
is as yet unidentified/unknown 
Cryptogenic epilepsy / 
Epilepsy of unknown 
origin 
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Human neurologists also classify seizures depending on their clinical and 
electroencephalographic (EEG) presentation (Chandler, 2006; Berg et al., 2010) with the 
two major categories being generalized and focal seizures, based on the origin and 
spreading of the epileptogenic activity. Applying this classification system to veterinary 
patients is difficult due to several reasons (Thomas, 2010; Muñana, 2013a). First of all, 
the seizure description is delivered by the owner, who is just an observer (Chandler, 
2006). Secondly, it is possible that not all human seizure types exist in dogs (Thomas, 
2010). Finally, EEG data are usually not available for veterinary patients and are difficult 
to interpret due to possible confounding factors, such as muscle and motion artifacts and 
the influence of sedation (Pellegrino and Sica, 2004; Thomas, 2010). Despite these 
disadvantages, several attempts to classify seizure types, based on their semiology, in 
dogs have been made (Schwartz-Porsche, 1994; Berendt and Gram, 1999; Licht et al., 
2002; Podell, 2004).  
Historically, focal seizures have been considered rare in dogs, and most dogs with 
idiopathic epilepsy were considered to have generalized tonic-clonic seizures (Schwartz-
Porsche, 1994). However, now it is known that focal seizures occur more frequently in 
dogs than previously thought (Jaggy and Bernardini, 1998; Berendt and Gram, 1999; 
Licht et al., 2002) and there is increasing evidence that focal seizures can be idiopathic 
(Heynold et al., 1997; Patterson et al., 2003, 2005a; Berendt et al., 2004a). 
 
1.2 Standard diagnostic work-up  
A detailed and accurate history is an essential part of the diagnosis of canine epilepsy. 
Other diseases in dogs can cause episodic seizure-like events, which have to be 
distinguished from epilepsy. The most important differential diagnoses are syncope, 
narcolepsy-cataplexy, episodic neuromuscular weakness, vestibular disorders, generalized 
tremor syndromes and compulsive behavior problems (Shell, 1993; Thomas, 2010). An 
epileptic seizure rarely occurs in the consultation room and therefore, a detailed 
description of the seizure, possibly together with a video of the event has to be critically 
analyzed.  
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A presumptive diagnosis of idiopathic epilepsy can be made based on the history, 
signalment of the dog and lack of other clinical or neurological signs. A definitive 
diagnosis of idiopathic epilepsy additionally needs an extensive blood work, structural 
brain imaging (Magnetic Resonance Imaging (MRI) or Computed Tomography (CT)) and 
analysis of cerebrospinal fluid (CSF) to exclude underlying causes for the seizures 
(Chandler, 2006). 
 
1.3 Standard medical treatment 
The ultimate goal of antiepileptic treatment is to reach seizure freedom without side 
effects, but a more realistic goal is to reduce the seizure frequency and severity to an 
acceptable level for the pet and his owner while avoiding serious side effects (Berendt, 
2004b; Thomas, 2010). The decision on when to start treatment with antiepileptic drugs 
(AEDs) follows general guidelines (see Table 2), but additional factors such as the 
general health of the dog, the owner’s lifestyle, financial limitations and comfort with the 
proposed therapy play an important role as well. So, a final decision has to be taken on an 
individual basis (Muñana, 2013a). 
 
Table 2: General criteria to start AED treatment in canine epilepsy 
Seizure frequency ≥ 1 /month 
Sudden increase in seizure frequency/severity 
History of cluster seizures / status epilepticus 
Presence of underlying, progressive brain disorder responsible for the seizures 
Severe seizures / severe postictal signs 
Owner has a strong desire to treat regardless of frequency / severity 
adapted from Thomas, 2010; Muñana, 2013a 
 
Owner compliance is fundamental for a successful treatment of canine epilepsy, so good 
client education is imperative. The dog owner has to be informed about the disease, the 
realistic goals of therapy and possible side effects of the AEDs. The owner must also 
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understand the need for regular AED administration and avoid dose alterations based on 
his/her own assessment of seizure control (Berendt, 2004b; Thomas, 2010; Muñana, 
2013a). 
Until recently, treatment options for dogs with epilepsy were limited to phenobarbital 
(PB) and potassium bromide, both relatively safe, effective and inexpensive AEDs (Al-
Tahan, 1985; Podell, 1993). PB is usually the initial drug of choice as it is effective in 
approximately 60 – 80% of epileptic dogs when plasma concentrations are maintained 
within the therapeutic range (Farnbach, 1984; Schwartz-Porsche et al., 1985). Bromide is 
thought to be less efficacious than PB as first-line AED in dogs (Boothe et al., 2012) and 
is most often added to PB when insufficient seizure control is reached. About 25% of PB 
resistant canine epilepsy patients become seizure free on polytherapy with PB and 
bromide (Podell, 1993). Side effects can be an important downside of these AEDs and, 
although some are reversible and resolve within the first weeks of therapy, others are 
more serious. A detailed monitoring with regular general blood work and serum 
concentration measurements is therefore advised for both AEDs. 
In Europe, a new AED, imepitoin, has been recently approved for the treatment of canine 
idiopathic epilepsy. The effectiveness seems comparable to PB, but the major advantage 
is that fewer side effects are expected (Löscher et al., 2013; Rundfeldt et al., 2014). 
Although this new AED seems promising, future larger and comparative studies in dogs 
are warranted.  
  
1.4 Refractory epilepsy 
In human medicine, refractory or drug resistant epilepsy has recently been defined as ‘a 
failure of adequate trials of two tolerated and appropriately chosen and used AED 
schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom’ (Kwan et al., 2010). A similar definition has not been established yet in 
veterinary medicine. The term refractory epilepsy describes a condition in which an 
animal fails to attain satisfactory seizure control or suffers intolerable side effects despite 
appropriate therapy with conventional AEDs (Muñana, 2013b). Throughout literature, 
refractory epilepsy has also been described as drug resistant, medically intractable or 
pharmacoresistant. Refractory epilepsy is an important problem in small animal practice 
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as it occurs in up to 30% of dogs with idiopathic epilepsy (Farnbach, 1984; Lane and 
Bunch, 1990). Interestingly, the incidence of refractory epilepsy is comparable in humans 
(Kwan and Brodie, 2000).  
 
The underlying pathogenesis of refractory epilepsy is unclear, but three major theories 
leading to drug refractoriness have been described: 1) a change in the neuronal network , 
2) a reduced sensitivity of drug targets to AEDs in epileptogenic brain tissue and 3) an 
overexpression of multidrug transporters leading to removal of AEDs from the 
epileptogenic tissue (Kwan and Brodie, 2006; Volk, 2008). Humans with refractory 
epilepsy are often resistant to multiple AEDs with a different MOA, which mainly 
supports the third theory (Löscher, 2007). Considerable data have been generated in 
support of all hypotheses, which reflects that the etiology of pharmacoresistance is likely 
multifactorial and varies between individuals (Kwan and Brodie, 2002). Inherent disease 
severity has recently been proposed to play a role as well (Rogawski and Johnson, 2008), 
which could be reflected in breed-related differences in seizure severity in dogs (Muñana, 
2013b). The contribution of the different hypotheses to canine refractory epilepsy remains 
to be elucidated (Volk, 2008).   
 
Many novel AEDs have been developed for the use in human epilepsy over the past 20 
years. Several of these drugs are unsuitable for use in dogs, because they are metabolized 
too quickly or because they are toxic (Löscher, 1993; Podell, 1998; Govendir et al., 
2005). The most important human AEDs that can be safely used as add-on treatment in 
dogs with refractory epilepsy are gabapentin, pregabalin, zonisamide and levetiracetam. 
They seem to have a wide therapeutic index and offer the potential of minimizing adverse 
effects, although the optimum use and their efficacy have not yet been fully determined in 
veterinary patients (Muñana, 2013a). Only retrospective or prospective open-label 
studies, including a small number of dogs, have been described for most of these AEDs 
(Dewey et al., 2004; Govendir et al., 2005; Platt et al., 2006; Volk et al., 2008; Muñana et 
al., 2012) so, it is possible that their efficacy is overestimated due to an important placebo 
effect recognized in canine epilepsy (Muñana et al., 2010). Similar as in human epilepsy 
trials, a reduction in seizure frequency has also been demonstrated in a considerable part 
of dogs receiving placebo treatment. This placebo response might be related to the natural 
waxing and waning course of the disease, but the owners expectations of a new treatment 
probably play an important role as well (Muñana et al., 2010). 
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1.5 Limitations of canine epilepsy 
The diagnosis, classification and treatment of epilepsy are slowly advancing fields in 
dogs compared to humans due to several reasons. Regarding the diagnosis and 
classification, a lot of subjectivity and misinterpretation can be present in the clinical 
description of the seizure, as it is provided by the owner instead of the patient. As 
mentioned before, EEG is not routinely used in dogs due to the lack of availability and 
expertise, due to a lot of artefacts and due to the need for sedation (Pellegrino and Sica, 
2004; Chandler, 2006). Another important limitation is that brain imaging, although 
improving and expanding also in veterinary medicine, is not at the same state-of-the-art 
level as in humans. Since micro-structural changes of the cortex are often identified as 
causes of symptomatic epilepsy in humans (Raymond et al., 1995), it is possible that 
these lesions are overlooked in dogs. Consequently, a proportion of dogs could be 
misclassified as having idiopathic epilepsy.  
The optimization of existing and the development of new treatment options for canine 
refractory epilepsy are limited by different reasons. First of all, owner compliance is 
fundamental to reach a successful AED treatment in dogs. Secondly, the efficacy of 
recent AEDs has not yet been established using well-controlled canine clinical trials 
(Muñana et al., 2010) and the number of AEDs with an acceptable metabolization is 
limited in dogs. Financial concerns cannot be ignored in veterinary medicine as well.  
The possibility exists that some dogs with difficult-to-control seizures have no true 
refractory epilepsy. False pharmacoresistance also occurs in human epilepsy (Smith et al., 
1999) and is not easily recognizable (Pati and Alexopoulos, 2010). The frequency of this 
phenomenon could even be higher in dogs than in humans, due to overlooked underlying 
causes in the diagnostic work-up or due to bad owner compliance in the treatment.  
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2. Brain SPECT 
 
2.1 Introduction 
Single photon emission computed tomography (SPECT) is, besides positron emission 
tomography (PET) and functional magnetic resonance imaging (fMRI), a non-invasive 
imaging technique that can be used to evaluate the functional state of the brain in vivo. In 
contrast to structural brain imaging techniques, such as CT or MRI, functional brain 
imaging offers the advantage to look beyond structural abnormalities and detect 
disturbances at the molecular level. Therefore, the use of SPECT provides an ideal 
application for understanding the pathophysiology of brain disorders (e.g. epilepsy) and 
for testing certain therapeutic strategies (e.g. vagus nerve stimulation (VNS)) in a 
preclinical setting (Khalil et al., 2011). SPECT can evaluate the regional cerebral blood 
flow (rCBF) which is an indirect reflection of brain metabolism and regional neuronal 
activity (Roy and Sherrington, 1890; Warwick, 2004). The main principle of SPECT is 
that a photon emitting radiopharmaceutical is injected in a subject (Abraham and Feng, 
2011). As the isotope decays, photons (gamma rays) are emitted from the body, which are 
then detected and recorded by one or more detectors rotating around the patient (Figure 
1). In this way, an image of the distribution of the radioligand in the target organ is 
obtained (Vermeire et al., 2011).  
 
Figure 1: Photons emitted from the dog’s brain (yellow dots) are registered  
by 3 detectors rotating around the head of the dog 
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Each detector consists of a collimator, a crystal and photomultiplier tubes. Collimators 
will only allow photons from a specific direction to pass through and will absorb scattered 
photons. Consequently, scattered photons will not reach the crystal. The crystal is an 
essential part of the detector that registers the photons and transforms them into a light 
signal. Finally, the light signals will be converted by the photomultiplier tubes into an 
electric current. This results in a three-dimensional image that can be presented as 
multiple two-dimensional images in the 3 spatial planes (Figure 2) (Vermeire et al., 
2011). 
 
 
Figure 2: Conventional SPECT study of a dog represented in the 3 planes 
 
 
An important advantage of using nuclear medicine techniques for experimental research 
is that repeated longitudinal studies can be performed in the same animal, so that each 
animal can serve as its own control (Groch and Erwin, 2000). Also, human dedicated 
cameras can be used for canine or feline brain research, because their brains are of 
sufficient size compared to rodents. An important limitation of SPECT is that attenuation, 
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scatter and partial volume effects can influence the images (Peremans et al., 2005). 
Consequently, the registered photons are not derived with certainty from the actual 
volume of interest (VOI), which precludes absolute quantification methods (Peremans et 
al., 2003). A semiquantitative analysis of brain perfusion in different VOIs has become 
the preferred method of quantification (Catafau, 2001). For each VOI a perfusion index 
(PI) is obtained by normalizing the radioactivity of a certain VOI to the radioactivity of 
the total brain or the cerebellum. This allows an estimation of the relative rCBF 
distribution within the brain (Peremans et al., 2001). 
 
2.2 Tracer 
A radiopharmaceutical systematically has two compounds: (1) a chemical substance (e.g. 
ethyl cysteinate dimer (ECD)) which directs the radiopharmaceutical to a certain target 
and (2) a radioactive marker (e.g. 
99m
technetium) which enables the radiopharmaceutical 
to be visualized (Vermeire et al., 2011). 
 
In the present work, 
99m
technetium-ethyl cysteinate dimer (
99m
Tc-ECD; Neurolite, 
Lamepro, the Netherlands) was used as a tracer to assess the rCBF. This technetium 
labeled lipophilic tracer crosses the blood brain barrier rapidly after intravenous (IV) 
injection. Once intracellular, it is converted into a hydrophilic compound and therefore is 
trapped within the brain (Figure 3), with a regional distribution proportional to the rCBF 
(Leonard et al., 1986). This frozen image of tracer distribution arises within 2 minutes 
after injection and remains stable for at least two hours in the human and canine brain, 
independent of rCBF changes occurring after the fixation time (Leveille et al., 1992; 
Ichise et al., 1997; Catafau, 2001; Peremans et al., 2002). This means that the SPECT 
images reflect brain activity at the time of tracer injection which leads to certain 
opportunities using this technique e.g. the tracer can be injected at the onset of an 
epileptic fit, while the image acquisition can be done later once the seizure is controlled. 
Furthermore, it is possible in veterinary medicine to obtain a frozen image reflecting 
regional brain perfusion in the awake animal, by injecting the tracer before acquisition 
under general anesthesia (Waelbers et al., 2010).  
 
 
12 
 
 General Introduction  
 
Figure 3: Schematic representation of entrapment of 
99m
Tc-ECD into a neuron 
(BBB = Blood Brain Barrier) 
 
 
2.3 Conventional versus high-resolution micro-SPECT 
 
Even with the use of a triple head gamma camera equipped with low-energy ultra-high 
resolution collimators positioned as close as possible to the animal’s head, resolution 
restriction remains one of the most important limitations of conventional SPECT 
(Vermeire, 2010). Certainly compared to PET, SPECT cameras suffer from lower spatial 
resolution and lower detection sensitivity (Peremans et al., 2005), and the partial volume 
effect can disable the precise anatomical localization of small brain structures and 
hampers absolute quantification methods (Peremans et al., 2003; Vermeire, 2010). The 
spatial resolution of the SPECT systems used in animals should be higher than in humans, 
because the subjects under investigation are smaller. This should result in a quality of 
SPECT images in animals at least equivalent to human studies (Peremans et al., 2005).  
 
Efforts have been made to improve the resolution of conventional SPECT systems by co-
registration with CT or MRI, motion correction, modeling of the detectors response and 
by the use of smaller pixel sizes (Beekman et al., 2001; Soret et al., 2007). The spatial 
resolution can further be increased by using multi-pinhole collimators (Figure 4) placed in 
front of a conventional gamma camera (= micro-SPECT, µ-SPECT or HiSPECT), which 
leads to a magnification of the image compared to conventional SPECT (Peremans et al., 
2005; Beekman and van der Have, 2007). The smaller the distance between the object and 
pinhole, the higher the magnification and resolution (Young et al., 1997).  
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A downside of the µ-SPECT system with multi-pinhole collimation is its decreased 
sensitivity so that more radioactivity or longer acquistion times are required (Peremans et 
al., 2005). 
 
 
 
Figure 4: Example of a multi-pinhole collimator (Bioscan, Inc.) 
  
  
Especially for heart and brain imaging, pinhole µ-SPECT is thought to be useful as small 
lesions may be masked by over- and underlying tissue radioactivity in conventional 
SPECT (Peremans et al., 2005). Dedicated small rodent µ-SPECT systems obtain 
resolutions of < 1mm using pinhole collimators. These systems, built for use in small 
rodents, cannot be used in dogs and cats due to a limited gantry opening (Beekman and 
van der Have, 2007; Peremans et al., 2011). Therefore, Bioscan developed a system in 
which a conventional triple-head gamma camera is equipped with three multi-pinhole 
collimators (so called HiSPECT). The feasibility of this technique, co-registered with 
MRI, has been confirmed to evaluate the rCBF of the feline brain (Waelbers et al., 2013), 
but has not yet been evaluated for canine brain imaging.  
 
2.4 SPECT and epilepsy 
 
Noninvasive functional brain imaging methods, including SPECT and PET are powerful 
tools used in the evaluation of human patients suffering from refractory focal seizures 
(Jayalakshmi et al., 2011; Kim and Mountz, 2011). These imaging modalities are mainly 
applied in the process of epileptogenic focus localization, but they can also help in 
elucidating the neurobiology of epilepsy (Van Paesschen et al., 2007). An accurate 
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localization of the ictal onset zone can be challenging, but is essential in the presurgical 
evaluation of human patients with refractory epilepsy (Kim and Mountz, 2011; von 
Oertzen et al., 2011). Of the different functional neuroimaging techniques, only SPECT 
has the unique capacity to image blood flow changes that occur at the onset of seizures 
due to the frozen image obtained at the moment of tracer injection. This allows 
postponement of the acquisition until the seizure is under control without any change in 
obtained perfusion image (Kim and Mountz, 2011). A true ictal image can never be 
obtained with PET, because compared to SPECT, the temporal resolution is lower due to 
a longer tracer uptake period (30-45 minutes). Therefore, PET is only feasible to use 
during the interictal phase. Functional MRI of seizures has been described more recently, 
but deals with specific challenges like patient safety and motion and noise artifacts that 
are unavoidable during seizures (Chaudhary et al., 2013). 
 
The use of functional brain imaging in dogs with epilepsy is a rather unexplored field, 
however, since not much is known about the pathophysiology and localization of canine 
epilepsy, these techniques could be promising. PET has been used to evaluate brain 
metabolism alterations in a cohort of epileptic Lagotto Romagnolo (Jokinen et al., 2013) 
and Finnish Spitz dogs (Viitmaa et al., 2014) and regional blood flow abnormalities, 
visible on SPECT, have been described in one epileptic Boxer dog (Lass et al., 2006).  
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3. Vagus nerve stimulation 
 
3.1 Introduction 
In the past decades, there has been a considerable expansion of treatment options for 
human refractory epilepsy. Although a substantial number of new AEDs has become 
available (Beghi, 2004), several long-term studies revealed that only few human patients 
became seizure free after initiating a third AED when two AEDs had failed (Kwan and 
Brodie, 2000; Mohanraj and Brodie, 2005, 2006). Therefore, non-pharmacological 
treatment options are becoming increasingly important in humans and are being 
considered earlier in the course of therapy. Different treatment modalities are currently 
available including the ketogenic diet, epilepsy surgery and neurostimulation. The 
ketogenic diet, which contains a high amount of fat and a low amount of carbohydrates, is 
used mainly for the treatment of refractory childhood epilepsy (Kossoff et al., 2009). The 
efficacy is rather limited and it is difficult to remain compliant in the long-term (Levy et 
al., 2012). Epilepsy surgery leads to seizure freedom in a considerable number of treated 
patients, but requires a strict patient selection based on an extensive pre-surgical work-up 
(Noachtar and Borggraefe, 2009). In the past decade, various types of neurostimulation 
have emerged as promising treatment modalities for humans with refractory epilepsy 
(Ben-Menachem, 2012).  
 
Only a limited number of the newer treatment strategies in humans have been 
investigated for canine epilepsy. The use of the ketogenic diet has been investigated in a 
small group of dogs with refractory epilepsy, but its effectiveness remains undetermined 
(Patterson et al., 2005b). Also, it has to be recognized that it is more difficult to induce 
ketosis in dogs in comparison with humans (Crandall, 1941; Patterson et al., 2005b). The 
surgical treatment of canine idiopathic epilepsy is still in its infancy. The main reason 
why this treatment modality in veterinary medicine has not yet been further developed is 
probably the difficulty in accurately localising the origin of canine seizures. Only the 
disconnective technique of callosotomy has been investigated in normal dogs and in a few 
dogs with idiopathic epilepsy. Short-term results seemed promising, but long-term results 
and larger studies are lacking (Bagley et al., 1995, 1996). Currently, many dogs with 
refractory epilepsy are eventually euthanized or die during uncontrollable seizures (Arrol 
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et al., 2012; Monteiro et al., 2012). For this group of dogs, it would be useful to have 
alternative treatment options. 
 
Detailed information on the different non-pharmacological treatment modalities and their 
use in the treatment of human and canine epilepsy is beyond the scope of this 
introduction, but can be read elsewhere (Martlé et al., 2014). In the present work we will 
focus on neurostimulation and more specifically on vagus nerve stimulation as an 
alternative treatment for refractory epilepsy.  
 
3.2 Neurostimulation 
A substantial part of humans suffering refractory epilepsy, will benefit from surgical 
resection. However, as many patients are not suitable candidates for resection (Duncan, 
2011), there is a need for alternative third-line therapies such as neurostimulation 
(Theodore and Fisher, 2004; Kotagal, 2011; Fridley et al., 2012; Rolston et al., 2012; Wu 
and Sharan, 2013). Neurostimulation refers to a group of treatment modalities in which 
electrical or magnetic pulses are delivered directly to or around nerve tissue in order to 
influence a pathological substrate and to achieve a therapeutic effect (Vonck et al., 2004; 
Boon et al., 2009).  
The following neurostimulatory treatments have been described for the treatment of 
human refractory epilepsy: vagus nerve stimulation (VNS), deep brain stimulation, 
trigeminal nerve stimulation and transcranial magnetic stimulation. These treatments are 
usually delivered independent of seizure activity, but more recently responsive 
neurostimulation has been developed (Gigante and Goodman, 2011). 
The electrical or magnetic pulses can be delivered either directly to the brain (intracranial 
stimulation) or indirectly, i.e. by stimulating cranial nerves or by transcranial magnetic 
stimulation (extracranial stimulation; (Boon et al., 2009)). Also, two major strategies can 
be followed regarding the target of stimulation. Firstly, the stimulation can be targeted 
towards crucial central nervous system structures with a triggering or propagating role in 
the epileptogenic network, such as the thalamus. Secondly, the stimulation can be 
targeted towards the epileptogenic focus itself, which of course implies prior knowledge 
on its localisation (Boon et al., 2009). 
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Although a substantial reduction in seizure frequency combined with an improved quality 
of life can be achieved in a considerable number of patients, these neurostimulation 
treatments are considered palliative, because seizure freedom is rarely achieved 
(Theodore and Fisher, 2004; Fisher, 2012). A seizure suppressing effect has been proven 
for most of these treatments, but the scientific and clinical applications have mainly 
preceded the knowledge of the mechanism of action (MOA) (Albert et al., 2009; Boon et 
al., 2009). The effectiveness of neurostimulation often improves over time, which could 
indicate a long-lasting neuromodulatory effect of these treatments, either at a molecular 
level or by reorganisation of certain brain circuits (Vonck et al., 2013; Wu and Sharan, 
2013). Other advantages are that stimulation parameters can be customised and adapted 
individually for each patient and that the treatment is possibly reversible (Theodore and 
Fisher, 2004; Gigante and Goodman, 2011; Wu and Sharan, 2013). The efficacy in 
controlling seizures seems quite similar between different types of neurostimulation and 
side effects are moderate, although comparative trials are warranted (Ben-Menachem, 
2012). The optimal targets and stimulation parameters for the different types of 
neurostimulation remain unknown. According to Ben-Menachem (2012), the biggest 
challenge for the future is to find out which types of patients and epilepsy syndromes are 
most sensitive to a specific type of neurostimulation.  
 
In this PhD thesis we will only focus on VNS. More detailed information about the other 
types of neurostimulation can be read elsewhere (e.g. Martlé et al., 2014).  
 
3.3 Vagus nerve stimulation 
3.3.1 Definition 
VNS is the intermittent electrical stimulation of the left cervical vagus nerve using an 
implantable VNS device. The device, which is surgically implanted in the left cervical 
region, consists of spiral-shaped electrodes that are wrapped around the vagus nerve and a 
pulse generator or neurostimulator that is subcutaneously implanted below the clavicle in 
humans and in the left cervical region in dogs (Figure 5). Subcutaneously tunnelled wires 
connect the stimulator with the electrodes. A program wand is used to obtain wireless 
communication between the stimulator and the programmer (Landy et al., 1993; Ben-
Menachem, 2002; Vonck et al., 2004). 
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Figure 5: A VNS Therapy
®
 System implanted in the left  
cervical region in a dog and a man 
(with permission of Cyberonics, Inc. and Prof. K Muñana) 
 
3.3.2 Anatomy of the vagus nerve 
The vagus nerve is the longest cranial nerve and traditionally was considered to be a 
parasympathetic efferent nerve. Now it is known that it is actually a mixed nerve with the 
majority of vagal nerve fibres (± 80%) being visceral afferents projecting widely 
throughout the central nervous system and providing the brain with visceral sensation 
from the head, neck, thorax and abdomen (Foley and DuBois, 1937; Agostoni et al., 
1957; Rutecki, 1990). The efferent fibres (± 20%) provide parasympathetic innervation of 
the heart, aorta, lungs and gastrointestinal tract, and also innervate the voluntary striated 
musculature of the larynx and pharynx (Agostoni et al., 1957). Different animal 
experiments have demonstrated that the efferent fibres are not required for the 
antiepileptic effect of VNS (Zabara, 1992; Hassert et al., 2004; Osharina et al., 2006). The 
afferent vagal fibres have their cell body in the nodose and jugular ganglia which relay 
ascending information predominantly to the nucleus of the solitary tract (NST) in the 
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caudal brainstem. The NST has widespread direct and indirect projections to a lot of areas 
in the brain (Groves and Brown, 2005; Fanselow, 2012) (Figure 6). Importantly, 
monoamine nuclei in the brainstem (locus coeruleus (LC) and the raphe nuclei (RN)) 
receive direct and/or indirect projections from the NST. Also, forebrain and limbic 
structures receive NST projections (Henry, 2002; Krahl and Clark, 2012). 
 
Figure 6: Schematic representation of the most important central afferent projections of 
the vagus nerve (NST: nucleus of the solitary tract; LC: locus coeruleus; RN: dorsal raphe 
nucleus; A: amygdala; Hyp: hypothalamus; Th: thalamus) 
 
The cervical part of the vagus nerve is accessible and the electrodes for VNS are usually 
implanted there. In the cervical region, each vagus nerve lies within the carotid sheath, 
between the carotid artery and the internal jugular vein. VNS systems used for the 
treatment of epilepsy are preferably implanted in the left cervical region to avoid cardiac 
side effects (Ben-Menachem, 2002).  
 
Important anatomical differences exist between the cervical vagus nerve in humans and 
dogs (Mizeres, 1955). In the human cervical region the vagus and sympathetic nerve are 2 
separate nerves, whereas in the canine cervical region, both nerves are fused, forming the 
vagosympathetic trunk. Both nerves are encapsulated in a common epineurial sheath and 
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the degree of fusion is dependent on the region. In the upper portion of the neck, just 
distal to the nodose and cranial cervical ganglion, the vagus and sympathetic nerves are 
completely fused and intermingled. In the middle cervical region a thin common 
perineurial septum can be visualised between both on histological examination. In the 
distal cervical and cranial thoracic region both nerves actually separate completely again, 
but often are still embedded within a common epineurial sheath (Mizeres, 1955). This has 
the important consequence that the VNS electrodes are usually wrapped around the 
vagosympathetic trunk as a whole in dogs.  
 
3.3.3 VNS and human epilepsy 
 VNS is the oldest and most frequently used neurostimulation modality for refractory 
epilepsy in humans (Ben-Menachem, 2012; Wu and Sharan, 2013). VNS was officially 
approved in 1994 in Europe and in 1997 in the USA for the treatment of focal-onset 
refractory seizures in patients > 12 years who are not candidates for surgical resection 
(Fisher and Handforth, 1999). This was mainly based on class I evidence gathered from 2 
large, randomized, placebo controlled, double-blinded, multi-centre studies (Ben-
Menachem et al., 1994; Handforth et al., 1998). Additional studies have also shown the 
effectiveness of VNS to treat refractory epilepsy in children and in certain generalised 
epilepsy types (Hauptman and Mathern, 2012; Thompson et al., 2012; Ryzi et al., 2013). 
In general, almost half of treated VNS patients have a reduction in seizure frequency of > 
50%, but only a small amount of treated patients become seizure-free (Vonck et al., 2004; 
Connor et al., 2012;). It has been demonstrated extensively now that the efficacy of VNS 
improves over time, which is probably caused by an additional chronic antiepileptic effect 
developing after several months of treatment (Morris and Mueller, 1999; Vonck et al., 
1999; Ben-Menachem, 2002; Boon et al., 2002; Rolston et al., 2012; Wu and Sharan, 
2013).  
 
There is substantial evidence indicating that modulation of brain activity occurs with 
VNS through stimulation of the afferent vagal fibres. Ascending fibres reach the NST and 
from there, widespread projections reach the limbic, reticular, and autonomic regions of 
the brain as well as other brainstem nuclei like the LC and RN (Ben-Menachem et al., 
1995). Different potential mechanisms that might mediate the antiepileptic effect of VNS 
have been investigated during the past decades. VNS induced EEG changes in animals 
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(Zanchetti et al., 1952; Chase et al., 1966, 1967), but human studies could not reproduce 
these results in an acute setting (Hammond et al., 1992a; Salinsky and Burchiel, 1993). 
However, Koo (2001) showed that long-term VNS caused a reduction in interictal spike 
discharges and a prolongation of the interspike interval in human patients. Crucial 
brainstem and intracranial structures that are influenced by VNS, such as the LC, the 
NST, the thalamus and limbic structures have been identified (Naritoku et al., 1995; Krahl 
et al., 1998; Osharina et al., 2006; Cunningham et al., 2008). The LC is thought to play a 
key role in the antiepileptic effect of VNS (Krahl et al., 1998; Fornai et al., 2011). VNS 
might exert its antiepileptic effect by modulating the release of certain neurotransmitters 
in the brain. Excitatory and inhibitory neurotransmission and the balance between both is 
often altered in the epileptic brain and antiepileptic therapies may target these 
neurotransmitters or their receptors (Meldrum, 1995). Therefore, the MOA of VNS may 
be based on regional gamma-aminobutyric acid (GABA) increases or glutamate and 
aspartate decreases. It has also been demonstrated that GABAA receptor density in the 
hippocampus was increased after a year of VNS in the responsive patients (Marrosu et al., 
2003). Besides the influence on amino acids, VNS might also affect the concentration of 
monoamines, such as serotonin (5HT), dopamine (DA) and norepinephrine (NE), which 
have been previously associated with seizure suppressing effects (Starr, 1996; Boon et al., 
2002; Giorgi et al., 2004; ). Neurochemical studies quantified neurotransmitter 
concentrations in human CSF before and after VNS and an increase in metabolites of 
5HT and DA, an increase in GABA and a decrease in aspartate levels were detected. 
Whether these findings were associated with the antiepileptic effects of VNS remained 
uncertain (Hammond et al., 1992b; Ben-Menachem et al., 1995). Norepinephrine, 
released by the LC, appears to play a pivotal role in the MOA of VNS as different animal 
studies found an increase of NE after VNS (Roosevelt et al., 2006; Raedt et al., 2011). 
Moreover, a causal link between increased NE levels in the hippocampus and the 
anticonvulsant effect of VNS has recently been shown in a limbic seizure model in rats 
(Raedt et al., 2011). A variety of functional neuroimaging studies using PET, SPECT or 
fMRI have shown that VNS causes acute and longer-term changes in brain regions with 
vagus innervation, which have been involved in depression, as well as in epilepsy (for a 
review: (Chae et al., 2003)). Despite all these investigations, there is still much to learn 
about the exact MOA of VNS. On-going research is mainly focused on revealing optimal 
stimulation parameters by comparing different stimulation paradigms and on the 
identification of predictive factors for responsiveness (Wu and Sharan, 2013). Recently, a 
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non-invasive, transcutaneous method of VNS - by stimulating the auricular branch of the 
vagus nerve at the left ear - was evaluated in humans with refractory epilepsy and this 
technique appeared to be safe and practicable in the long term (Stefan et al., 2012). VNS 
is in general very well tolerated and side effects, although quite frequently seen, are most 
of the time mild and reversible (Schachter and Saper, 1998). The most commonly 
reported side effects of VNS in humans are presented in Table 3. Although refractory 
epilepsy was the original application for VNS, it is now also an approved additional 
treatment for depression and is currently under investigation for other applications like 
heart failure, anxiety, obesity, migraine, eating disorders and Alzheimer’s disease (Groves 
and Brown, 2005; Beekwilder and Beems, 2010). 
 
 
Table 3: Reported side effects of vagus nerve stimulation (VNS) in humans 
Acute, surgery related Chronic, often stimulation 
related 
Chronic, not related with 
stimulation 
Infection Coughing Lead breakage 
Hemorrhage Voice alteration – hoarseness Infection 
Left vocal-cord paresis Throat pain Gastro-esophageal reflux 
disease 
Lower facial weakness Dyspnea – shortness of breath  
Bradycardia and asystole 
during device test 
Dyspepsia – vomiting  
Pain at the implant site Swallowing difficulties – 
aspiration (children) 
 
Seroma formation Contractions of 
sternocleidomastoid muscle 
 
Paresthesia Paresthesia  
Headache Gagging  
Coughing Drooling  
Voice alteration - hoarseness Sleep apnea  
Nausea   
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3.3.4 Vagus nerve stimulation and canine epilepsy 
An experimental study in dogs (Zabara, 1992) provided essential information to initiate 
clinical trials with VNS for refractory epilepsy in humans. Zabara (1992) demonstrated 
that chemically induced seizures in dogs could be aborted by stimulation of the cervical 
vagus nerve. Ocular compression, which is an indirect way of stimulating the vagus 
nerve, has been beneficial for controlling seizures in dogs (Speciale and Stahlbrodt, 
1999). Only one randomised, placebo controlled, double-blinded cross-over study 
evaluated the safety and efficacy of VNS in 10 dogs with refractory epilepsy using a 
similar implantable device as in humans (Muñana et al., 2002). No significant difference 
in seizure frequency, duration and severity was detected between the treatment and 
control period of 13 weeks, but when the final 4 weeks of both periods were compared, a 
significant decrease in seizure frequency was found during the treatment period. VNS 
appears to be safe in dogs with comparable minimal side effects as in humans. 
Furthermore, owner satisfaction was relatively high (Muñana et al., 2002). Obviously, 
additional studies are needed. A major advantage of using VNS in dogs is its 
independence of the localisation of the epileptogenic focus and of owner compliance. 
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 Scientific Aims  
The continuous search for and development of improved diagnostic techniques have led 
to a major evolution in human epilepsy. The introduction of structural and functional 
imaging modalities such as high-field MRI and nuclear imaging techniques (PET and 
SPECT) were important milestones. The past decade, functional imaging techniques such 
as SPECT have been introduced in veterinary research as well. 
The specific aims of the first part of this PhD thesis were: 
1/ to assess interictal changes in regional cerebral blood flow and neuronal 
activity in dogs with spontaneous idiopathic epilepsy using SPECT 
2/ to investigate the feasibility of µ-SPECT to evaluate the regional brain 
perfusion in healthy Beagle dogs and to define the normal regional brain 
perfusion pattern based on MRI 
 
The last 15 years, different neuromodulatory treatments have been developed to treat 
human refractory epilepsy, of which VNS is the most established. Further research is still 
needed to elucidate the precise MOA, to identify predictive factors for response and to 
determine the most optimal stimulation parameters of VNS. Since human and canine 
epilepsy share a lot of similarities, the second part of this PhD thesis is dedicated to the 
examination of the MOA of VNS in healthy Beagle dogs. Hereby, a new experimental 
stimulation paradigm, microburst VNS, was evaluated and compared with standard VNS.  
The specific aims of the second part of this PhD thesis were: 
1/ to describe the surgical implantation technique of a VNS Therapy
®
 System 
in healthy Beagle dogs 
2/ to evaluate regional brain perfusion changes using µ-SPECT after acute 
standard and microburst VNS in healthy Beagle dogs  
3/ to evaluate changes in the CSF monoamine concentrations induced by 
acute standard and microburst VNS in healthy Beagle dogs 
4/ to assess the influence of acute standard and microburst VNS on the seizure 
threshold in a canine PTZ model 
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5/ to evaluate cardiac rhythm, using Holtermonitoring, in healthy Beagle dogs 
during standard and microburst VNS 
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Sources and manufacturers 
a
 Airis Mate, Hitachi Med.Corp., Tokyo, Japan 
b
 Domitor, Pfizer, Louvain la Neuve, Belgium 
c
 Propovet, Abbott, Queensborough, UK 
d 
Isoflo, Abbott, Queensborough, UK 
e
 Triad, Trionix, Twinsburg, OH, USA 
f
 Gardenal, Sanofi-Aventis, Diegem, Belgium 
g
 Epikal, ASTfarma, Oudewater, the Netherlands 
h 
Mysoline, AstraZeneca, Brussels, Belgium 
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Summary 
 
We evaluated the feasibility of interictal Single Photon Emission Computed Tomography 
(SPECT) to detect alterations in regional cerebral blood flow and neuronal activity in 
dogs with idiopathic epilepsy. Twelve dogs with idiopathic epilepsy underwent interictal 
99m
technetium-ethyl cysteinate dimer (
99m
Tc-ECD) SPECT of the brain. Different cortical 
volumes of interest (VOIs), 1 VOI at the cerebellum and 1 VOI at the subcortical area 
were evaluated by semiquantitative analysis and compared with a control group (18 
dogs). Significant hypoperfusion (P = 0.02) was present in the subcortical area, which 
includes the thalamus, of epileptic dogs. This hypoperfusion was not associated with 
seizure frequency, age at onset of seizures, duration of epilepsy, or time since the last 
seizure. Interictal SPECT did not reveal cortical or cerebellar perfusion alterations. The 
subcortical area may play an important role in the pathophysiology of canine idiopathic 
epilepsy. 
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Introduction 
 
In dogs with primary, idiopathic epilepsy, structural brain imaging such as with computed 
tomography or magnetic resonance (MR) imaging are typically within normal limits 
except for occasional reversible postictal changes that can be visible on MR images 
(Mellema et al., 1999). Functional brain imaging could provide valuable information 
regarding neuronal activity in these dogs. Single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) can be used to assess the functional 
state of the brain. These techniques enable three-dimensional visualization of functional 
parameters such as cerebral blood flow (CBF) and brain metabolism (Peremans et al., 
2001). Measurement of regional CBF by SPECT can allow detection of impaired 
neuronal function, which is not visualized by conventional MR imaging (Podreka et al., 
1997). It is known that neuronal activity and metabolism are reflected by brain perfusion 
(Roy and Sherrington, 1890). In this regard, brain perfusion SPECT is a useful technique 
to evaluate neuronal activity indirectly. 
In humans, SPECT is used for presurgical evaluation of most refractory types of partial 
epilepsies to identify the epileptogenic area (Boon et al., 1989; Nehlig et al., 2004). 
Epileptogenic foci are usually characterized by decreased interictal and increased ictal 
blood flow (Oommen et al., 2004; Buch et al., 2008). SPECT provides a unique 
opportunity to investigate interictal CBF (Yune, 1998), however interictal SPECT 
imaging has a lower sensitivity for localizing the seizure onset site compared with ictal 
SPECT (Devous et al., 1998).  
Since little is known about brain perfusion in epileptic dogs, this study was performed to 
evaluate brain perfusion alterations on interictal SPECT images in dogs with idiopathic 
epilepsy and to investigate the feasibility of interictal SPECT to detect foci of abnormal 
neuronal activity which could be related to seizures in the dog. 
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Materials & Methods 
 
Animals, clinical variables and diagnostic evaluation 
Dogs evaluated between February and October 2007 for recurrent generalized or partial 
seizures, or presented in status epilepticus, were studied if they were suspected to have 
primary, idiopathic epilepsy. The neurologic evaluation in the dogs presented in status 
epilepticus was repeated after recovery from the seizure to avoid errors in interpretation 
caused by postictal deficits. The age at the first seizure had to be between 6 months and 5 
years. Exclusion criteria were other clinical or neurologic signs and abnormalities on 
neurologic examination. Underlying causes for the seizures were evaluated by a complete 
blood examination (cell blood count, biochemistry including liver enzymes, BUN, 
creatinine, albumin, total protein, glucose, ammonia or bile acids, and serum electrolytes 
[Na, K, Ca]), MR imaging of the brain (0.2 T
a
) and a cerebrospinal fluid (CSF) 
examination. 
The age at the time of SPECT had to exceed 1 year, because young dogs have alterations 
in brain perfusion related to brain maturation (K. Peremans, personal communication). 
The time between the last seizure and SPECT did not exceed 30 days, because recent 
seizure activity potentially increases the sensitivity to detect perfusion alterations (Giobbe 
and Castellano, 1997). Therefore, the SPECT scan was scheduled as soon as possible 
after the last seizure. This interval was mainly determined by practical issues like tracer 
and SPECT availability, possibility of the owner to bring the dog to the faculty,… 
SPECT 
For evaluation of brain perfusion 
99m
Tc-ECD (±925 MBq) was injected intravenously 
(IV) before sedation or anesthesia. Premedication was 25–50 μg/kg medetomidin 
hydrochloride
b
 given IV 10 min after injection of the radiopharmaceutical. General 
anesthesia was induced with IV propofol
c
 and maintained with isoflurane
d
 in 100% 
oxygen to effect. All dogs were in ventral recumbence and the detectors positioned as 
closely as possible to the head. Acquisition was started 20–30 min after 
radiopharmaceutical injection. SPECT was performed using a triple head gamma camera
e
 
equipped with ultra-high-resolution parallel hole collimators (tomographic resolution 
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FWHM=8 mm). Data were acquired for 20 min in step-and-shoot mode (120 steps, 
10 s/step, 3° steps), over a circular 360° rotation on a 128 × 128 matrix. Images were 
processed using filtered back projection and a Butterworth filter. Pixel size was 1.72 mm. 
The perfusion images were automatically registered to a template using BRASS software 
(Brain Registration and Automated SPET Semiquantification, Nuclear Diagnostics), after 
which the different volumes of interest (VOIs) were semiquantified using a predefined 
region map. VOIs were drawn over the different cortical regions (olfactory, frontal, 
temporal, parietal, and occipital lobes), 1 VOI over the cerebellum and 1 VOI over the 
subcortical area (Peremans et al., 2001). The latter VOI mainly contained the thalamus 
and basal ganglia. Further differentiation of this subcortical area was not possible because 
of the small size of the individual structures and the limited resolution of the SPECT 
system. Average counts per pixel were calculated for all regions. A perfusion index (PI) 
was obtained by normalizing the average regional counts to total counts of all VOIs. 
Control group 
The PI was compared for all regions with the PIs of a normal data base that consisted of 
18 normal control dogs (11 males and seven females) of different breeds with a mean 
(±SD) age of 41.4±22.9 months and a mean (±SD) body weight of 20.1±7.1 kg (Table 1). 
These dogs had no history of seizures or neurological or behavioral disease, and were not 
receiving medication. The SPECT data of these normal control dogs were previously 
collected in a normal data base and were available on site at the moment of this study. 
Statistical analysis 
Nonparametric statistical analysis was performed using SPSS (Statistical Software 
Package for the Social Sciences, v.15). The Wilcoxon Signed Ranked test and the Pearson 
Chi-Square test were used to compare respectively the age and the gender of the epileptic 
group with the control group. To evaluate regional brain perfusion alterations and to look 
for associations with clinical variables (recent seizure frequency, age at onset of seizures, 
duration of the epilepsy, and time since the last seizure) a Mann–Whitney U-test and a 
Spearman correlation test were respectively used. Level of significance was set at P ≤ 
0.05. 
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Table 1: demographics of the control dogs (n=18) 
 
Breed Sex Age at presentation
* 
Kooiker Dog F 60 
Mongrel M 18 
Dachshund M 78 
Foxhound F 45 
Kooiker Dog M 56 
Border Collie F 64 
Mongrel M 18 
German Shepherd M 60 
Mongrel M 36 
Mongrel M 36 
Border Collie M 72 
Border collie M 24 
German Shepherd F 56 
German Shepherd F 70 
Beagle M 14 
Beagle M 14 
Beagle F 12 
Beagle F 12 
* : expressed in months 
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Results 
 
Twelve dogs met the criteria. There were 11 males and 1 female with a mean (±SD) age 
of 36.8±11.4 months at presentation and a mean (±SD) body weight of 32.1±15.5 kg. All 
dogs had a history of generalized seizures and 1 dog was presented in status epilepticus. 
In 10 dogs some signs of a focal seizure onset had been noticed by the owner before the 
seizure, such as anxiety and restlessness (4 dogs), seeking attention (2 dogs), rhythmic 
contractions of a hind limb (2 dogs), tonic jaw opening (6 dogs), and salivation (6 dogs). 
In 2 dogs a focal seizure onset was not described by the owner. The demographics and 
clinical variables of the epileptic dogs are summarized in Table 2.  
Blood examination was normal in all dogs. MR imaging did not reveal any significant 
abnormality in any dog. Four dogs had mild ventriculomegaly, and 2 had mild asymmetry 
of the lateral ventricles without a mass effect or other visible lesion. White blood cell 
count of the CSF was within limits in all dogs (<8 cells/μl). Two dogs had a mildly 
elevated CSF protein level (41.8 and 40.2 mg/dl, reference <30 mg/dl), due to iatrogenic 
blood contamination. It was concluded that all dogs had primary, idiopathic epilepsy. 
The duration of epilepsy before presentation was variable, with a mean of 9.8 months 
(range, 0.5–39 months). The mean (±SD) age at the first seizure was 27±9.6 months. Four 
dogs (33.3%) had ≤1 seizure a month, 6 dogs (50%) had 2–4 seizures a month, 1 dog 
(8.3%) had 5–10 seizures a month and 1 dog (8.3%) more than 10 seizures a month. 
Eleven dogs (91.7%) received antiepileptic treatment at the moment of the study. Eight 
dogs (66.7%) received phenobarbital (PB)
f
, 2 dogs (16.7%) received PB and potassium 
bromide
g
 and 1 dog (8.3%) received primidone
h
. The duration of treatment was variable 
(mean: 262 days; range, 12–1224 days). 
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Table 2: Demographics and clinical variables of the epileptic dogs (n=12) 
Breed Sex Weight 
(kg) 
Age at 
presentation* 
 
Age at first 
seizure* 
Duration  
Epilepsy* 
 
Seizure  
Frequency† 
Time since 
last seizure 
German Shepherd M 36 46 45.5 0.5 B 5-30 days 
Golden Retriever M 36 52 13 39 A 5-30 days 
Border collie F 13 25 19 6 D 1-5 days 
English Bulldog M 35 34 29 5 B < 24 hours 
Golden Retriever M 37 46 34 12 A 5-30 days 
German Pointer M 29 35 34.5 0.5 B 1-5 days 
German Shepherd M 29 57 37 20 B 5-30 days 
Malinois M 30 34 28 6 C 1-5 days 
English Staff.Bullterrier M 23 39 21 18 A < 24 hours 
Bordeaux Dog M 74 20 15 5 B 5-30 days 
Miniature Schnauzer M 8 33 31 2 B 1-5 days 
White Swiss Shepherd M 35 20 17 3 A 5-30 days 
 
* : expressed in months 
†: A: ≤ 1 seizure/month, B: 2-4 seizures/months, C: 5-10 seizures/month, D: > 10 seizures/month 
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There was no significant difference in age (P = 0.67) or gender (P = 0.1) between the 
epileptic dogs and the control group. SPECT was performed within 24 h after the last 
seizure in 2 dogs (16.7%), between 1 and 5 days after the last seizure in 4 dogs (33.3%) 
and between 5 and 30 days after the last seizure in 6 dogs (50%). The PIs of all the VOIs 
of the epileptic group were compared with the PIs of the control group (Figure 1). A 
significant hypoperfusion (P = 0.02) was present in the subcortical, thalamic area of the 
epileptic dogs compared with control dogs. In this VOI the epileptic dogs had a mean 
(±SD) PI of 1.078±0.090 and the mean (±SD) PI of the control group in that area was 
1.151±0.058. There were no cortical or cerebellar differences in regional CBF between 
the two groups. There was no significant association between the degree of perfusion in 
the subcortical region of the epileptic dogs and the clinical variables (seizure frequency, 
age at onset of seizures, duration of the epilepsy, and time since last seizure). 
 
 
Figure 1: Mean perfusion indices (±SD) of the epileptic and the control dogs from the 
different VOIs. LF: left frontal lobe; RF: right frontal lobe; LT: left temporal lobe; RT: 
right temporal lobe; LP: left parietal lobe; RP: right parietal lobe; LO: left occipital lobe; 
RO: right occipital lobe; BO: olfactory bulb; SC: subcortical region; CER: cerebellum 
* significant difference between both groups, P ≤ 0.05.   
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Discussion 
 
The gold standard for seizure localization in humans has been invasive intracranial EEG 
recording, but this carries some operative risks (Spencer et al., 1997). Recent advantages 
in neuroimaging offer the possibility of localizing seizures safely and noninvasively 
(Spencer and Bautista, 2000). The major practical application is the use of SPECT to 
detect the epileptogenic focus, but functional imaging can also be an important tool to 
better understand the neurobiology of epilepsy (Van Paesschen et al., 2007). This was 
also one of the goals of this study, because there are many unanswered questions about 
the pathophysiology, classification, and nomenclature of epilepsy in dogs. 
All the dogs in the study had generalized seizures. Generalized seizures in dogs can have 
a focal onset, described previously as the aura, so searching for an epileptogenic focus 
can be useful (Berendt and Gram, 1999). A major limitation of epilepsy in dogs is the 
dependency on the owner to observe and describe the seizures and a number of subtle 
clinical signs in humans that give a clue to the origin of the epileptic fit, can never be 
confirmed in animals (Berendt and Gram, 1999). Most dogs in this study experienced 
some clinical signs at the beginning of the seizure which could be a sign of a focal onset 
of the seizure. These signs included seeking attention from the owner, rhythmic 
contractions of a specific limb, tonic opening of the jaw, anxiety, salivation, and 
restlessness. A focal onset of the seizures was not observed in two dogs, but could have 
been missed due to the lack of supervision during the seizures. 
In this study, 
99m
Tc-ECD was used as a tracer. 
99m
Tc-ECD is lipophilic and is rapidly 
cleared from blood. In the human and canine brain, the lipophilic complex 
99m
Tc-ECD 
crosses the intact blood brain barrier and is trapped intracellular within 2 min in 
proportion to CBF, probably by de-esterification to polar complexes (Walovitch et al., 
1994; Peremans et al., 2001). The uptake and distribution of the tracer, which are a 
reflection of the rCBF, remain unchanged for 2 h (Ichise et al., 1997; Peremans et al., 
2001; Waelbers et al., 2012). The image obtained when performing SPECT is a static 
image of brain perfusion at the time of injection. This has the major advantage that any 
influence of sedative or anesthetic agents on brain perfusion can be avoided by injecting 
the tracer before sedation or anesthesia. 
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Evaluation of the SPECT images was done by semiquantification with normalization of 
regional counts to total counts of the individual brain, which is more objective than visual 
analysis (Slomka et al. 1997; McNally et al., 2005). Visual comparison of images, as 
performed in the past, has some disadvantages, including difficulty in making 
comparisons between corresponding slices and the lack of quantitative assessment 
(Russo, 1981). Automated registration of the perfusion data to a template combined with 
an automatically applied region map results in a more reliable analysis of brain perfusion 
images, as compared to manual registration and visual interpretation (Slomka et al., 
1997). Therefore, semiquantitative analysis was the evaluation method in this study. 
Significant hypoperfusion was found in the subcortical region of the epileptic dogs. An 
important part of this subcortical area consists of the thalamus, although it was not 
possible to visualize the thalamus in detail due to the resolution limits. The function of the 
thalamus in seizures could be causative. In the centrencephalic theory it is proposed that 
most generalized seizure activity originates in deep structures of the thalamus and brain 
stem and is thereafter projected to the cortex (Russo, 1981; Bagley et al., 1996). Some 
interictal SPECT studies in humans with temporal lobe epilepsy allowed identification of 
thalamic hypoperfusion and a primary role of the thalamus in the initiation or propagation 
of seizures in several types of epileptic disorders was proposed (Henry et al., 1990; Yune 
et al., 1998). It is possible that idiopathic epilepsy in dogs is most comparable to 
idiopathic generalized epilepsy in people, for example the childhood absence seizures. 
Using PET in this type of epilepsy in children, focal activation in the thalamus during 
absences was found, emphasizing the key role of this structure in the pathogenesis of 
absence seizures (Prevett et al., 1995). The significant hypoperfusion in the subcortical, 
thalamic area of epileptic dogs could also be explained as a consequence of seizures. In 
this regard, corticothalamic diaschisis is a possible contributing factor. The diaschisis 
phenomenon is hypoperfusion and hypometabolism in a portion of the brain distant from 
the site of damage due to an interruption of its afferent axonal supply (Yune et al., 1998). 
Further investigation of thalamic dysfunction and alterations in blood flow is needed in 
dogs, and also in humans, before drawing more definitive conclusions. Significant 
cortical perfusion alterations were not detected in the epileptic group, however, it is 
possible that by evaluating the mean regional PIs of the epileptic dogs as a group, 
perfusion alterations in individual epileptic dogs or side differences might not have been 
56 
 
 Chapter 1  
noticed. It is probable that, also in dogs, interictal SPECT is less sensitive than ictal 
SPECT to detect cortical epileptogenic foci. 
We evaluated interictal SPECT in epileptic dogs. In humans, interictal SPECT is part of a 
multimodality work-up for refractory epilepsy. Combining imaging modalities integrates 
the strengths of various modalities and at the same time eliminates one or more 
weaknesses of an individual modality (Van Paesschen et al., 2007; Goffin et al., 2008). 
Although interictal brain SPECT can be useful for localization of the seizure focus (Yune 
et al., 1998), interictal SPECT is less sensitive in identifying epileptogenic foci than either 
ictal or immediate postictal studies (Matsuda et al., 1997; Devous et al., 1998; Goffin et 
al., 2008). The highest sensitivity is obtained by combining ictal with interictal perfusion 
SPECT (Spanaki et al., 1999). However, there are practical difficulties in performing 
routine ictal studies and also the interpretation can be difficult (Menzel et al., 1997). Ictal 
SPECT perfusion is only available in tertiary care human hospitals (Goffin et al., 2008). 
A true ictal injection is required, but not always achieved and early secondary 
generalization of a seizure can lead to difficulties in interpreting an ictal SPECT (Rowe et 
al., 1997; Wiest et al., 2005). Ictal SPECT in dogs could provide useful information, but 
this would be practically difficult. It is also possible that ictal SPECT in dogs would 
provide more information about seizure propagation than about the epileptogenic focus, 
because seizures in dogs tend to generalize rapidly. 
In 2 dogs, the SPECT scan was performed within 24 h of the last seizure. In humans, a 
safety margin of 24 h after the last seizure is usually allowed before performing interictal 
SPECT to reduce the effect of prior seizures (Oommen, 2004). To our knowledge, no 
exact definition of the timing when a postictal state switches to an interictal state exists. 
In humans, postictal perfusion changes lasted only up to 3 h after the seizure (Oommen et 
al., 1993). Therefore, postictal perfusion changes, although they cannot be excluded, were 
probably not of great influence in these 2 dogs, because the time between the last seizure 
and the SPECT exceeded 12 h in both dogs. In the future, it would be interesting to 
compare immediate postictal and interictal brain perfusion changes in epileptic dogs. 
As part of a multimodality work-up, it would have been useful to include interictal EEG 
in our dogs. However, some limitations accompany the use of scalp EEG in dogs. The 
large temporal muscles can cause muscle artifacts and may also attenuate the amplitude 
of the brain waves and mask true spike activity. Also the effect of sedation, which is 
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almost indispensable in dogs, can influence the EEG results (Russo, 1981). Other 
limitations of our study are the small number of patients and the heterogenicity in the 
demographics and clinical variables of the dogs. Furthermore, it is important to recognize 
that because all epileptic dogs except 1 received antiepileptic drugs at the moment of the 
SPECT scan, an influence of these drugs on brain perfusion cannot be excluded. This is 
also a possible confounding factor in many human SPECT studies, but unfortunately 
there are only few human studies in which the influence of these drugs on brain perfusion 
and metabolism has been investigated. For example, PB and phenytoin can cause diffuse 
cerebral hypoperfusion (Jibiki et al., 1993). To minimize these effects on global brain 
perfusion in our study, PIs where used. These are ratios of the regional brain perfusion 
normalized to the total counts of the brain. Of course, it is possible that antiepileptic drugs 
could alter regional brain perfusion depending on their mechanism. There is a need for 
further studies that evaluate the influence of antiepileptic drugs on brain perfusion before 
conclusions can be drawn. 
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Conclusion 
 
In conclusion, using interictal SPECT in epileptic dogs we identified alterations in 
subcortical brain perfusion. The subcortical area, including the thalamus may play an 
important role in the pathophysiology of canine idiopathic epilepsy. Interictal SPECT did 
not allow identification of cortical alterations in brain perfusion. Future studies on larger 
patient groups are needed and comparison of interictal with ictal SPECT should be 
attempted if practically achievable. 
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Sources and manufacturers 
a
 HiSPECT, Bioscan, Paris, France 
b
 Airis Mate, Hitachi Med.Corp., Tokyo, Japan 
c
 Neurolite, Lamepro, Raamdonksveer, The Netherlands 
d 
Dolorex, MSD AH, Brussels, Belgium 
e
 Propovet, Abbott Laboratories, Queensborough, UK 
f 
Isoflo, Abbott Laboratories, Queensborough, UK 
g
 Triad, Trionix, Twinsburg, OH, USA 
h 
Multimodality, Hermes, Nuclear Diagnostics 
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Summary 
 
Conventional Single Photon Emission Computed Tomography (SPECT) precludes a 
detailed evaluation of the subcortical region. Micro-SPECT (µ-SPECT) has a higher 
resolution, but has not been used to evaluate the dog’s brain until now. In this study, µ-
SPECT of the brain was evaluated in 10 Beagle dogs. Magnetic Resonance Imaging 
(MRI) of the brain was used to draw a new region map containing 19 volumes of interest 
(VOIs). Semi-quantitative analysis of the µ-SPECT data was performed and the regional 
cerebral perfusion was represented by the perfusion indices (PIs).   
The highest perfusion was found in the parietal cortex and the lowest in the piriform 
cortex. An asymmetry towards the left hemisphere in general and a regional asymmetry in 
the frontal, temporal and parietal cortex were found. 
This study shows that functional imaging of the canine brain is possible using µ-SPECT 
and it describes the normal regional brain perfusion in the adult Beagle dog. 
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Introduction 
 
Single Photon Emission Computed Tomography (SPECT) and Positron Emission 
Tomography (PET) evaluate the functional state of the brain in a non-invasive way. 
SPECT assesses neuronal function indirectly by measuring the regional cerebral blood 
flow (rCBF) (Roy and Sherrington, 1890). Moreover, impaired neuronal function which 
is not visualized by conventional MRI can be detected (Podreka et al., 1997).  
In human medicine, SPECT functional brain imaging is currently used in the diagnostic 
work-up for a wide variety of neurological disorders such as dementia, cerebrovascular 
disorders and epilepsy (Masdeu et al., 2006). In humans with refractory epilepsy, 
functional neuroimaging by SPECT or PET is frequently used as part of a multimodality 
work-up in the presurgical evaluation to identify the epileptogenic focus (Boon and 
Williamson, 1989; Matsuda et al., 1997; Menzel et al., 1997; Podreka et al., 1997; la 
Fougère et al., 2009). Although long-term intracranial EEG evaluation remains the gold 
standard to localize the epileptogenic focus, functional brain imaging techniques have the 
advantage that they are less invasive and not primarily dependent on electrical brain 
activity. Furthermore, functional brain imaging can also help to gain a better insight into 
the neurobiology of epilepsy (la Fougère et al., 2009).
 
Also in dogs, where refractory 
epilepsy occurs commonly (Chandler, 2006), brain SPECT could become a useful 
diagnostic tool. The classification and localization of canine epilepsy remain largely 
unknown, so it is important to optimize techniques, such as SPECT, that could contribute 
to the classification and localization of canine epilepsy.  
The regional brain perfusion evaluated by conventional fan-beam SPECT in normal dogs 
has been described previously (Peremans et al., 2001) and could be used as a reference 
atlas to evaluate different canine pathophysiological changes (Peremans et al., 2002; 
Martlé et al., 2009; Vermeire et al., 2009a). The same type of SPECT study has been 
performed by our group interictally in dogs with idiopathic epilepsy and revealed a 
significant hypoperfusion in the subcortical region (Martlé et al., 2009). Until now, the 
resolution of the conventional gamma camera system used in canine SPECT studies 
(Peremans et al., 2002; Martlé et al., 2009; Vermeire et al., 2009a; Waelbers et al., 2011) 
was insufficient to evaluate different structures within the subcortical region 
(hippocampus, thalamus and corpus striatum) and the brainstem. Furthermore, the VOI 
map, which is used to evaluate the regional brain perfusion, was previously created based 
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on Computed Tomography (CT) which provides less anatomical detail than MRI 
(Peremans et al., 2001). Therefore it would be useful to increase the resolution capacity of 
this technique. 
To increase resolution, µ-SPECT systems have been developed (Wirrwar et al., 2001). 
With this technique, the image is magnified and the resolution increased compared to 
conventional SPECT, by using pinhole collimators (Young et al., 1997). Micro-SPECT 
imaging systems in rodents have been developed because of the existing need for high 
spatial resolution techniques in preclinical studies. The combined sensitivity and spatial 
resolution achieved by µ-SPECT make a detailed in vivo imaging feasible in small 
laboratory animals (Weber et al., 1994). Since most of the µ-SPECT systems are 
specifically built for use in small rodents, the limited gantry opening precludes their use 
in dogs. The HiSPECT system
a
 is a multi-pinhole collimated µ-SPECT system for use on 
conventional gamma camera systems and can be adapted to larger animals (Peremans et 
al., 2011). This system consists of pinhole apertures fixed on a multi-detector gamma 
camera and has already been used successfully on the feline brain (Dobbeleir et al., 2006; 
Waelbers et al., 2012a; Waelbers et al., 2013). To the author’s knowledge, there are no 
studies describing brain perfusion evaluated by µ-SPECT in the normal dog. Reliable and 
high-resolution normal reference SPECT data of the canine brain are necessary. 
Therefore, the aims of this study were (1) to investigate the feasibility of µ-SPECT of the 
canine brain, (2) to create a new, MRI-based region map and (3) to define the normal 
regional brain perfusion pattern in the adult Beagle dog.    
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Materials & Methods 
 
Subjects 
Ten male castrated healthy, drug naïve Beagle dogs, aged between 1.5 and 2 years, 
weighing between 14 and 19 kg were included in this study. The dogs had no history of 
neurological or other diseases and were trained to being handled for imaging procedures. 
The study was approved by the local Ethics Committee of the Faculty of Veterinary 
Medicine, Ghent University (EC 2010/020).  
Magnetic Resonance Imaging 
A permanent, 0.2 T magnet
b
 was used to perform MRI of the brain in all dogs to rule out 
pathology and to create a new VOI map. The dogs were positioned in dorsal recumbence 
with the head and neck extended and a human knee coil was used. Sagittal, transverse and 
dorsal T1- and T2-weighted spin echo sequences were performed in all dogs under 
general anaesthesia. Slice thickness was 4mm in all planes with no interslice gap in all 
studies. 
Tracer 
After placing a 20G intravenous catheter in the cephalic vein, the dogs were allowed to 
relax for five minutes. Then, Technetium-99m-Ethyl Cysteinate Dimer (
99m
Tc-ECD)
c
 
(injected activity: range 555-792 MBq, mean ± SD: 730.6 ± 68.9 MBq) was injected IV 
in the awake dog.  
Anesthetic protocol 
Twenty min after tracer injection, the dogs were premedicated with butorphanol
d
 0.3 
mg/kg IV. Anaesthesia was induced 10 min after premedication, using 2-5 mg/kg 
propofol
e
 IV to effect and maintained, after endotracheal intubation, with isoflurane
f
 in 
oxygen. Acquisition started 5 min after induction meaning that there was a time span of 
35 min between tracer injection and the start of the acquisition in all dogs. Dogs were 
allowed to breathe spontaneously during acquisition and heart rate and peripheral 
hemoglobin saturation (SpO2%) were monitored with a pulse oximeter. During the 
acquisition SpO2 remained above 92% in all subjects.  
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µ-SPECT 
All dogs were positioned in ventral recumbence. Micro-SPECT was performed using a 
conventional triple head gamma camera
g
, equipped with three multi-pinhole collimators
a
 
(6 multi-focused holes, 3 mm Ø). The radius of rotation (ROR) was set at 21.5 cm. The 
resolution of the system was 2.25 mm (Dobbeleir et al., 2006). Data were acquired in 
step-and-shoot mode (10 steps, 36° angular step, 120 s/step) and the total acquisition time 
was 20 min for each dog. Images were reconstructed using a dedicated ordered subset-
expectation maximization (OSEM) algorithm (nine iterations, five subsets) (Scivis) and a 
Butterworth filter was applied (order 5, cut-off frequency 2.5 cycles/cm). The µ-SPECT 
data were fitted to the MRI images with the help of fusion software. 
Semi-quantitative analysis 
A VOI map was created by 3 investigators (VM, KP and SV) based on the MR images of 
one dog. Nineteen VOIs were manually delineated: left and right frontal, temporal, 
parietal, piriform and occipital cortical regions (LF, RF, LT, RT, LP, RP, LPy, RPy, LO, 
RO); left and right thalamus (LTh, RTh), hippocampus (LHi, RHi) and corpus striatum 
(LCs, RCs) and one VOI was drawn over the cerebellum (CER), the olfactory bulbs (BO) 
and the brainstem (BS). For the delineation of the hippocampal VOI it was impossible to 
include all parts of the hippocampus because the VOI would otherwise have been too 
small at certain areas (tail and head of the hippocampus), which could have created 
additional partial volume effects. Therefore, the hippocampal body was delineated. 
Additionally, the µ-SPECT images of all dogs were fused to the µ-SPECT image of the 
dog used to create the VOI map, using BRASS software from Hermes (Brain Registration 
and Automated SPET Semi-quantification, Nuclear Diagnostics). Using this automated 
registration method, a compensation for size and shape differences was applied. A new 
mean dog µ-SPECT template image was created which can be used for future µ-SPECT 
studies. From the fitted µ-SPECT data, the counts and voxels of every VOI were 
determined and perfusion indices (PIs), representing the regional perfusion of every brain 
region, were calculated by normalizing the counts/voxel of each VOI to the counts/voxel 
of the whole brain (all VOIs). The perfusion within one brain hemisphere was represented 
by the left and right hemispheric PI which was calculated by normalizing the left or right 
hemispheric counts/voxel to the counts/voxel of all VOIs. Regional asymmetry was 
furthermore evaluated by comparing the PIs of the 8 bilateral VOIs. A bilateral frontal 
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(rostral = RPI) and occipital PI (caudal =CPI) was calculated in each dog by normalizing 
the bilateral frontal counts/voxel to the counts/voxel of all VOIs and respectively the 
bilateral occipital counts/voxel to the counts/voxel of all VOIs. A rostro-caudal gradient 
was defined as (R-C/R+C) x 100 where R is the bilateral frontal PI and C the bilateral 
occipital PI. A cortical PI (CoPI) was calculated in each dog by normalizing the 
counts/voxel of all cortical VOIs (= LF, RF, LT, RT, LP, RP, LPy, RPy, LO, RO) to the 
counts/voxel of all VOIs and a subcortical PI (SCoPI) was calculated by normalizing the 
counts/voxel of all subcortical regions (LTh, RTh, LHi, RHi, LCs, RCs) to the 
counts/voxel of all VOIs. A cortical-subcortical index was calculated and defined as 
(CoPI/SCoPI) x 100.  
Statistical analysis 
The Statistical Package for Social Sciences (PASW Statistics 19, SPSS) was used to 
perform the analyses. Due to the lack of normal distribution of data non-parametric tests 
were used. The related samples Wilcoxon signed ranked test was applied to evaluate 
regional and hemispheric left-right differences. The significance of the R-C gradient (H0: 
R-C=0) and the Co-SCo index (H0: Co-SCo=1) was evaluated using the one-sample 
Wilcoxon Signed Rank Test. The significance level was set at P < 0.05. 
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Results 
 
The MRI of the brain was normal in each dog. The brain of all dogs fitted within the field 
of view of the µ-SPECT. Figure 1 shows a dorsal view of a part of the VOI map and a 
mean µ-SPECT image at the same level. The mean of the obtained perfusion images of 
all dogs is shown in Figure 2 in the 3 planes (sagittal, dorsal and transverse). A dorsal 
view after fitting of the µ-SPECT images on the MRI images of one dog is shown in 
Figure 3. The mean PIs for the different VOIs ranged between 0.72 and 1.21 and are 
outlined in Figure 4. The highest PI was found in the parietal cortex and the lowest in the 
piriform cortex.   
 
 
Figure 1: Dorsal view of a part of the VOI map (A) and the mean dorsal µ-SPECT image 
(B) of the canine brain. Different volumes of interest are outlined: olfactory bulbs (1), 
frontal lobe (2, 3), temporal lobe (4, 5), corpus striatum (6, 7), thalamus (8, 9), 
hippocampus (10, 11) and the cerebellum (12) 
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Figure 2: The µ-SPECT images (mean of all dogs) represented in the 3 planes (dorsal, 
transverse and sagittal) 
 
Figure 3: A dorsal µ-SPECT image fitted on a corresponding  
dorsal MR image of one dog 
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Figure 4: The mean perfusion indices (± SD) per VOI (BO: olfactory bulbs; CER: 
cerebellum; BS: brainstem; LF, RF: left and right frontal cortex; LT, RT: left and right 
temporal cortex; LPy, RPy: left and right piriform cortex; LP, RP: left and right parietal 
cortex; LO, RO: left and right occipital cortex; LCs, RCs: left and right corpus striatum; 
LTh, RTh: left and right thalamus; LHi, RHi: left and right hippocampus) 
 
A significant difference between the right and left hemispheric PI was detected (P = 
0.005) with an overall tracer uptake asymmetry towards the left (Table 1). A significant 
regional asymmetry towards the left was found in the temporal (P = 0.037), frontal (P = 
0.028) and parietal cortex (P = 0.005) (Table 1).  
 
A significant negative rostro-caudal gradient (P = 0.005) was present in all dogs (mean: -
5.2%, SD: 1.9%) meaning that there existed a higher perfusion in the occipital versus the 
frontal cortices (Table 2). No obvious differences were found between the cortical and 
subcortical PI which was also reflected in a mean (±SD) Co-SCo index of 99.4% ± 5.6% 
(P = 0.721) (Table 2).   
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Table 1: The regional and hemispheric bilateral Perfusion Indices (mean ± SD) 
VOI L R P (L vs. R)* 
piriform 0.72 ± 0.05 0.70 ± 0.06 0.285 
temporal 1.03 ± 0.03 0.99 ± 0.05 0.037 
frontal 1.01 ± 0.03 0.96 ± 0.04 0.028 
hippocampus 0.95 ± 0.05 0.93 ± 0.03 0.093 
thalamus 1.09 ± 0.08 1.05 ± 0.05 0.074 
corpus striatum 1.07 ± 0.05 1.06 ± 0.06 0.508 
occipital 1.08 ± 0.07 1.09 ± 0.07 0.445 
parietal 1.21 ± 0.07 1.15 ± 0.05 0.005 
hemispheric 1.07 ± 0.02 1.03 ± 0.02 0.005 
* Perfusion indices of the left side (L) are compared with the perfusion indices of the 
corresponding VOI on the right side (R). P-values are reported. 
The piriform, temporal, frontal, occipital and parietal VOIs are cortical regions; the 
hippocampus, thalamus and corpus striatum VOIs are subcortical regions. 
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Table 2: The individual and mean (± SD) Cortical Perfusion Indices (CoPI), the 
Subcortical Perfusion Indices (SCoPI), the Cortical-Subcortical (Co-SCo) Indices, the 
frontal Perfusion Indices (RPI), the occipital Perfusion Indices (CPI) and the Rostro-
Caudal Gradients (R-C). 
Dog CoPI SCoPI Co-SCo (%) RPI CPI R-C (%) 
1 1.05 1.13 93.0 1.00 1.08 -3.9 
2 1.05 1.09 96.3 1.01 1.10 -4.4 
3 1.04 1.06 97.9 1.01 1.05 -1.8 
4 1.05 1.05 100.1 0.98 1.08 -5.1 
5 1.04 1.12 93.2 0.98 1.08 -5.1 
6 1.03 1.07 96.9 1.01 1.21 -9.0 
7 1.04 1.08 96.5 0.99 1.15 -7.1 
8 1.08 0.99 109.2 1.03 1.15 -5.2 
9 1.06 1.02 104.2 1.03 1.16 -6.0 
10 1.05 0.99 106.6 1.04 1.14 -4.7 
mean 1.05 1.06 99.4 1.01 1.12 -5.2 
SD 0.01 0.05 5.6 0.02 0.05 1.9 
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Discussion 
 
This study is, to our knowledge, the first to describe the regional brain perfusion in the 
dog evaluated with 
99m
Tc-ECD µ-SPECT. The results of this study show that with a 
system using multi-pinhole collimation for a conventional gamma camera system 
(=HiSPECT) the perfusion of the complete brain can be evaluated in Beagle dogs. With 
the ROR set at 21.5 cm a resolution of 2.25 mm could be obtained (Dobbeleir et al., 
2006). This resolution is less than that of dedicated small rodent micro-systems (<1 mm) 
(Beekman and van der Have, 2007), however, this is compensated by the larger size of 
the object under investigation. The obtained resolution of 2.25 mm is much better than the 
resolution of the conventional gamma camera SPECT (7-8 mm) (Peremans et al., 2005). 
This improved resolution allowed us to evaluate the regional perfusion in 19 different 
regions: 10 cortical regions, 6 subcortical regions, the brainstem, olfactory bulbs and 
cerebellum, whereas only 10 regions could be evaluated with the conventional fan-beam 
SPECT (Peremans et al., 2001). A previous interictal conventional SPECT study of our 
group (Martlé et al., 2009) found a significant hypoperfusion in the subcortical region, but 
the limited resolution of this system precluded a more detailed evaluation of this 
subcortical hypoperfusion. Therefore, performing µ-SPECT of the brain in epileptic dogs 
could contribute to the detection of epileptogenic foci and to the classification of canine 
epilepsy. The currently available pinhole plates, which were used in the past for mouse, 
rat and cat studies, seem appropriate to evaluate the canine brain. However, the field of 
view is limited and may hamper its use in the evaluation of the brain of larger dog breeds 
(> 20 kg).   
The regional perfusion of the canine brain is represented in this study by the regional 
perfusion indices. The highest perfusion index was found in the parietal lobes and the 
lowest in the piriform lobes. In a previous conventional canine SPECT study (Peremans 
et al., 2001) the highest regional perfusion was found in the subcortical region and the 
lowest in the frontal cortex which is not in agreement with our findings. The major reason 
for this discrepancy is the difference in study protocol and in techniques used for 
acquiring and processing of data. Firstly, in the study from Peremans et al. (2001), 10 
regions were evaluated, the piriform lobe and the brainstem were not included and the 
subcortical region (including the hippocampal, thalamic and striatal area) was globally 
evaluated. The region map of our study is more detailed (19 regions) and was created 
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based on MR instead of CT images which make it difficult to compare the absolute 
regional perfusion indices of both studies. Secondly, in the first study (Peremans et al., 
2001) different hardware was used and a different processing protocol was applied on the 
data. Thirdly, sedation was given prior to tracer injection in the study of Peremans et al 
(2001). The effect of sedation with medetomidine on the regional cerebral blood flow in 
dogs was recently demonstrated by Waelbers et al. (2011) and therefore in more recent 
canine SPECT studies, the tracer is injected in the awake dog before the administration of 
any sedative or anesthetic. The important timing of injection of the tracer is also 
emphasized in human SPECT studies (Catafau, 2001).  
A significant tracer uptake asymmetry towards the left brain hemisphere was detected in 
our study. Also regional asymmetries were detected in the temporal, frontal and parietal 
cortex towards the left. It is important to realize that general and regional brain 
asymmetries exist in normal dogs because the identification of rCBF abnormalities in 
brain SPECT is often based on the detection of interhemispheric asymmetries (Aubert-
Broche et al., 2003; Vermeire et al., 2009b). Asymmetries in regional uptake in the 
normal dog were not described previously (Peremans et al., 2001; Waelbers et al., 2011). 
It is possible that they have not been detected due to the resolution limits and 
consequently higher prevalence of partial volume effects of the conventional SPECT 
system. Different human SPECT studies in healthy volunteers also found left-right 
asymmetries in hemispheric perfusion (Catafau et al., 1996; Krausz et al., 1998; Lobaugh 
et al., 2000; Van Laere et al., 2001). In contrast to our findings, the perfusion in the right 
hemisphere in humans is often higher than in the left. In human subjects, these 
hemispheric asymmetries in perfusion have been explained by volumetric differences 
between the right and left hemisphere (Catafau et al., 1996), but other hypotheses such as 
functional differences could also contribute. These hypotheses need to be further 
investigated in dogs.  
A significant rostro-caudal gradient was found in our adult dogs with the higher PI in the 
occipital compared to the frontal cortex. This finding is in agreement with previous 
human and canine studies (Koyama et al., 1997; Peremans et al., 2001; Van Laere et al., 
2001) and recently a similar negative rostro-caudal gradient was detected in a µ-SPECT 
study in normal adult cats (Waelbers et al., 2013). The perfusion in the global cortical and 
subcortical region was comparable with a Co-SCo index of nearly 100% (99.4%, Table 
2). This index has not often been used in previous studies, but could be interesting to 
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apply in the future as a first screening tool to detect changes in cortical or subcortical 
perfusion in clinical or experimental studies.  
This study has some limitations. It is known that anaesthesia influences brain perfusion 
(Waelbers et al., 2011; Waelbers et al., 2012a) and could therefore be considered a 
confounding factor. However, the tracer was injected prior to sedation or anaesthesia, 
therefore allowing an undisturbed distribution. This means that anaesthesia effects will 
not have influenced our results. Furthermore, because the lipophilic tracer crosses the 
blood-brain barrier rapidly and is transformed into a hydrophilic form and as a 
consequence, trapped within the neuron, the µ-SPECT image is a fixed image within 5 
min after the tracer injection (Walovitch et al., 1994). As was shown previously 
(Waelbers et al., 2012b), a stable image, representing the rCBF at the moment of tracer 
injection, is obtained in dogs as long as the acquisition starts between 15 and 40 min after 
tracer administration, which was respected in this study (injection – acquisition interval of 
35 min). 
For this study a homogenous group of young adult male Beagle dogs was used. This has 
the consequence and limitation that breed, gender and age influences on the normal 
regional perfusion pattern in the dog cannot be evaluated in this study. Peremans et al. 
(2001) did not find an influence of age and gender on the conventional SPECT images of 
dogs, but only 1 older dog was included. Consequently, the effects of aging on 
conventional SPECT images were investigated in dogs older than 8 years and significant 
differences in regional perfusion were detected (Peremans et al., 2002). So, future canine 
µ-SPECT studies should investigate this as well. 
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Conclusion 
 
Performing high-resolution µ-SPECT of the brain in dogs is feasible and a resolution of 
2.3 mm can be obtained. The perfusion pattern in adult male dogs has the highest and 
lowest uptake in the parietal and the piriform cortex, respectively. Furthermore, a normal 
hemispheric asymmetry towards the left and a negative rostro-caudal gradient is present 
in the normal Beagle dog. Knowledge of this normal canine rCBF pattern, including 
normal asymmetries, is important before evaluating the results of 
99m
Tc-ECD µ-SPECT in 
clinical and experimental studies in dogs.                                 
 
 
 
 
 
 
 
  
81 
 
 Chapter 2  
References 
 
Aubert-Broche, B., Grova, C., Jannin, P., Buvat, I., Benali, H., Gibaud, B., 2003. 
Detection of inter-hemispheric asymmetries of brain perfusion in SPECT. Phys Med Biol 
48, 1505-1517. 
Beekman, F., van der Have, F., 2007. The pinhole: gateway to ultra-high-resolution three-
dimensional radionuclide imaging. Eur J Nucl Med Mol Imaging 34, 151-161. 
Boon, P., Williamson, P., 1989. Presurgical evaluation of patients with intractable partial 
seizures. Indications and evaluation techniques for resective surgery. Clin Neurol 
Neurosurg 91, 3-11. 
Catafau, A.M., 2001. Brain SPECT in clinical practice: Part I: Perfusion. J Nucl Med 42, 
259-271. 
Catafau, A.M., Lomeña, F.J., Pavia, J., Parellada, E., Bernardo, M., Setoain, J., Tolosa, 
E., 1996. Regional cerebral blood flow pattern in normal young and aged volunteers: a 
99m
Tc-HMPAO SPET study. Eur J Nucl Med 23, 1329-1337. 
Chandler, K. 2006. Canine epilepsy: what can we learn from seizure disorders? Vet J 172, 
207-217. 
Dobbeleir, A., Audenaert, K., Peremans, K., 2006. Cat brain perfusion with a multi-
pinhole SPECT imaging system. Eur J Nucl Med Mol Imaging 33, 285. 
Koyama, M., Kawashima, R., Ito, H., Ono, S., Sato, K., Goto, R., Kinomura, S., 
Yoshioka, S., Sato, T., Fukuda, H., 1997. SPECT imaging of normal subjects with 
Technetium-99m-HMPAO and Technetium-99m-ECD. J Nucl Med 38, 587-592. 
Krausz, Y., Bonne, O., Gorfine, M., Karger, H., Lerer, B., Chisin, R., 1998. Age-related 
changes in brain perfusion of normal subjects detected by 99mTc-HMPAO SPECT. 
Neuroradiology 40, 428-434. 
la Fougère, C., Rominger, A., Förster, S., Geisler, J., Bartenstein, P., 2009. PET and 
SPECT in epilepsy: a critical review. Epilepsy Behav 15, 50-55. 
Lobaugh, N.J., Caldwell, C.B., Black, S.E., Leibovitch, F.S., Swartz, R.H., 2000. Three 
brain SPECT regions-of-interest templates in elderly people: normative values, 
hemispheric asymmetries, and a comparison of single- and multihead cameras. J Nucl 
Med 41, 45-56. 
Martlé, V., Peremans, K., Audenaert, K., Vermeire, S., Bhatti, S., Gielen, I., Polis, I., Van 
Ham, L., 2009. Regional brain perfusion in 12 epileptic dogs evaluated by Technetium-
99m-Ethyl Cysteinate Dimer SPECT. Vet Radiol Ultrasound 50, 655-659. 
82 
 
 Chapter 2  
Masdeu, J.C., Arbizu, J., Toledo, J., Valero, M., 2006. SPECT and PET in neurology. 
Neurologia 21, 219-225. 
Matsuda, H., Fukuchi, T., Onuma, T., Ishida, S. Non-invasive cerebral blood flow 
measurement using 
99m
Tc-hexamethylpropylene amine oxime (HMPAO) and SPECT in 
interictal temporal lobe epilepsy. In: A Textbook of SPECT in Neurology and Psychiatry, 
De Deyn, P.P., Dierckx, R.A., Alavi, A., Pickut, B.A. (Eds.), John Libbey & Company, 
London, UK, 1997. pp. 247-253.  
Menzel, C., Grünwald, F., Hufnagel, A., Pavics, L., Reichmann, K., Ruhlmann, J., Elger, 
C.E., Biersack, H.J. Functional neuroimaging with CGU-PET and rCBF SPECT: 
targeting the epileptogenic focus. In: A Textbook of SPECT in Neurology and Psychiatry, 
De Deyn, P.P., Dierckx, R.A., Alavi, A., Pickut, B.A. (Eds.), John Libbey & Company, 
London, UK, 1997. pp.259-265. 
Peremans, K., De Bondt, P., Audenaert, K., Van Laere, K., Gielen, I., Koole, M., 
Versijpt, J., van Bree, H., Verschooten, F., Dierckx, R., 2001. Regional brain perfusion in 
10 normal dogs measured using Technetium-99m ethyl cysteinate dimer SPECT. Vet 
Radiol Ultrasound 42, 562-568. 
Peremans, K., Audenaert, K., Blanckaert, P., Jacobs, F., Coopman, F., Verschooten, F., 
van Bree, H., van Heeringen, K., Mertens, J., Slegers, G., Dierckx, R., 2002. Effects of 
aging on brain perfusion and serotonin-2A receptor binding in the normal canine brain 
measured with single photon emission tomography. Prog Neuropsychopharmacol Biol 
Psychiatry 26, 1393-1404. 
Peremans, K., Cornelissen, B., Van Den Bossche, B., Audenaert, K., Van de Wiele, C., 
2005. A review of small animal imaging planar and pinhole SPECT ɣ camera imaging. 
Vet Radiol Ultrasound 46, 162-170. 
Peremans, K., Vermeire, S., Dobbeleir, A., Gielen, I., Samoy, Y., Piron, K., 
Vandermeulen, E., Slegers, G., van Bree, H., De Spiegeleer, B., Dik, K., 2011. 
Recognition of anatomical predilection sites in canine elbow pathology on bone scans 
using micro-single photon emission tomography. Vet J 188, 64-72. 
Podreka, I., Baumgartner, C., Olbrich, A., Relic, A., Pietrzyk, U., Serles, W., Novak, K., 
Wimberger, D., Aull, S., Lindinger, G., Lurger, S., Brücke, T., Punz, E., Stellamor, V. 
HMPAO SPECT and video-EEG monitoring in candidates for surgical treatment of 
epilepsy. In: A Textbook of SPECT in Neurology and Psychiatry, De Deyn, P.P., 
Dierckx, R.A., Alavi, A., Pickut, B.A. (Eds.), John Libbey & Company, London, UK, 
1997. pp.233-245. 
Roy, C.S., Sherrington, C.S., 1890. On the regulation of the blood supply of the brain. J 
Physiol 11, 85-108. 
83 
 
 Chapter 2  
Van Laere, K., Versijpt, J., Audenaert, K., Koole, M., Goethals, I., Achten, E., Dierckx, 
R., 2001. 
99m
Tc-ECD brain perfusion SPET: variability, asymmetry and effects of age and 
gender in healthy adults. Eur J Nucl Med 28, 873-887. 
Vermeire, S., Audenaert, K., Dobbeleir, A., De Meester, R., Vandermeulen, E., Waelbers, 
T., Peremans, K., 2009a. Regional cerebral blood flow changes in dogs with anxiety 
disorders, measured with SPECT. Brain Imaging Behav 4, 342-349. 
Vermeire, S. Audenaert, K., De Meester, R., Dobbeleir, A., Vandermeulen, E., Waelbers, 
T., Peremans, K., 2009b. Hemispheric asymmetry of the cerebral blood flow in a 
Beauceron dog with pathological anxiety. In: Proceedings of the International Veterinary 
Behaviour Meeting, Edinburgh, UK, pp. 298-299. 
Waelbers, T., Peremans, K., Vermeire, S., Duchateau, L., Dobbeleir, A., Audenaert, K., 
Polis, I., 2011. The effect of medetomidine on the regional cerebral blood flow in dogs 
measured using Technetium-99m-Ethyl Cysteinate Dimer SPECT. Res Vet Sci 91, 138-143. 
Waelbers, T., Peremans, K., Vermeire, S., Piron, K., Doom, M., Boer, V.O., de Leeuw, H., 
Vente, M.A.D., Dobbeleir, A., Gielen, I., Audenaert, K., Polis, I., 2012a. Effects of 
medetomidine and ketamine on the regional cerebral blood flow in cats: A SPECT study. 
Vet J 192, 81-88. 
Waelbers, T., Peremans, K., Vermeire, S., Piron, K., Polis, I., 2012b. Regional distribution 
of technetium-99m-ECD in the canine brain: optimal injection-acquisition interval. Journal 
of Veterinary Behavior: Clinical Applications and Research 7, 261-267. 
Waelbers, T., Peremans, K., Vermeire, S., Dobbeleir, A., Boer, V., de Leeuw, H., Vente, 
M.A., Piron, K., Hesta, M., Polis, I., 2013. Regional brain perfusion in 12 cats measured 
with technetium-99m-ethyl cysteinate dimer pinhole single photon emission computed 
tomography (SPECT). J Feline Med Surg 15, 110-115. 
Walovitch, R.C., Cheesman, E.H., Maheu, L.J., Hall, K.M., 1994. Studies of the retention 
mechanism of brain perfusion imaging agent 99mTc-bicisate (99mTc-ECD). J Cereb Blood 
Flow Metab 14 (Suppl.), 4-11. 
Weber, D.A., Ivanovic, M., Franceschi, D., Strand, S.E., Erlandsson, K., Franceschi, M., 
Atkins, H.L., Coderre, J.A., Susskind, H., Button, T., Ljunggren, K., 1994. Pinhole SPECT: 
an approach to in vivo high resolution SPECT imaging in small laboratory animals. J Nucl 
Med 35, 342-348. 
Wirrwar, A., Schramm, N., Vosberg, H., Müller-Gärtner, H.W., 2001. High resolution 
SPECT in small animal research. Rev Neurosci 12, 187-193. 
Young, K., Daniel, G.B., Bahr, A., 1997. Application of the pin-hole collimator in small 
animal nuclear scintigraphy: a review. Vet Radiol Ultrasound 38, 83-93. 
 
84 
 
 
 
 
 
 
 
 
 
 
PART II: 
THE MECHANISM OF ACTION OF  
VAGUS NERVE STIMULATION IN  
THE HEALTHY BEAGLE DOG 
 
 
 
85 
 
 Chapter 3  
 
 
CHAPTER 3 
 
VAGUS NERVE STIMULATION IN DOGS: 
SURGICAL IMPLANTATION TECHNIQUE, 
COMPLICATIONS, LONG-TERM FOLLOW-UP 
AND PRACTICAL CONSIDERATIONS 
 
V Martlé
1
, L Van Ham
1
, P Boon
2
, J Caemaert
3
, M Tshamala
1
, K Vonck
2
,  
R Raedt
2
, I Polis
1
 and S Bhatti
1
 
 
1 
Department of Small Animal Medicine and Clinical Biology, 
Faculty of Veterinary Medicine, Ghent University, Belgium 
2
 Laboratory for Clinical and Experimental Neurophysiology, Department of Neurology, 
3
 Department of Neurosurgery 
Ghent University Hospital, Belgium 
 
 
 
 
Adapted from: 
Martlé, V., Van Ham, L., Boon, P., Caemaert, J., Tshamala, M., Vonck, K., Raedt, R., 
Polis, I., Bhatti, S. Vagus nerve stimulation in dogs: surgical implantation technique, 
complications, long-term follow-up and practical considerations. Veterinary Surgery, 
Under Review.  
86 
 
 Chapter 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sources and manufacturers 
a
 Cyberonics, Inc., Houston Texas, USA 
b Dolorex, MSD AH, Brussels, Belgium 
c
 Propovet, Abbott Laboratories, Berkshire, UK  
d Isoflo, Abbott Laboratories, Berkshire, UK 
e
 Rimadyl, Zoetis Belgium, Louvain-la-Neuve, Belgium 
f
 Zoetis Belgium, Louvain-la-Neuve, Belgium 
g Vetergesic, Alstoe Limited, York, UK  
h Clavubactin, Le Vet BV, Oudewater, the Netherlands   
87 
 
 Chapter 3  
Summary 
 
The aims of this study were to describe the implantation procedure of a vagus nerve 
stimulation (VNS) device in dogs and to report complications experienced during short- 
and long-term follow-up.  
A VNS Therapy
®
 System was implanted in the left cervical region of anesthetized healthy 
Beagle dogs (n = 10). During and one day after implantation, electrocardiography (ECG) 
and impedance testing of the system were performed. The dogs were monitored daily and 
the impedance of the system was determined regularly. The VNS devices were surgically 
removed 3 years after implantation.  
The implantation procedure succeeded in all dogs without intra-operative complications. 
The ECG monitoring and impedance test were within normal limits during and one day 
after surgery. Postoperative seroma formation was common. One dog developed an 
irreversible Horner’s syndrome leading to removal of the device. Another dog developed 
a trauma-induced damage of the lead requiring surgical revision. The device could be 
safely removed in all dogs, however the electrodes were left in place to avoid damage to 
the nerve. At removal, the anchor tether was dislodged in 40% of dogs and the lead was 
twisted in 50% of dogs.  
The implantation of a VNS Therapy system is safe and feasible in dogs, although, seroma 
formation, twisting of the lead and dislodgement of the anchor tether were common. 
Practical considerations to improve the technique are suggested. A regular evaluation of 
the lead impedance is important, as altered values can indicate serious complications.  
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Introduction 
 
Vagus nerve stimulation (VNS) is an intermittent stimulation of the cervical vagus nerve 
using a commercially available implantable device (VNS Therapy
®
 System
a
). This device 
consists of a pulse generator, helical electrodes that are coiled around the vagus nerve and 
a connecting lead (Landy et al., 1993). In human medicine, VNS is an established 
adjunctive treatment for refractory epilepsy. In people whose seizures are unresponsive to 
medical and surgical therapy, VNS can reduce seizure frequency and increase quality of 
life (Vale et al., 2011). Currently, VNS is also approved for the treatment of refractory 
depression and under the investigation for other disorders like migraine, Alzheimer’s 
disease, eating disorders, neuropsychiatric disorders and chronic heart failure (George et 
al., 2002; Beekwilder and Beems, 2010; Schwartz, 2011). 
Vagus nerve stimulation is not yet an established treatment in dogs, but can become 
increasingly important in the treatment of refractory epilepsy. Refractory epilepsy is an 
important problem in small animal practice as it occurs in up to 30% of dogs with 
idiopathic epilepsy (Farnbach, 1984; Lane and Bunch). Since many dogs with poorly 
controlled seizures do not survive, the search for alternative treatment options is 
warranted (Martlé et al., 2013). A key advantage of VNS in dogs is the independency of 
seizure focus localization. Zabara (1992) demonstrated an acute abortive effect of 
electrical stimulation of the cervical vagus nerve on chemically induced seizure activity in 
experimental dogs. VNS also seemed to reduce the seizure frequency in some dogs with 
idiopathic refractory epilepsy using a similar implantable device as in humans (Muñana et 
al., 2002). 
The surgical implantation technique is a minimally invasive procedure that has been well 
described in humans (Reid, 1990; Landy et al., 1993; Schachter and Saper, 1998). The 
left vagus nerve is usually chosen for the treatment of epilepsy, as the goal is to influence 
the brain and to avoid side effects on the heart. There seems to be a higher risk of 
bradycardia with right-sided VNS (Cohn, 1912; Ardell and Randall, 1986; Kamath et al., 
1992). The surgical technique in dogs is quite comparable as in humans and has been 
described briefly before (Muñana et al., 2002).
 
 
In humans, VNS therapy is usually well tolerated and has a low incidence of side effects 
(Ramsay et al., 1994). Three categories of complications have been recognized: (1) 
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surgical complications, (2) hardware or technical complications and (3) stimulation 
related complications. Here, we will focus on the first two categories. The most 
frequently reported surgery related complications in humans are vocal cord paralysis and 
infection. Intra-operative bradycardia or asystole (during impedance test of the system), 
cervical hypoesthesia, traumatic damage to surrounding blood vessels and keloid 
development have been reported less frequently (Kahlow and Olivecrona, 2013). With 
devices implanted in a moving subject, technical or hardware complications are 
inevitable. The most common appears to be a fracture of the lead needing surgical 
revision (Kahlow and Olivecrona, 2013), but the incidence has diminished considerably 
in humans with the development of newer leads with improved fatigue tolerance (Landy 
et al., 1993). The implantation of a similar device in 10 dogs with refractory epilepsy 
appeared to be safe and well tolerated. During the intraoperative impedance test of the 
device in dogs, transient bradycardia or even asystole appeared quite common (30%). 
Post-operative side effects were minor and often transient and were monitored during 6 
months after implantation. Horner’s syndrome, seroma formation and migration of the 
pulse generator have been described (Muñana et al., 2002).  
This study aims to provide a detailed description of a slightly modified surgical 
implantation procedure of a VNS Therapy System in dogs in the left cervical region and 
to describe surgical and technical complications that have been encountered during the 
postoperative and long-term follow-up period of 3 years. This information will be useful 
for the implantation of other hardware devices (e.g. pacemakers) in the cervical region of 
dogs as well.   
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Materials & Methods 
 
Animals 
Ten male castrated, healthy Beagle dogs, aged between 1.5 and 2 years, weighing 14 to 
19 kg were included in this study. This study was part of a larger research project 
investigating the mechanism of action of VNS in dogs and approval of the local Ethics 
Committee of the Faculty of Veterinary Medicine, Ghent University (EC 2010/020) was 
obtained. All guidelines for animal welfare, imposed by the Ethical Committee, were 
respected. The dogs had no history of neurological or other diseases.  
The implantable device 
A VNS Therapy
®
 System
a
 was surgically implanted in the left cervical region of all dogs. 
The system consists of a pulse generator (Demipulse model 103), 3 helices and a 
connection lead (Model 304, 3.0 mm) in between (Figure 1). The pulse generator, which 
looks similar to a cardiac pacemaker, is housed in a titanium case of 45 x 32 x 6.9 mm, 
weighing around 16 g. The helices are 3 spiral coils, of which the most proximal 2 supply 
the electrical stimulation (anode and cathode electrode), while the most distal one is the 
anchor or tethering coil. The function of this anchor tether is to avoid traction on the 
nerve with movement of the neck (Fahy, 2010). A programming wand (Model 201) and 
software are used to communicate with and program the device.  
Anesthetic protocol  
After premedication with 0.3 mg/kg butorphanol
b
 given intravenously (IV), general 
anesthesia was induced with propofol
c
 (2-6 mg/kg IV to effect) and maintained with 
isoflurane
d
 in oxygen. Before surgery carprofen
e
 (4 mg/kg IV) and antibiotics (Clamoxyl, 
10 mg/kg IV and Synulox, 12.5 mg/kg SC)
f 
were administered to each dog and an intra-
arterial 22G catheter was placed aseptically in a dorsal pedal artery. During the surgical 
procedure, there was a continuous monitoring of end tidal CO2 concentration (ET CO2 
%), inspiratory oxygen fraction (FiO2), peripheral hemoglobin saturation (SpO2%) 
respiratory rate (RR) and pulse rate (PR). Also, regular arterial blood pressure 
measurements were obtained every 10 minutes and continuous ECG monitoring was 
performed. 
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Figure 1: A VNS Therapy® System implanted in a man 
(with permission of Cyberonics, Inc.) 
 
 
Surgical implantation procedure  
The dogs were placed in right lateral recumbence with the head and neck rotated 45° 
clockwise. The left thoracic limb was mildly retracted caudally. The skin was surgically 
prepared over the entire left cervical region, extending past the dorsal and ventral 
midlines. Two incisions in the cervical region were made: a dorsal incision for placement 
of the pulse generator and a ventral incision for placement of the helical electrodes around 
the left vagosympathetic trunk. The position of both incisions is demonstrated in Figure 2. 
The ventral linear skin incision of about 4 cm length was made approximately 0.5 cm 
dorsal and parallel to the jugular furrow. The subcutaneous tissues were incised and blunt 
dissection between the brachiocephalic and omotransversarius muscle was performed 
until the carotid sheath was identified. The carotid sheath was opened and the 3 
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containing structures (common carotid artery, vagosympathetic trunk and internal jugular 
vein) were identified.  
 
 
Figure 2: Localization of the ventral and dorsal incision 
 
The vagosympathetic trunk was freed from the surrounding connective tissue and isolated 
with 2 vessel loops to ease manipulation (Figure 3). The 2 helical electrodes and anchor 
tether were coiled around the nerve beginning with the anchor tether, next placing the 
positive electrode (anode) and then placing the negative electrode (cathode) most 
cranially towards the head of the dog (Figure 4). Attention was paid to manipulate only 
the helical sutures and not the helices themselves to avoid damage of the electrodes. To 
provide adequate slack and neck movement, 3 strain relief loops were formed in the lead 
and the lead was fixated to the underlying fascia at 3 points between the ventral and 
dorsal incision site using silicone tie-downs and non-absorbable sutures. Then, a dorsal 4 
cm linear skin incision was made about 2 cm from the dorsal midline with the caudal 
extent of the incision just cranial to the left scapula. A pocket underneath the fascia, just 
large enough for the pulse generator to easily fit in, was created by blunt dissection. A 
shunt-passing tool
a
 was used to create a tunnel and guide the lead from the ventral 
incision to the pocket. The tunnel and lead passed underneath the brachiocephalic muscle. 
The lead was connected to the pulse generator using a hex screwdriver
a
 and at that time 
the impedance of the system was tested to confirm the integrity of the system. The 
residual part of the lead was wound and placed next to the pulse generator in the 
subfascial pocket. The pulse generator was fixated with 1 or 2 non-absorbable 
polyfilament sutures to the underlying tissue. Then, the wounds were closed routinely. 
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Figure 5 shows the schematic representation of a VNS device implanted in a dog. Within 
48 hours after surgery a second impedance test was performed in the awake dogs while 
ECG was monitored to detect any change in heart rate or rhythm. A postoperative healing 
period of 1 month was respected before activation of the system.  
   
 
 
 
 
Figure 5: Schematic representation of a VNS device implanted  
in the left cervical region of a dog 
Figure 3: The left vagosympathetic 
trunk isolated with 2 vessel loops 
at the ventral incision site 
 
Figure 4: The 3 helices placed 
around the left vagosympathetic  
trunk at the ventral incision site 
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Post-operative care and follow-up 
For pain relief, buprenorphine
g
 0.01 mg/kg was administered intramuscularly (IM) every 
6 hours the first 24 hours after surgery. Carprofen
e
 (2 mg/kg BID) and amoxicillin- 
clavulanic acid
h
 (12.5 mg/kg BID) were continued orally for 5 days. The first week after 
surgery, the dogs remained in the hospitalization area for close monitoring. A general 
examination together with a control of pupil size and wound healing was performed on a 
daily basis the first week. Subsequently, the dogs and their wounds were inspected on a 
daily basis and a thorough general examination was performed every week. 
Impedance evaluation 
The lead impedance of the VNS Therapy System was evaluated regularly using the 
System Diagnostics section of the software
a
. During this test, the pulse generator delivers 
a short pulse (130 µs) at 0.25 mA. Likewise, the programming software will report the 
lead impedance. Normal lead impedance is defined as a value between 600 and 7000 
Ohms (Cyberonics Physician’s manual, 2001). As mentioned before this impedance test 
was performed during surgery and within the first 48 hours after surgery. Subsequently, 
the impedance was evaluated every week the first 2 months after surgery, every 2 weeks 
the following 6 months and every 2 months until 1.5 year after surgery. Additional 
evaluations of the lead impedance were performed when abnormalities or complications 
were suspected.  
Removal of the devices 
The VNS device was surgically removed 3 years after the implantation. The helices were 
left in place, to avoid the potential for nerve injury during their removal. The lead was cut 
just below the anchor tether and was completely removed together with the silicone tie-
downs and pulse generator. The pocket of the pulse generator was excised. Both wounds 
were closed routinely.  
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Results 
 
Surgical implantation and anesthetic monitoring 
The implantation of the VNS Therapy System succeeded in all dogs and no intraoperative 
abnormalities or complications were noticed. During the whole surgical procedure and 
especially during the impedance test of the device no signs of bradycardia or asystole 
were detected with ECG. The other anesthetic parameters (ET CO2%, FiO2, SpO2%, RR 
and arterial blood pressure) remained stable as well throughout the procedure. ECG 
monitoring, performed within 48 hours after the implantation during the second 
impedance test, did not reveal changes in heart rate or rhythm.  
Minor transient postoperative complications 
Seroma formation was common in our study. Three dogs developed a seroma at the 
ventral incision site, 3 dogs developed a seroma at the dorsal incision site and one dog 
developed both. Some seromas required draining and placement of a mild pressure 
bandage. In most dogs, a seroma developed approximately 10 days after implantation and 
resolved within 2 to 3 weeks (mean duration of the seroma (± SD) was 12 (± 5) days). 
None of the dogs developed signs of infection.  
One dog developed hoarseness the first day after the implantation which resolved 
spontaneously within 2 days.  
Complications requiring device removal or revision surgery: 2 cases 
Case 1: Horner’s syndrome  
One dog developed a left-sided Horner’s syndrome 22 days after surgery (Figure 6). This 
particular dog had also developed a seroma at the ventral and dorsal incision site. At the 
ventral incision site, the seroma was present from day 9 to 11 after surgery. The seroma at 
the dorsal incision site appeared 12 days after surgery. Several drainages combined with 
placement of a bandage were performed and the seroma resolved 32 days after the 
implantation. The Horner’s syndrome was still present at that time. General physical and 
neurological examination revealed no other abnormalities. The lead impedance, which 
was within normal limits before, suddenly had changed around the time of the onset of 
the Horner’s syndrome (from 1140 to 532 Ohms). This led to the suspicion that the 
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system was not functioning properly and that there was a problem at the level of the 
vagosympathetic trunk causing the irreversible Horner’s syndrome.  
 
Figure 6: Left-sided Horner’s syndrome (case 1) 
 
Radiography (RX) and ultrasound (US) of the left cervical region were performed. Both 
remained inconclusive about the cause of the Horner’s syndrome. However, on US the 
left-sided vagosympathetic trunk was focally thickened (0.22 mm Ø) compared to the 
right-sided nerve (0.11 mm Ø).  
Because the Horner’s syndrome persisted, surgical exploration was imperative and was 
performed 5 months after initial implantation. The surgical approach was similar to the 
initial implantation. After identifying the left vagosympathetic trunk, it was seen that the 
anchor tether (distal helix) was no longer wound around the nerve, but it was 
encapsulated by a migrated silicone tie-down and both were compressing the 
vagosympathetic trunk (Figure 7). After removal of the helices the nerve had a red and 
swollen appearance and this dog was excluded from further VNS research. Thus, the lead 
and pulse generator were removed. When the pulse generator was removed, the lead 
underneath had a twisted, knotted appearance. The Horner’s syndrome has improved over 
time but a mild anisocoria remains present 3 years after removal of the device.  
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Figure 7: Surgical exploration of case 1: the anchor tether (arrowhead) is encapsulated in 
a migrated silicone tie-down (asterisk) and both are compressing the vagosympathetic 
trunk (arrow) 
 
Case 2: Traumatic lead damage 
Another dog suddenly developed a seroma at the dorsal incision site 5 months after the 
implantation and this was probably induced by trauma (e.g. dog fight, dog play, 
scratching, rubbing). Together with the seroma development, the impedance was 
unmeasurably low (< 200 Ohms). Before, the impedance was stable around 1200 Ohms. 
RX of the cervical region showed an irregular, twisted appearance of the lead (Figure 8). 
Although the seroma resolved within a few days, the impedance value still remained low, 
so surgical exploration was performed the next week. After opening the dorsal incision 
site, the lead showed a twisted, knotted appearance (Figure 9) surrounded by fibrous 
tissue. At the ventral incision site, the lead between both incisions had an abnormal 
yellow to brown color reflecting damage of its silicone sheath (Figure 10). The 3 helices 
were nicely in place around the vagosympathetic trunk and encapsulated in fibrous tissue. 
To avoid damaging the nerve by excessive manipulation, the lead was cut just below the 
anchor tether and a new set of electrodes was placed cranial to the old ones. The new lead 
was then fixated similarly as before and connected to the same pulse generator. The 
system was tested intra-operatively and a normal lead impedance was obtained.  
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Figure 8: Lateral RX of the cervical region (case 2): the lead 
has a twisted, irregular appearance (arrowheads) 
 
   
    
 
 
 
  
Figure 9: The lead at the level of the  
pulse generator (asterisk) has a twisted  
and knotted appearance  
Figure 10: The lead between the 
dorsal and ventral incision site has  
an abnormal color (arrowhead) 
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Lead impedances 
During the intraoperative device test, the impedance values were within normal limits in 
all dogs (mean ± SD: 972 ± 170 Ohms). Also, during the second device test within 48 
hours after surgery no abnormal impedance values were detected (mean ± SD: 790 ± 62 
Ohms). Until 1.5 year after implantation, the impedances remained normal in all dogs 
except for the 2 cases described above.  
Removal of the devices 
In 8 dogs the device was removed after 3 years at the end of the study, in 1 dog it was 
removed 5 months after implantation due to the Horner’s syndrome (case 1) and in 
another dog the device was removed after 1.5 years due to the development of primary 
hypothyroidism.  
In 5 dogs (50%), the lead had a twisted appearance, most commonly at the level of the 
pulse generator. Traumatic damage of the silicone sheath was detected in 3 of these 5 
dogs. At the level of the vagosympathetic trunk the distal helix (= anchor tether) was 
detached from the nerve in 4 dogs (40%).  
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Discussion 
 
The implantation of a VNS Therapy system in the left cervical region is a minimally 
invasive, feasible technique in dogs. No intraoperative complications occurred, but 
transient seroma formation was common during the early postoperative period. Twisting 
and damage of the lead and movement of the anchor tether was also frequently noticed. 
Two complications requiring surgical revision or removal of the device were associated 
with sudden changes in the impedance value. 
In humans, complications related to the surgical implantation of a VNS Therapy System 
are uncommon and usually minor and transient (George et al., 2000; Kotagal, 2011). 
Postoperative side effects related to the surgical implantation of a device in the cervical 
region seem to be more common in dogs than humans. This is not surprising as dogs do 
not adjust their natural behavior after surgery and they do not understand what they have 
been implanted with and why.  
Bradycardia or asystole during intraoperative device testing has been reported in dogs and 
humans (Asconape et al., 1999; Muñana et al., 2002). Cardiac effects of VNS are not 
unexpected because of the vagus nerve’s efferent influence on the heart. Therefore, the 
VNS electrodes are usually implanted around the left vagus nerve for the treatment of 
epilepsy, because the left vagus nerve has less cardiac input than the right in humans and 
dogs (Cohn, 1912; Ardell and Randall, 1986; Kamath et al., 1992). Additionally, the 
electrode contacts are placed in an orientation (negative pole rostral) with the aim of 
primarily activating afferent cervical vagal fibers, however co-activation of the efferent 
fibers cannot be fully prevented (Banzett et al., 1999). A higher incidence of cardiac side 
effects during surgery in dogs than in humans was reported previously (Muñana et al., 
2002). This might seem illogical on the one hand, since in dogs the electrodes are 
wrapped around the vagosympathetic trunk, as both nerves are fused in the cervical 
region (Mizeres, 1955). Consequently, additional sympathetic stimulation and influence 
on the heart cannot be excluded. On the other hand, anatomical differences of the cardiac 
branches of the vagus nerve are most likely responsible for this higher incidence of 
bradycardia in dogs (Muñana et al., 2002). In humans, care is taken to place the VNS 
electrodes distal to the superior and inferior cervical cardiac branches of the vagus nerve 
(Reid, 1990). In dogs, it is impossible to spare the cardiac branches from stimulation, 
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because these branches leave the nerve more distally in the thoracic cavity (Muñana et al., 
2002). No intraoperative ECG changes were detected in our study, but the impedance test 
was performed at a lower output current (0.25 mA) compared to the previous canine VNS 
study (1 mA) (Muñana et al., 2002). Also, in our study the anesthetic protocol was 
carefully chosen to minimize cardiorespiratory depression (Lamont et al., 2007). 
Vocal cord palsy affects about 1 to 6% of people after implantation and is usually 
transient (Kahlow and Olivecrona, 2013). It is probably related to intraoperative 
manipulation of the vagus nerve or disruption of the blood supply in the area (Fernando 
and Lord, 1994; Vonck et al., 2004). Transient hoarseness was obvious in 1 dog in our 
study, but may have been underestimated as these Beagle dogs do not bark or whine on 
command.  
The surgical implantation procedure of a commercially available VNS device in dogs has 
been described previously (Muñana et al., 2002); however, small adaptations were made 
in our study. In our dogs, a smaller type of pulse generator was used and both incisions 
were smaller. At the ventral incision site, the carotid sheath was approached by blunt 
dissection between the brachiocephalic and omotransversarius muscle, avoiding incision 
through muscle tissue. The pulse generator was not placed in a subcutaneous pocket, but 
underneath the fascia, to create an extra protective layer and a tighter pocket. For similar 
reasons the lead was tunneled below the brachiocephalic muscle instead of 
subcutaneously. Despite these efforts, a higher incidence of seromas was present (70% 
compared to 20% (Muñana et al., 2002)). Our study was performed in experimental 
Beagle dogs, whereas Muñana et al. (2002) implanted the device in client-owned dogs 
with refractory epilepsy. Although efforts have been made to monitor the Beagle dogs 
closely during the postoperative period, they will have been less supervised than a client-
owned dog. This might have contributed to the higher seroma development in our study.   
Possible improvements of the surgical technique in the future could be to place 
implantable devices in a more stable anatomical position for example more dorsally in the 
cervical region or even caudal to the interscapular region. The placement of the pulse 
generator underneath the cervical musculature can also be considered, but communication 
with the programming wand could be altered and surgical revisions or removals will be 
more difficult. Postoperatively, we recommend to place a preventive mildly compressive 
cervical bandage (Domenech et al., 2005). Still, placing an adequately compressive 
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bandage in the canine cervical region for several days remains a true challenge. Also, 
since excessive movement of the neck could have contributed to the seroma formation, 
serious restriction of movement during the first 2 weeks after surgical implantation can be 
useful.  
One dog in our study developed a left-sided Horner’s syndrome indicating damage to the 
left sympathetic nerve. Horner’s syndrome has been reported as rare complication in 
humans undergoing surgical implantation of the device and is most likely due to transient 
dysfunction of third-order sympathetic fibers within the carotid sheath (Kim et al., 2001). 
This complication was noticed in 20% of dogs with refractory epilepsy, 24 hours after 
implantation and it spontaneously resolved within 2 to 4 weeks (Muñana et al., 2002). 
The anatomical differences between the human and canine cervical vagus nerve most 
likely account for the higher incidence of Horner’s syndrome in dogs. In dogs, the 
cervical vagus nerve is fused with the sympathetic nerve to form the vagosympathetic 
trunk (Mizeres, 1955), whereas in humans, the cervical portion of the vagus nerve is 
adjacent to, but completely separated from the sympathetic nerve. In our dog, Horner’s 
syndrome occurred 22 days after surgery which indicates that causes directly related to 
the surgical implantation, such as a transient compromise of blood supply to the 
sympathetic nerve, local edema or direct mechanical damage resulting from manipulation 
of the nerve, seemed unlikely. Surgical exploration 5 months after the initial implantation 
revealed a dislodgement of the distal anchor tether and migration of the silicone tie-down 
both compressing the nerve. This was the only dog that developed a seroma at both 
incision sites. It is unclear whether there is an association between both complications, 
but the seroma at the dorsal incision site could have caused unwanted movement and 
twisting of the pulse generator or lead underneath and subsequently traction on the lead 
distally at the level of the nerve. The lead at the level of the pulse generator certainly had 
a twisted appearance. 
The lead of the dog suffering an external trauma 5 months after the surgery had a similar 
twisted and knotted appearance at the level of the pulse generator. This seems comparable 
to the “pacemaker Twiddler syndrome” described both in humans and dogs, which is 
characterized by accidental or deliberate rotation of an implanted pulse generator leading 
to winding, dislodgement or even fracture of the lead (Bayliss et al., 1968; Young and 
Bailey, 2002; De Monte et al., 2013). This hypothesis assumes that the sutures fixating 
the pulse generator in the pocket got loosened. Twiddling in animals may be caused by 
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scratching with a paw, but local muscular action during normal activities seems more 
likely to contribute (Been and Darke, 1988). It seems reasonable that a twisted lead will 
be more prone to traumatic damage due to increased fatigue of the wire. Remarkably, 
when the devices were removed 3 years after implantation, the lead had an abnormally 
twisted appearance in 3 other dogs as well. Since we used human leads, we hypothesized 
that these might have been too long. The leads need to be sufficient in length to avoid 
traction on the nerve and to allow strain-relief loops, but in each dog, a few additional 
windings had to be placed together with the pulse generator in the subfascial pocket. The 
use of customized leads in the future, adapted to the size of the dog, is advisable. 
Additionally, improved fixation techniques for the pulse generator as well as for the lead 
are warranted.   
Impedance measurements were regularly performed in this study using the System 
Diagnostics test of the software. This test evaluates the lead impedance of the VNS 
Therapy System, as well as the pulse generator’s ability to deliver the programmed 
stimulation (Cyberonics Physician’s manual, 2001). It is an essential test during and after 
surgery to assure the integrity of the system. Sudden changes in impedance values can 
indicate complications as observed in the 2 dogs requiring surgical exploration.  
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Conclusion 
 
The implantation of a VNS Therapy system in the left cervical region is a minimally 
invasive, feasible technique in dogs. Intra-operative complications did not arise. 
Postoperatively, several complications occurred such as seroma formation, twisting and 
traumatic damage of the lead and movement of the distal helix. Hence, all efforts should 
be made to prevent seroma formation as this transient complication can also contribute to 
movement and damage of the system. Regular impedance testing is important as altered 
impedance values can indicate serious complications requiring surgical revision of the 
system. 
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Summary 
 
Vagus nerve stimulation (VNS) is an effective adjunctive treatment for refractory 
epilepsy in humans, but its mechanism of action (MOA) and optimal stimulation 
parameters are still unknown. Functional neuroimaging studies could provide better 
insight into the brain structures involved in the activity of VNS, but have not yet been 
described in dogs. The aim of this study was to investigate the effect of acute VNS on the 
regional cerebral blood flow (rCBF) in dogs using micro-SPECT (µ-SPECT). 
Additionally, a novel stimulation paradigm (microburst VNS) was used and compared 
with standard VNS. 
A VNS Therapy
®
 System was implanted in ten Beagle dogs. µ-SPECT was performed 
after sham, standard and microburst VNS in a randomized, cross-over study. Nineteen 
volumes of interest (VOIs) were semi-quantitatively analyzed and perfusion indices (PIs) 
were calculated. Furthermore, a rostro-caudal gradient (R-C), an asymmetry index (AI) 
and a cortical-subcortical index (Co-SCo) were determined. The SPECT results after 
standard and microburst VNS were compared pairwise with sham stimulation.  
Acute standard VNS did not cause significant rCBF alterations. Acute microburst VNS 
caused a significant hypoperfusion in the left frontal lobe (P = 0.023) and in the right 
parietal lobe (P = 0.035). Both stimulation paradigms did not cause changes in R-C, AI 
nor Co-SCo. 
Microburst VNS seems more potent than standard VNS to modulate the rCBF in the dog. 
Our results promote further research towards the antiepileptic effect of microburst VNS in 
dogs and humans. 
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Introduction 
 
Vagus nerve stimulation (VNS) is a well-established adjunctive treatment in human 
patients with medically or surgically refractory epilepsy (Ben-Menachem, 2002; Boon et 
al., 2002). Several studies, including two large double-blinded randomized clinical trials 
have shown effectiveness of VNS, which even increases over time, in different forms of 
human epilepsy (Ben-Menachem et al., 1994; DeGiorgio et al., 2000; Groves and Brown, 
2005).  
Neither the exact antiepileptic MOA nor the optimal stimulation parameters for VNS are 
known (Chae et al., 2003; Alexander and McNamara, 2012), despite a lot of research in 
humans with refractory epilepsy (Boon et al., 2002) and in experimental animal models 
(Zanchetti et al., 1952; Chase et al., 1967; Lockard et al., 1990; Woodbury and 
Woodbury, 1990; Zabara, 1992; Naritoku et al., 1995; Takaya et al., 1996; Krahl et al., 
1998; Fernandez-Guardiola et al., 1999; Walker et al., 1999; Krahl et al., 2001; 
Dedeurwaerdere et al., 2005a; Alexander and McNamara, 2012). A better understanding 
of the exact MOA is important, because it could lead to the identification of predictive 
factors for responsiveness and to optimization of stimulation parameters. Functional brain 
imaging studies have the potential to reveal better insight into the brain structures 
involved in the activity of VNS. The main conclusion of human Positron Emission 
Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and 
functional Magnetic Resonance Imaging (fMRI) studies is that VNS causes immediate 
and long-term changes in anatomical structures belonging to the afferent vagus nerve 
pathways, although there is some disagreement between different studies (Boon et al., 
2002; Chae et al., 2003). A lot of confounding factors may be responsible for this 
discrepancy (Dedeurwaerdere et al., 2005b). As our study is performed in healthy dogs, 
the epilepsy-related factors are avoided and the true effect of VNS on the rCBF is 
assessed. In addition, we believe that it is useful to expand the research into the MOA of 
VNS from rodents towards canines as quite some similarities exist between human and 
canine epilepsy (Chandler, 2006). Furthermore, the canine and human brain size and 
function share more similarities than the rodent and human brain. Until now, only a few 
studies examining the antiepileptic effect or MOA of VNS in dogs have been performed 
(Zabara, 1992; Speciale and Stahlbrodt, 1999; Muñana et al., 2002; Castoro et al., 2011; 
Yoo et al., 2013). 
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There is a continuous search for more effective stimulation paradigms and in this study, a 
recently developed experimental stimulation paradigm, called microburst VNS, is 
evaluated and compared with standard VNS. The rationale of the microburst stimulation 
is that multiple stimulations within a short time period could induce a more robust 
synaptic response at central vagal targets (Ito and Craig, 2005, 2008; Alexander and 
McNamara, 2012).  
The aim of our study was to evaluate the effect of acute VNS on the regional brain 
perfusion in healthy dogs using µ-SPECT. Furthermore, a recently developed 
experimental stimulation paradigm, microburst VNS, was compared with standard VNS.  
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Materials & Methods 
 
Animal preparation 
This study was approved by the local Ethics Committee of the Faculty of Veterinary 
Medicine, Ghent University (EC 2010/020). All guidelines for animal welfare, imposed 
by the Ethical Committee, were respected. To minimize gender, breed and age influences, 
ten male castrated healthy Beagle dogs, aged between 1.5 and 2 years, weighing between 
14 and 19 kg were included in this study. The dogs had no history of neurological or other 
diseases and were trained to being handled for imaging procedures. Low-field MRI of the 
brain was performed in all dogs to exclude intracranial abnormalities. 
All animals were implanted with a VNS Therapy
®
 System
a
, consisting of a pulse 
generator (Demipulse
TM 
Model 103) and a lead with helical electrodes (single-pin bipolar 
Lead, 3.0 mm size). A previously described surgical technique (Zabara, 1992; Muñana et 
al., 2002) was used. The 3 helical electrodes were coiled around the isolated 
vagosympathetic trunk. During surgery, the end tidal CO2 concentration, inspiratory 
oxygen fraction, peripheral hemoglobin saturation (SpO2%) and pulse rate were 
continuously monitored. At the same time, the heart rhythm was analyzed by visual 
assessment of an electrocardiogram (ECG). The lead impedance was measured to ensure 
the integrity of the stimulation electrode and the functionality of the stimulation. A 
second device test was performed within 48 hours after surgery and at that time an 
additional ECG was evaluated during 10 min to monitor for any changes in heart rate or 
rhythm. A healing period of one month was respected during which no VNS was 
performed.  
Stimulation parameters  
For this study, acute VNS was defined as 55 min of intermittent active stimulation. To 
achieve adequate duty cycles during the 55 min of stimulation it was chosen to give 
rapid-cycling stimulation, meaning an on-time of stimulation of 7 seconds and an off-time 
of 18 seconds. Two types of active stimulation (standard and microburst VNS) and a 
sham stimulation were given to each dog. The microburst VNS is a novel stimulation 
paradigm where stimulation is delivered in small bursts instead of single pulses as in 
standard VNS (Figures 1 and 2). Stimulation parameters used for standard VNS included 
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a pulse width of 500 µs and an inter-pulse interval of 33 ms (30 Hz). Stimulation 
parameters for microburst VNS included a pulse width of 500 µs, an inter-pulse interval 
of 3.3 ms (300 Hz), 3 pulses/burst and an inter-burst interval of 0.4 s. The stimulation 
frequency of 300 Hz was chosen based on neurophysiological studies which used similar 
stimulation parameters. In these studies, high frequency stimulation was used to enhance 
synaptic transfer and produce vagal-evoked responses in the thalamus (Ito and Craig, 
2005, 2008). The optimal stimulation output current was individually determined one 
month after the implantation during a ramping-up procedure (with increasing steps of 
0.125 mA) and was defined as the highest current for which no cough was elicited, 
similar as in a previous canine VNS study (Muñana et al., 2002). This output current was 
checked on a weekly basis and adapted if necessary. For the sham stimulation the animals 
underwent the same procedures as with active VNS except that the output current was set 
at 0 mA. 
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Figure 1: ON/OFF Standard VNS: Graphical representation of the waveform for 
intermittent standard stimulation (s = seconds; ms = milliseconds; mA = milliampere) 
 
 
 
Figure 2. ON/OFF Microburst VNS: Graphical representation of the waveform for 
intermittent microburst stimulation (s = seconds; ms = milliseconds; mA = milliampere) 
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Study design 
In a randomized, single-blinded cross-over study, Technetium-99m-Ethyl Cysteinate 
Dimer (
99m
Tc-ECD) µ-SPECT was performed three times in each dog after sham 
stimulation, standard and microburst VNS with a mean wash-out period of 20 days 
(range: 7 - 34 days) between different paradigms. VNS was started 45 min before 
injection of the tracer and was continued for 10 more minutes after injection. During VNS 
the dogs were continuously under direct supervision to monitor possible side effects.  
Tracer 
After 45 min of VNS, 
99m
Tc-ECD
b
 (injected activity: range 742-794 MBq, mean ± SD: 
765 ± 13 MBq) was injected IV in the awake dog.  
 
 
 
Figure 3: Timeline of the different proceedings during an acute VNS experiment  
(T x = x minutes) 
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Anesthetic protocol 
Before the start of the experiment a catheter was placed in the cephalic vein and the dogs 
were allowed to relax for five minutes. The dogs were sedated with butorphanol
c
 and 
general anesthesia was induced with intravenous propofol
d
 to effect and maintained, after 
endotracheal intubation, with isoflurane
e
 in oxygen. The timing of sedation, induction and 
start of the acquisition with respect to the 55 min of VNS is illustrated in Figure 3. There 
was a time span of 35 min between tracer injection and the start of the acquisition in all 
dogs, which fits within the ideal time span of 15 to 40 min to obtain optimal SPECT data 
in the dog (Waelbers et al., 2012). Dogs were allowed to breathe spontaneously during 
acquisition and heart rate and peripheral hemoglobin saturation (SpO2%) were monitored 
using a pulse oximeter. During the acquisition SpO2 remained above 92% in all subjects.  
µ-SPECT imaging 
All dogs were positioned in ventral recumbence. Micro-SPECT was performed using a 
standard triple-head gamma camera
f
, equipped with three multi-pinhole collimators
h
 (6 
multi-focused holes, 3 mm Ø). The radius of rotation (ROR) was set at 21.5 cm. The 
resolution of the system was 2.3 mm (Dobbeleir and Peremans, 2006). Data were 
acquired in step-and-shoot mode (10 steps, 36° angular step, 120 s/step) and the total 
acquisition time was 20 min for each dog. Camera and table positioning were recorded to 
ensure optimal intra-individual comparison.  
Processing protocol and data analysis 
Images were reconstructed using a dedicated ordered subset-expectation maximization 
(OSEM) algorithm (nine iterations, five subsets) (Scivis) and a Butterworth filter was 
applied (order 5, cut-off frequency 2.5 cycles/cm). The individual dog’s perfusion images 
were automatically registered to a previously created template, generated from the same 
10 dogs before implantation of the VNS system using BRASS software (Brain 
Registration and Automated SPECT Semi-quantification, Nuclear diagnostics). Using this 
automated registration method, a compensation for size and shape differences was 
applied. The regional brain activity was quantified based on a predefined region map 
consisting of 19 volumes of interest (VOIs): left and right frontal, temporal, parietal, 
piriform and occipital cortical regions (LF, RF, LT, RT, LP, RP, LPi, RPi, LO, RO); left 
and right thalamus (LTh, RTh), hippocampus (LHi, RHi) and corpus striatum (LCs, RCs); 
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the cerebellum (CER), the olfactory bulbs (BO) and the brainstem (BS) (Martlé et al., 
2013). A routinely used semi-quantification procedure (BRASS, Hermes, Nuclear 
Diagnostics) was employed to calculate the counts and voxels of every VOI. Perfusion 
indices (PIs), representing the regional perfusion in every VOI, were calculated by 
normalizing the counts/voxel of each VOI to the counts/voxel of the whole brain (all 
VOIs). Additionally, a rostro-caudal gradient, an asymmetry index and a cortical-
subcortical index were calculated for each µ-SPECT study, as previously defined (Martlé 
et al., 2013).  
The optimal stimulation currents used for standard and microburst VNS were statistically 
compared using a paired T-test. Statistical analysis was based on a mixed model with 
period and condition as fixed effects and dog as random effect. The two VNS conditions 
(standard and microburst) were compared pairwise with sham using Dunnett’s multiple 
comparisons technique. For these comparisons with control adjusted P-values are 
reported. Global level of significance was set at P < 0.05 and data are presented as mean 
± standard deviation (SD).  
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Results 
 
The MRI of the brain was normal in all dogs. During surgical implantation of the VNS 
device no changes in heart rate and rhythm on ECG or other complications were noted. 
Testing of the lead impedance of the device was normal during surgery (mean: 972 ± 170 
Ohms, normal range: 200-7000 Ohms) and within 48 hours after surgery (mean: 790 ± 62 
Ohms) in all dogs. Also, no ECG changes were noticed at that time.  
One dog had to be excluded from the study because of the development of an irreversible 
Horner’s syndrome 22 days after the surgery. So eventually, nine dogs participated in the 
study. Only mild, transient post-operative complications such as seroma formation at the 
site of surgery (7 dogs) and hoarseness (1 dog) were noticed. All dogs tolerated the VNS 
very well and no side effects were detected during stimulation. 
The stimulation parameters that were used for the VNS were fixed except for the 
stimulation output current which was individually determined. The optimal output current 
used for standard VNS ranged between 0.375 and 1 mA (mean ± SD: 0.639 ± 0.190 mA) 
and for microburst VNS a range between 0.250 and 1 mA (mean ± SD: 0.625 ± 0.220 
mA) was used. No significant difference was found between the optimal output currents 
used in the two different conditions (P = 0.68).  
Table 1 represents the PIs of the different VOIs for the three stimulation conditions. 
Acute standard VNS did not cause significant regional brain perfusion alterations. Acute 
microburst VNS caused a significant hypoperfusion in the left frontal lobe (P = 0.023) 
and in the right parietal lobe (P = 0.035). No significant effect of standard or microburst 
VNS was found on the R-C gradient, AI and Co-SCo index (Table 2).       
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Table 1: 
99m
Tc-ECD Perfusion Indices after sham (Sh), standard (St) and microburst (M) 
VNS in 9 dogs (represented as mean ± SD) 
VOI Sh St M 
BS 0.61 ± 0.11 0.61 ± 0.11 0.62 ± 0.11 
BO 0.74 ± 0.10 0.75 ± 0.08 0.76 ± 0.09 
CER 1.00 ± 0.03 1.01 ± 0.06 1.01 ± 0.03 
LPi 0.67 ± 0.09 0.65 ± 0.07 0.69 ± 0.07 
RPi 0.62 ± 0.08 0.63 ± 0.05 0.63 ± 0.06 
LT 1.08 ± 0.03 1.07 ± 0.03 1.07 ± 0.03 
RT 1.02 ± 0.04 1.03 ± 0.04 1.02 ± 0.03 
LF 1.08 ± 0.04 1.07 ± 0.06 1.06 ± 0.04
*
 
RF 0.98 ± 0.04 1.00 ± 0.03 0.99 ± 0.03 
LO 1.20 ± 0.07 1.19 ± 0.06 1.19 ± 0.06 
RO 1.20 ± 0.07 1.20 ± 0.05 1.19 ± 0.06 
LP 1.25 ± 0.03 1.25 ± 0.03 1.24 ± 0.03 
RP 1.23 ± 0.05 1.22 ± 0.02 1.21 ± 0.04
*
 
LHi 0.97 ± 0.06 1.00 ± 0.06 0.97 ± 0.04 
RHi 0.95 ± 0.07 0.97 ± 0.06 0.93 ± 0.04 
LTh 1.15 ± 0.05 1.14 ± 0.05 1.13 ± 0.04 
RTh 1.07 ± 0.05 1.06 ± 0.03 1.07 ± 0.04 
LCs 1.13 ± 0.05 1.13 ± 0.04 1.15 ± 0.05 
RCs 1.10 ± 0.03 1.12 ± 0.05 1.11 ± 0.06 
 
VOI = volume of interest, BS = brainstem, BO = olfactory bulbs, CER = cerebellum, LPi 
= left piriform cortex, RPi = right piriform cortex, LT = left temporal cortex, RT = right 
temporal cortex, LF = left frontal cortex, RF = right frontal cortex, LO = left occipital 
cortex, RO = right occipital cortex, LP = left parietal cortex, RP = right parietal cortex, 
LHi = left hippocampus, RHi = right hippocampus, LTh = left thalamus, RTh = right 
thalamus, LCs = left corpus striatum, RCs = right corpus striatum 
*
 significant difference with sham control, adjusted P-value lower than 0.05 
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Table 2: Rostro-caudal gradients (R-C), asymmetry indices (AI) and cortical-subcortical 
indices (Co-SCo) after sham (Sh), standard (St) and microburst (M) VNS in 9 dogs 
(represented as mean ± SD) 
 Sh St M P 
St vs. Sh 
P 
M vs. Sh 
R-C -7.72 ± 2.53 -7.07 ± 1.90 -7.10 ± 1.97 0.69 0.72 
AI -5.30 ± 2.58 -3.90 ± 2.60 -4.43 ± 3.39 0.35 0.64 
Co-SCo 99.40 ± 4.55 98.74 ± 3.67 99.14 ± 3.53 0.73 0.95 
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Discussion 
 
This 
99m
Tc-ECD µ-SPECT study investigated the effect of acute standard and microburst 
VNS on the regional brain perfusion in dogs. A hypoperfusion in the left frontal and right 
parietal cortex was found after microburst VNS whereas acute standard VNS did not 
elicit changes in rCBF.  
Interestingly, microburst VNS, which could be a promising new stimulation paradigm, 
seems to have more potency than standard VNS to induce SPECT changes in the brain of 
normal dogs. The reason to develop and use microburst stimulation is mainly based on 
the phenomenon of paired-pulse facilitation, meaning that two stimulations of a 
presynaptic terminal within a short period of time result in a larger evoked synaptic 
response to the second stimulation (Zucker and Regehr, 2002). In primate studies to map 
evoked potentials in the thalamus, paired-pulse stimulations of the vagus nerve at 300 Hz 
frequency produced multi-unit discharges at central vagal targets, particularly within the 
parafascicular and basal ventromedial nucleus of the thalamus (Ito and Craig, 2005, 
2008). Further, in a study to map vagal-evoked single-unit activity in the monkey 
thalamus, it was reported that the probability of producing an evoked response increased 
as the number of high frequency stimulation pulses was increased from single, paired to 
triple stimuli (Hallowitz and MacLean, 1977). Therefore, it can be expected that short 
bursts of stimulation of the vagus nerve (“microbursts”) are more potent to influence 
central effectors of VNS and could possibly be associated with a stronger antiepileptic 
effect than standard VNS. A recent study in the rat kindling model suggested that 
microburst stimulation may indeed be an improved stimulation paradigm (Alexander and 
McNamara, 2012). Based on our results, further research to investigate the antiepileptic 
effect of microburst VNS in dogs with spontaneous epilepsy or in canine seizure models 
is warranted. 
Unexpectedly, no significant rCBF alterations were induced using standard VNS 
parameters. Possibly, the duration of the stimulation was too short, although SPECT or 
PET changes have been detected even after a shorter period of VNS using standard 
parameters in rats and humans (Garnett et al., 1992; Henry et al., 1998; Ring et al., 2000; 
Van Laere et al., 2002, Barnes et al., 2003; Dedeurwaerdere et al., 2005b; Vonck et al., 
2008). Still, it would be interesting to assess the chronic effects of VNS on the rCBF in 
dogs. Although the actual effect of VNS in healthy subjects could be evaluated in this 
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study, the possible different reaction to VNS between an epileptic and a healthy brain 
must be taken into account as well. Finally, it also has to be acknowledged that the power 
of this study could have been too low to show effects of standard VNS. 
Several SPECT and PET studies of the brain have already been performed in humans 
with epilepsy and their general conclusion is that VNS causes changes in anatomic 
structures that are part of the afferent vagus nerve pathways (Boon et al., 2002; Chae et 
al., 2003). More specifically, changes in the thalamus and limbic structures are the most 
consistent findings (Garnett et al., 1992; Ko et al., 1996; Henry et al., 1998, 1999; Ring et 
al., 2000; Vonck et al., 2000; Van Laere et al., 2002; Barnes et al., 2003; Vonck et al., 
2008). However, a lot of disagreement exists regarding other activated structures and the 
type of change (hypo- or hyperperfusion). Surprisingly, neither standard nor microburst 
VNS caused significant changes in the thalamic or hippocampal region in dogs. These 
discrepancies could be due to different confounding factors (Dedeurwaerdere et al., 
2005b). An important one is that previous studies in human epileptic patients could not 
always exclude the effect of seizures or previous resective surgery on SPECT or PET 
results, with the thalamus and limbic system often involved in seizure activity as well 
(Henry et al., 1990; Yune et al., 1998; Boon et al., 2002). Also in dogs with idiopathic 
epilepsy, interictal SPECT changes have been demonstrated, especially in the subcortical, 
thalamic region (Martlé et al., 2009). Therefore, we decided to evaluate the effect of VNS 
in healthy dogs that did not suffer from epilepsy or other neurological diseases. A pilot 
study investigating PET changes induced by VNS in healthy rats described significant 
changes mainly in the hippocampus of the rats, but the thalamus was not involved 
(Dedeurwaerdere et al., 2005b). A lot of other factors can be responsible for the variation 
across different studies such as species differences, differences in methodology and study 
design in general. In contrast with humans, where the electrodes for VNS are positioned 
around the vagus nerve, in dogs these electrodes are placed around the vagosympathetic 
trunk as a whole as in the cervical region both nerves are fused. It cannot be excluded that 
this additional sympathetic stimulation influenced the results of our study. More 
specifically, VNS related (stimulation parameters and duration of stimulation) and 
imaging related factors (imaging modality, type of tracer, image acquisition and analysis) 
are difficult to compare between different studies as well. Unfortunately, there is not a 
single consistent way of analyzing functional brain images and very different approaches 
have been used to process VNS – SPECT/PET data. Some studies used VOI analysis 
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(Henry et al., 1998, 1999; Ring et al., 2000; Vonck et al., 2000; Van Laere et al. 2002; 
Vonck et al., 2008), as in our study, but others were based on statistical parametric 
mapping (SPM) (Garnett et al., 1992; Barnes et al., 2003) or voxel-based analysis (Ko et 
al., 1996). Finally, previous functional brain imaging studies in humans did not use 
microburst VNS as a stimulation paradigm, which makes a comparison difficult.  
In our study, a significant hypoperfusion was found after acute microburst VNS in two 
cortical regions (the left frontal and right parietal lobe). Several human studies, 
investigating the effect of acute VNS on the rCBF in people with epilepsy or depression, 
detected similar involvement of the frontal and parietal lobes (Henry et al., 1998; Barnes 
et al., 2003; Conway et al., 2006). VNS induced PET changes in the parietal lobes were 
also detected by Ko et al. (1998, 1999) and a fMRI study performed during VNS in 4 
human patients with intractable partial seizures described an activation of the frontal and 
parietal structures bilaterally (Sucholeiki et al., 2002). It cannot be concluded from our 
study if these cortical rCBF changes are involved in the antiepileptic MOA of VNS, but it 
seems reasonable that suppression of the regional perfusion and so indirectly of the 
neuronal activity (Roy and Sherrington, 1890) in certain cortical regions could have a 
seizure suppressing effect.  
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Conclusion 
 
Acute microburst VNS suppresses the regional perfusion in the frontal and parietal cortex 
in normal dogs. These findings support further research into the antiepileptic effect of this 
stimulation paradigm both in humans and dogs. 
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Summary 
 
Vagus nerve stimulation (VNS) is an established treatment for refractory epilepsy in 
humans, but the precise mechanism of action (MOA), predictive responsive factors and 
the optimal stimulation parameters remain to be elucidated. 
We aimed to investigate the effect of two VNS paradigms on cerebrospinal fluid (CSF) 
neurotransmitter levels and on the seizure threshold in the canine pentylenetetrazole 
(PTZ) model. 
Eight Beagle dogs, implanted with a VNS Therapy
®
 System, participated in a cross-over 
study. Levels of serotonin (5HT), norepinephrine (NE) and dopamine (DA) were 
quantified in the CSF after one hour of sham, standard and microburst VNS with a wash-
out period of 1 month. One week later, the PTZ seizure threshold was determined. As a 
positive control, the PTZ seizure threshold was determined after a single oral dose of 
phenobarbital (PB).  
Standard and microburst VNS caused a significant increase of NE levels in the CSF (P = 
0.03 and P = 0.02 respectively). No significant changes in 5HT or DA levels were 
detected. Standard and microburst VNS did not cause significant changes in the PTZ 
seizure threshold compared to sham. PB caused an increase in the PTZ threshold 
compared to baseline (P < 0.001). 
VNS induces an increase of NE in the canine brain, which supports previous findings 
indicating that the MOA of VNS is mediated by the locus coeruleus-norepinephrine 
(LC/NE) system. Importantly, this study demonstrates that this increase in NE is 
measurable in the CSF. One hour of VNS did not affect seizure threshold in the canine 
PTZ model. Therefore, the role of NE in the antiepileptic effect of VNS in dogs remains 
to be elucidated. 
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Introduction 
 
Vagus nerve stimulation (VNS) often leads to a considerable reduction in seizure 
frequency in patients with refractory epilepsy (Ben-Menachem, 2002). However, 
approximately one third of implanted patients does not respond to even long-term 
treatment with VNS (DeGiorgio et al., 2000). Since the antiepileptic mechanism of action 
(MOA) of VNS is not fully understood, no rational hypotheses can be derived to help 
identify predictive factors for clinical response. Also, the currently applied stimulation 
parameters are not evidence-based. Further elucidation of the MOA could lead to an 
improvement of VNS efficacy by identifying early biomarkers for response or biomarkers 
for optimized stimulation paradigms.  
 
Studies in rats have demonstrated neurotransmitter changes induced by VNS in specific 
brain structures using microdialysis (Hassert, et al., 2004; Roosevelt et al., 2006; Follesa 
et al., 2007; Raedt et al., 2011; Manta et al., 2013) and the most consistent finding was a 
local increase in extracellular norepinephrine (NE) levels of the hippocampus (Roosevelt 
et al., 2006; Raedt et al., 2011; Manta et al., 2013), amygdala (Hassert et al., 2004) or 
prefrontal cortex (Follesa et al., 2007; Manta et al., 2013). Other studies measured 
neuronal firing rates in the LC, a nucleus in the brainstem that sends noradrenergic input 
to many levels of the central nervous system, to investigate the effect of VNS on the 
noradrenergic system (Dorr and Debonnel, 2006; Manta et al., 2009). Importantly, it was 
shown in rats that the LC/NE system is not only activated by VNS, but that its activation 
and concurrent increased NE levels correlate with the antiepileptic effects of VNS (Krahl 
et al., 1998; Raedt et al., 2011). Although these studies have revealed important clues 
about the role of NE in the antiepileptic MOA of VNS, they currently cannot be translated 
into a clinically applicable strategy in patients to screen for optimal VNS candidates or 
optimal stimulation parameters. In this context, it is useful to investigate whether VNS 
induces neurotransmitter changes in the CSF and whether these changes can be correlated 
with an antiepileptic effect. To examine the relevance of certain neurotransmitter changes 
as biomarkers, it is important that the antiepileptic effect of VNS is simultaneously 
evaluated in the same group of animals. 
 
At this moment, the optimal VNS parameters remain unknown and the standard 
stimulation parameters used for VNS are rather empirical (Fanselow, 2012). There is a 
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continuous search for more effective stimulation paradigms and in this study, a recently 
developed experimental stimulation paradigm, called microburst VNS, is evaluated and 
compared to standard VNS. The rationale of the microburst stimulation is that multiple 
stimulations within a short time period could induce a more robust synaptic response at 
central vagal targets (Ito and Craig, 2005, 2008; Alexander and McNamara, 2012). The 
antiepileptic capability of microburst VNS in humans and dogs has not yet been 
described. 
 
The aim of this study was (1) to evaluate neurotransmitter changes in the CSF of dogs 
after one hour of standard and microburst VNS and (2) to assess whether these 
stimulation paradigms induce changes in the PTZ seizure threshold in the same dogs.  
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Materials & Methods 
 
Animals 
Eight healthy male castrated Beagle dogs, aged between 3 and 3.5 years old, weighing 13 
to 18 kg were included in this study. The dogs had no history of neurological or other 
diseases. They had a VNS Therapy
®
 System
a
 implanted in the left cervical region under 
general anesthesia. This study was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University (EC 2011-160). All guidelines for animal welfare, 
imposed by the Ethical Committee, were respected. The dogs were habituated to the VNS 
activation/deactivation procedure and to the examination room. 
VNS stimulation parameters  
For this study, acute VNS was defined as 1 hour of intermittent active stimulation. To 
achieve adequate duty cycles during this short period of stimulation it was chosen to give 
rapid-cycling stimulation, meaning an on-time of stimulation of 7 seconds and an off-time 
of 18 seconds. Two types of active stimulation (standard and microburst VNS) and a 
sham stimulation were given to each dog. The microburst VNS is an experimental 
stimulation paradigm where electrical stimuli are delivered in small bursts instead of 
single pulses as in standard VNS. Stimulation parameters used for the standard VNS 
included a pulse width of 500 µs and a frequency of 30 Hz. Stimulation parameters used 
for microburst VNS included a pulse width of 500 µs, a frequency of 300 Hz, 3 
pulses/burst and an inter-burst interval of 0.4 s. The stimulation output current was 
individually determined during a ramping-up procedure (with increments of 0.125 mA) 
and was defined as the highest current for which no cough was elicited, similar as in a 
previous canine VNS study (Muñana et al., 2002). This output current was checked on a 
weekly basis and adapted when necessary. For the sham stimulation the animals 
underwent the same procedures as with active VNS stimulation except that the output 
current was set at 0 mA. 
Experimental design (Figure 1) 
In a first cross-over study, three cisternal CSF samples were obtained from each dog 
following three different acute VNS paradigms (one hour of sham, standard or microburst 
VNS). One week after each CSF tap, a PTZ experiment was performed following the 
same acute stimulation paradigm. The order of stimulation paradigms was randomized in 
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each dog and blinded for the persons evaluating the PTZ experiments. A wash-out period 
of 1 month was respected between consecutive CSF taps and between successive PTZ 
experiments. The VNS was administered to awake and freely moving dogs.  
 
In a second cross-over experiment and as a positive control of our canine PTZ model we 
determined the PTZ threshold after a single oral dose of PB (20 mg/kg) and compared it 
to the baseline PTZ threshold in each dog. 
 
 
 
Figure 1: Timeline to demonstrate the experimental design of the VNS cross-over study 
(A) and the phenobarbital (PB) cross-over study (B). The order of the 3 different 
stimulation paradigms (sham, standard and microburst VNS) was randomized in each 
dog. Also, the order of baseline or post-PB PTZ threshold determination was randomized 
in each dog 
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VNS – CSF experiment 
Before the start of the experiment a catheter was placed in the cephalic vein and the dogs 
were allowed to relax for five minutes. Then, the VNS Therapy System was activated 
(standard or microburst VNS) or pseudo-activated (sham stimulation) for 60 minutes. 
During this time the dogs were awake, able to move around in the examination room and 
under direct supervision. After one hour, the VNS was stopped and the dogs were sedated 
with butorphanol
b
 (0.3 mg/kg IV). Ten minutes later general anesthesia was induced with 
intravenous propofol
c
 (2-6 mg/kg to effect) and a CSF tap was performed at the 
cerebellomedullary cistern with the dog positioned in right lateral recumbence.  
CSF analysis 
An antioxidant solution (50 µl) containing 100 mM acetic acid, 3.3 mM L-cysteine, 0.27 
mM disodium edetate and 12.5 µM ascorbic acid was added to the CSF (200 µl) to 
preserve the monoamines. All samples were stored at – 80°C until liquid chromatography 
(LChr) analysis.  
 
The LChr system consisted of a temperature-controlled (15°C) FAMOS autosampler
d 
with a sample loop injection volume of 10 µL, a Dionex DEGASYS DG-1210 degasser, a 
307 Gilson piston pump and a DECADE II electrochemical detector with a µ-VT03 flow 
cell (0.7 mm glassy carbon working electrode, 25 µm spacer)
e
. The detection potential 
was set at + 450 mV versus a Ag/AgCl reference electrode. The mobile phase was a 
mixture of 89% V/V aqueous buffer solution (100 mM sodium acetate trihydrate, 20 mM 
citric acid monohydrate, 2 mM sodium decanesulfonate, 0.5 mM disodium edentate, pH 
5.5) and 11% V/V acetonitrile. The flow rate of the mobile phase was set at 60 µL/min. 
The stationary phase consisted of a microbore UniJet C8 column (100 x 1.0 mm, 5 µm)
f
 
on which separation of the monoamines was performed at 35°C. Data acquisition was 
carried out by specific software
g
. 
VNS – PTZ experiment 
One week later and similarly as for the CSF experiments, a catheter was placed in the 
cephalic vein and the dogs were allowed to relax for five minutes before the start of the 
experiment. Then, the VNS Therapy System was activated (standard or microburst VNS) 
or pseudo-activated (sham stimulation). During VNS, the dogs were awake, able to move 
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around in the examination room and under direct supervision. After 55 minutes of 
stimulation, the dogs were placed on a table and an IV line for PTZ infusion was 
connected to the catheter. After 60 minutes of VNS, an infusion of 3% PTZ in 0.9% NaCl 
was started and delivered at a constant rate of 3 ml/min using a syringe pump
h
, following 
a previously described protocol (Löscher et al., 2004). At the moment of the first whole 
body myoclonic twitch, the infusion was immediately stopped and a diazepam
i
 bolus (1 
mg/kg IV) was administered to avoid generalization or repetition of the myoclonic twitch. 
However, when generalization of the seizure occurred, it was controlled with a bolus of 
propofol
 
(2-3 mg/kg IV). VNS continued during the PTZ infusion and was stopped after 
the administration of the diazepam bolus. The dogs were monitored for additional 
seizures the first 24 hours after each PTZ experiment. 
Phenobarbital – PTZ experiment 
An additional cross-over positive control experiment was performed in which the PTZ 
threshold was determined after a single oral dose of PB
j
 and compared with the baseline 
PTZ threshold (without PB). In each dog, both PTZ threshold determinations were 
performed in a randomized order with a wash-out period of three weeks to ensure 
sufficient clearance of PB. PB was administered orally (20 mg/kg) and 3 hours post 
dosage administration (= approximate tmax) a blood sample for serum concentration 
monitoring was taken and the PTZ infusion was started. At the moment of the first whole 
body myoclonic twitch the PTZ infusion was stopped and a diazepam bolus (0.2 mg/kg 
IV) was administered.  
PTZ threshold determination 
For each PTZ experiment, the PTZ threshold was defined as the amount of PTZ (in 
mg/kg) required to provoke the first whole body myoclonic twitch. The exact moment of 
the first whole body myoclonic twitch after the start of the infusion was determined by 
post-experimental video analysis by two blinded observers. As a fixed concentration and 
infusion rate of PTZ was used, the threshold dose of PTZ could then be calculated.  
Statistical analysis 
The output currents used for standard and microburst VNS were statistically compared 
using a paired T-test. The different stimulation paradigms were compared with respect to 
CSF and PTZ results using a mixed model with period and stimulation paradigm as fixed 
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effects and dog as random effect and were tested at the 5% significance level. CSF and 
PTZ results for the two VNS conditions (standard and microburst) were compared 
pairwise with sham using Dunnett’s multiple comparisons technique and adjusted P-
values for these multiple comparisons are reported.  
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Results 
 
No obvious side effects of the VNS were noticed. In one dog, muscle tremors or spasms 
of the left front limb were noticed during the on-time of stimulation. The output current 
used for standard VNS ranged between 0.250 and 1.250 mA (mean ± SD: 0.516 ± 0.289 
mA) and for microburst VNS a range between 0.250 and 1.125 mA (mean ± SD: 0.500 ± 
0.250 mA) was used. No significant difference was found between the output currents 
used in the two different conditions (P = 0.35). 
 
The results for the CSF neurotransmitter levels are presented in Table 1. Both standard 
and microburst VNS caused a significant increase of NE levels in the CSF (p = 0.03 and p 
= 0.02, respectively) (Figure 2A). This increase was noticed in six dogs (75%) and a 
mean increase in NE of 45% and 44% was achieved after standard and microburst VNS 
respectively. In the dog where the muscle tremors of the left thoracic limb were noticed 
during VNS, NE levels were not increased. No significant alterations in DA or 5HT levels 
were detected in the CSF after acute standard or microburst VNS. 
 
Table 1: Mean (± SD) CSF monoamine concentrations (in nM) after the 3 different 
stimulation paradigms (n=8) 
Monoamine Sham Standard Microburst 
DA 0.143 (± 0.078) 0.190 (± 0.135) 0.222 (± 0.170) 
NE 0.366 (± 0.096) 0.499 (± 0.125)* 0.481 (± 0.148)* 
5HT 0.744 (± 0.398) 0.947 (± 0.972) 0.604 (± 0.155) 
SD = standard deviation, nM = nanomolair, DA = dopamine, NE = norepinephrine, 5HT 
= serotonin; * significant difference with sham control, adjusted P-value lower than 0.05 
 
 
In the PTZ experiment, the appearance of the first clinically observable whole body 
myoclonic twitch was similar within each dog. The PTZ thresholds were not significantly 
different after acute standard or microburst VNS compared to sham (Figure 2B). The PTZ 
threshold after a single oral dose of PB was significantly increased compared to the 
baseline PTZ threshold (P < 0.001) with a mean increase of 63% (Figure 3). The serum 
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concentration of PB was situated within the therapeutic range (20–45 µg/ml, (Farnbach, 
1984)) in all dogs. Secondary generalization of the myoclonic twitch was noticed during 5 
of the 24 VNS – PTZ experiments in 3 dogs and during 4 of the 16 PB – PTZ 
experiments in 3 dogs. The 3 dogs experiencing a generalized seizure were not the same 
animals each time except for one dog whose whole body myoclonic twitch evolved into a 
generalized tonic-clonic seizure in each PTZ experiment. No additional seizures were 
seen during the 24 h monitoring period after each experiment. 
 
 
Figure 2: Graphical representation of the CSF NE levels (nM) (mean ± SD) (A) and the 
PTZ seizure thresholds (mean ± SD) (B) after acute sham, standard and microburst VNS 
*Significant difference with sham control (P < 0.05) 
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Figure 3: Graphical representation of the PTZ seizure threshold (mean ± SD) after PB 
administration (post PB) compared to the baseline threshold.  
*Significant difference with sham control (P < 0.05) 
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Discussion 
 
The first objective of our study was to assess whether acute VNS results in 
neurotransmitter changes measurable in the CSF of a dog model. Dogs were used in this 
study, since the use of this animal model for translational research may have certain 
advantages. First of all, the collection of CSF in dogs is a standard procedure with few 
complications when performed by an experienced veterinary neurologist (Cook and 
DeNicola, 1988). Although CSF can be collected in rodents as well, it leads more often to 
blood contamination, neurological complications and only a small amount of fluid can be 
collected compared to dogs (Pegg et al., 2010). Secondly, the prevalence and semiology 
of naturally occurring canine epilepsy are comparable to human epilepsy (Chandler, 
2006) which renders translational research for new epilepsy treatments in a canine model 
justified. Also from a veterinary point of view, research towards non-pharmacological 
treatments for refractory canine epilepsy is needed (Martlé et al., 2014, Muñana et al., 
2013). Finally, the canine PTZ model, in which a myoclonic twitch is induced in healthy 
dogs by intravenous infusion of the chemical convulsant pentylenetetrazole has been well 
described previously (Löscher et al., 2004, 2013) and the same protocol was used in this 
study. 
 
In this study, a significant increase of NE was detected in the canine CSF after one hour 
of VNS. Also in rats VNS activates the LC/NE system (Hassert, et al., 2004; Dorr and 
Debonnel, 2006; Roosevelt et al., 2006; Follesa et al., 2007; Manta et al., 2009; Raedt et 
al., 2011; Manta et al., 2013). Activation of the LC/NE system has a crucial role in the 
seizure-suppressing effect of VNS (Krahl et al., 1998; Raedt et al., 2011). In a rat model 
for limbic seizures, VNS-induced increase of hippocampal NE levels is a biomarker for 
the antiepileptic efficacy of VNS (Raedt et al., 2011). Despite this valuable information, 
these studies used microdialysis or extracellular unitary recordings in specific brain 
structures. However, these invasive techniques are not practical to use in patients as a 
screening tool for responsiveness to VNS. Collection of CSF on the other hand is a less 
invasive and standard procedure which could be performed in potential VNS candidates 
after a short period of, for example, external stimulation of the vagus nerve (Stefan et al., 
2012). Until now, only little is known about the influence of VNS on CSF 
neurotransmitters. Two studies evaluated the effect of chronic VNS on certain CSF 
metabolites in human epileptic patients (Hammond et al., 1992; Ben-Menachem et al., 
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1995). However, NE levels were not measured in these studies. To our knowledge, NE 
levels in the CSF were only investigated in depressed patients before and after two 
months of VNS and no significant alteration was demonstrated (Carpenter et al., 2004). 
As our study demonstrates that VNS induces an increase of NE detectable in the CSF of a 
dog model, it supports also further research towards non-invasive biomarkers of NE 
increase in humans. Recently, it was shown that VNS induces an increase of the P300 
amplitude, a non-invasive marker of LC/NE activity in humans and that this increase was 
correlated with a positive response to therapy (De Taeye et al., 2014). 
 
A second important aim of this study was to assess the antiepileptic effects of acute VNS 
in the same canine subjects. However, no significant increases of the PTZ seizure 
threshold after one hour of standard or microburst VNS could be demonstrated in this 
canine PTZ model. Our model was validated by a positive control test with PB, a 
clinically established antiepileptic drug in dogs (Farnbach, 1984). A significant increase 
of the PTZ threshold of 63% was found in our dogs after a single oral dose of PB (20 
mg/kg) compared to baseline, which is in correspondence with the increase of 83% 
detected by Löscher et al. (2013). 
 
One could argue that VNS is possibly not able to exert anticonvulsive effects against 
PTZ-induced seizures. Nevertheless, Zabara (1992) has shown an acute abortive effect of 
VNS on PTZ induced convulsions in two dogs and in the rat PTZ model a positive effect 
of VNS on seizure severity has been demonstrated by several research groups (Takaya et 
al., 1996; Krahl et al., 2001, 2003; Zhang et al., 2008; Sahin et al., 2009).
  
 
In our study, the prophylactic anticonvulsive property of one hour of VNS was evaluated; 
this timing was based on a rat PTZ study where one hour of VNS was sufficient to induce 
antiepileptic effects (Takaya et al., 1996). To increase the number of pulses delivered to 
the nerve during this short period of stimulation, we decided to use a rapid-cycling 
stimulation protocol instead of the 5 minutes off – 30 seconds on intermittent stimulation 
most often used in a clinical setting. Despite the use of this stimulation protocol, one hour 
of VNS may have been too short to lead to an antiepileptic effect in dogs, certainly 
because it is known from human studies that the effectiveness of VNS improves over time 
(Morris and Mueller, 1999; Vonck et al., 1999; Ben-Menachem, 2002; Boon et al., 2002). 
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It would be interesting to evaluate the antiepileptic effects of chronic VNS and to see 
whether correlations exist with acute changes in NE CSF levels within the same subjects.  
 
It is also possible that VNS could be less effective in dogs than in humans. Studies 
investigating the antiepileptic effect of VNS in dogs are limited and performed on a small 
number of dogs (Zabara, 1992; Speciale and Stahlbrodt, 1999; Muñana et al., 2002), 
however, they have shown some antiepileptic effectiveness. Zabara (1992) demonstrated 
an acute abortive effect on chemically induced seizures in dogs. Furthermore, some dogs 
with spontaneous refractory epilepsy, implanted with a similar VNS device as in humans, 
seemed to respond to VNS (Muñana et al., 2002).  
 
In our study, it was demonstrated that microburst VNS, a recently developed 
experimental stimulation paradigm, is as potent as standard VNS to induce an increase in 
NE levels in the canine CSF. The rationale of microburst stimulation is mainly based on 
the phenomenon of paired-pulse facilitation, meaning that two stimulations of a 
presynaptic terminal within a short period of time result in a larger evoked synaptic 
response to the second stimulation (Zucker and Regehr, 2002). Hence, it has been shown 
that multiple stimulations of the vagus nerve within a short period of time evoked a larger 
response at central vagal targets (Ito and Craig, 2005, 2008). Therefore, it can be expected 
that short bursts of stimulation of the vagus nerve (“microbursts”) are more potent in 
affecting central mediators of VNS and could possibly be associated with a stronger 
antiepileptic effect compared to standard VNS. A recent study in the rat kindling model 
suggested that microburst stimulation may indeed represent an improved stimulation 
paradigm (Alexander and McNamara, 2012). In our study, the effects of microburst and 
standard VNS on CSF neurotransmitter levels and PTZ thresholds are comparable. 
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Conclusion 
 
To the author’s knowledge, this is the first study describing a significant increase in NE in 
the canine CSF after two different VNS paradigms, which further supports that the LC-
NE system is involved in the MOA of VNS. However, no immediate antiepileptic effect 
of acute VNS could be demonstrated in this canine PTZ model. Considering the important 
protective role of NE in seizures, further research on this VNS induced NE increase in the 
CSF is recommended, both in dogs and humans. 
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Summary 
 
Vagus nerve stimulation (VNS) is an established treatment for epilepsy and depression in 
human patients. Both in humans and dogs, the optimal stimulation parameters remain 
unknown. Delivering afferent bursts of stimulation may be promising to increase efficacy, 
but requires evaluation of potential effects on the heart due to unavoidable efferent 
stimulation. The present study investigated heart rate variability in healthy Beagle dogs 
treated with 1 hour of sham, standard or microburst left-sided VNS in a cross-over design. 
No significant differences were found between the stimulation paradigms for any of the 
cardiac parameters. Short-term left-sided VNS, including a novel bursting pattern 
(microburst VNS), had no effect on the heart rhythm in ambulatory healthy dogs. Studies 
in a larger number of animals with long-term VNS are recommended.  
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Introduction 
 
VNS is an effective treatment for human epilepsy and depression with the vagus nerve 
providing a unique entrance to the brain (Beekwilder and Beems, 2010). The optimal 
stimulation parameters for VNS are unknown (Ben-Menachem, 2012). There is a 
continuous search for more effective stimulation paradigms and in this study, the 
influence on the heart of a recently developed experimental stimulation paradigm, called 
microburst VNS, is evaluated and compared to standard VNS in dogs. 
 
This study is part of a research project investigating the effects of VNS on the canine 
brain. The primary aim of this study was to screen for possible cardiac side effects of 
acute VNS. The initial goal was not to affect the heart, so therefore the VNS system was 
implanted on the left side with the electrode contacts placed in an orientation that 
primarily aims at activating afferent cervical vagal fibers, required for central nervous 
system effects in treating disorders like epilepsy.  
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Materials & Methods 
 
Nine Beagle dogs, aged between 1.5 and 2 years, implanted with a VNS Therapy
®
 
System in the left cervical region participated in this randomized, sham-controlled, cross-
over study. Holter monitoring was performed during 55 minutes of sham, standard and 
microburst VNS in each dog. Stimulation parameters used for both VNS paradigms are 
summarized in Table 1. The optimal stimulation output current was individually 
determined during a ramping-up procedure and was set subthreshold for coughing. To 
achieve maximum stimulation on-time during the 55 minutes of VNS, the rapid duty 
cycle of the VNS therapy system (7s on and 18s off time) was used. In the sham 
stimulation condition, the animals underwent similar procedures except that the output 
current was set at 0 mA.  
 
Table 1: The stimulation parameters used in this study for intermittent standard and   
microburst VNS 
Standard VNS Microburst VNS 
Signal frequency (Hz) 30 Signal frequency (Hz) 300 
Pulse duration (µs) 500 Pulse duration (µs) 500 
Signal on-time (s) 7 Number of pulses/burst 3 
Signal off-time (s) 18 Interburst interval (s) 0.4 
  Burst on-time (s) 7 
  Burst off-time (s) 18 
 
 
The Holter data were processed using specific software
a
. Since the dogs were handled in 
the beginning and at the end of the VNS session, the initial and final 10 minutes were not 
used for statistical analysis to avoid interference of stress or manipulation. So, for each 
experiment 35 minutes, corresponding to 84 duty cycles of VNS, were analyzed. The 
following parameters were determined: number of QRS, mean NN (mean normal to 
normal interval), SDNN (standard deviation of all normal to normal intervals), SDANN 
(standard deviation of the averages of NN intervals), rMSSD (square root of the mean of 
the sum of the squares of differences between adjacent NN intervals), pNN50 (numbers 
of pairs of adjacent NN intervals differing by more than 50 ms in the entire recording 
divided by the total number of all NN intervals), SDNNIDX (the mean of the standard 
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deviations of NN intervals of all 5 min segments in the entire recording), VLF Power 
(very low frequency power, < 0.04 Hz), LF Power (low frequency power, 0.04 – 0.15 
Hz), HF Power (high frequency power, 0.15 – 0.4 Hz). The low frequency/high frequency 
ratio (LF/HF) was used to quantify the sympathovagal balance as an indicator of 
autonomic modulation. A mixed model analysis was performed and Bonferroni correction 
was applied. 
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Results 
 
The Holter parameters during the 3 different stimulation paradigms are represented as a 
mean ± SD in Table 2. No significant differences were detected for any of the parameters 
between sham, standard or microburst VNS.  
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Table 2: Results of the different Holter parameters (represented as mean ± SD) during the 
3 stimulation paradigms (n=9). Also, the P-values of the pairwise comparison with sham 
stimulation are reported. 
Holter parameter Sham Standard Microburst P 
(St vs Sh) 
P 
(MB vs 
Sh)  
# QRS 3801 ± 632 3717 ± 472 3450 ± 461 1.00 0.18 
meanNN (ms) 567 ± 79 574 ± 77 619 ± 87 1.00 0.20 
SDNN (ms) 130 ± 42 151 ± 56 176 ± 71 1.00 0.11 
SDANN (ms) 41 ± 22 60 ± 38 75 ± 40 0.88 0.06 
SDNNIDX (ms) 119 ± 73 119 ± 29 159 ± 114 1.00 1.00 
rMSSD (ms) 92 ± 54 109 ± 57 132 ± 57 1.00 0.17 
pNN50 (%) 35 ± 19 38 ± 16 45 ± 15 1.00 0.22 
VLF Power (ms
2
) 6956 ± 4264 14336 ± 11976 15904 ± 11391 0.31 0.12 
LF Power (ms
2
) 4323 ± 4509 5413 ± 5271 9291 ± 14064 1.00 1.00 
HF Power (ms
2
) 4420 ± 3728 8629 ± 7926 8563 ± 6030 0.27 0.29 
LF/HF 1.1 ± 0.6 0.9 ± 0.5 1.0 ± 0.8 1.00 1.00 
 
St vs Sh: standard versus sham pairwise comparison; MB vs Sh: microburst versus sham 
pairwise comparison; # QRS: number of QRS; meanNN: mean NN interval; SDNN: 
standard deviation of all normal to normal intervals; SDANN: standard deviation of the 
averages of NN intervals; SDNNIDX: the mean of the standard deviations of NN 
intervals of all 5 min segments in the entire recording; rMSSD: square root of the mean of 
the sum of the squares of differences between adjacent NN intervals; pNN50: numbers of 
pairs of adjacent NN intervals differing by more than 50 ms in the entire recording 
divided by the total number of all NN intervals; VLF Power: very low frequency power; 
LF Power: low frequency power; HF Power: high frequency power; LF/HF: low 
frequency/high frequency ratio; ms: milliseconds 
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Discussion 
 
Acute left-sided standard and microburst VNS did not affect the heart rate variability in 
this group of healthy awake dogs. Given the important relationship of the vagus nerve to 
cardiac function, the potential occurrence of cardiac arrhythmias was a serious initial 
concern when using VNS to treat human refractory epilepsy (Asconape et al., 1999). 
Despite this initial concern, clinically relevant cardiac side effects are rarely noticed 
during left-sided VNS in humans. To avoid cardiac complications the left vagus nerve is 
usually chosen as it has less cardiac influence than the right nerve in humans and dogs 
(Kahlow and Olivecrona, 2013; Kamath et al., 1992; Munana et al., 2002; Spuck et al., 
2008). This can be explained by an asymmetrical vagal innervation of the heart: the right 
vagus nerve is more associated with the cardiac atria and innervates the sinoatrial node, 
whereas the left vagus nerve is more associated with the ventricles and innervates the 
atrioventricular node (Groves and Brown, 2005). Also, VNS therapy electrode contacts 
are placed in an orientation (negative pole rostral) that primarily activates afferent 
cervical vagal fibres. Furthermore, electrodes are placed at a location distally from the 
branching off of efferent cardiac vagal branches in humans in order to avoid stimulation 
of these fibres during VNS. However, it is impossible to completely avoid activation of 
efferent fibres, vagal cardiac branching may differ individually and bradycardia and 
asystole have been described anecdotally, mainly during the intraoperative testing of the 
device where anaesthesia appeared to play a major role. (Asconape et al., 1999; Schwartz, 
2011). 
 
Important anatomical differences exist between the human and canine cervical vagus 
nerve which, in theory, could also lead to differences in the cardiac influence of VNS. In 
dogs, the vagus nerve is fused with the sympathetic nerve in the cervical region, so the 
electrodes are wrapped around the vagosympathetic trunk. Furthermore, the cardiac 
branches leave the vagus nerve more distally in the thoracic region in dogs, so it is 
impossible to spare these branches when the electrodes are placed around the nerve 
(Muñana et al., 2002). One study reported intraoperative bradycardia in 30% of dogs 
(Muñana et al., 2002) which seemed quite high, but no cardiac side effects were reported 
in the non-anaesthetized dogs which is in agreement with our findings. A comparison of 
different stimulation protocols was not performed in this previous study. 
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The influence of microburst stimulation, a recently developed stimulation paradigm, on 
the heart has not been investigated previously. The rationale of the microburst stimulation 
is that multiple stimulations within a short time period could induce a more robust 
synaptic response at central vagal targets (Alexander and McNamara, 2012; Ito and Craig, 
2005, 2008). So, the possibility exists that this could also lead to a greater effect on the 
heart compared to standard VNS. No clinically relevant cardiac effects were found in our 
study that should be considered as a pilot trial with a relatively low number of dogs and 
short-term stimulation.   
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Conclusion 
 
Short-term left-sided standard and microburst VNS had no effect on the heart rhythm of 
healthy Beagle dogs, although larger and long-term VNS studies are warranted. 
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A major evolution occurred in both the diagnosis and therapy of human epilepsy during 
the past decades. The introduction of functional imaging modalities such as Single Photon 
Emission Computed Tomography (SPECT) and new therapeutic options such as vagus 
nerve stimulation (VNS) were important milestones. Despite this, the diagnostic accuracy 
of and therapeutic options for canine epilepsy remain limited. A better understanding of 
the pathophysiology of canine epilepsy could further improve the classification of this 
common disorder, and lead to the optimization of existing and the development of new 
therapeutic options. Furthermore, investigating canine epilepsy is not only useful from a 
veterinary point of view, but the epileptic dog can also serve as a translational animal 
model for human epilepsy (Löscher, 1997).  
This research project tries to address both diagnostic and therapeutic limitations of canine 
epilepsy. Therefore, it consisted of two parts addressing different research questions. In 
the first part, we investigated whether Single Photon Emission Computed Tomography 
(SPECT) could be a feasible technique to detect cerebral perfusion alterations in dogs 
with idiopathic epilepsy and if these alterations could be related to the origin of seizures. 
Furthermore, an attempt was made to improve the resolution of brain SPECT in dogs. In 
the second part, the effect of vagus nerve stimulation (VNS) on the canine brain was 
investigated in healthy Beagle dogs. Functional brain imaging, neurochemical and 
seizure-suppressing effects of VNS were examined in a canine model. Furthermore, a 
new burst type of stimulation (microburst) was compared with standard VNS. 
 
1. SPECT and canine idiopathic epilepsy 
 
In human medicine, functional brain imaging techniques can detect epileptogenic foci in 
morphologically unremarkable areas, and they are less invasive than intracranial 
electroencephalography (EEG) evaluation. Furthermore, these techniques can improve the 
understanding of the pathophysiology of epilepsy, as their unique ability to image in vivo 
changes in the brain has provided valuable insights into the mechanisms of 
epileptogenesis and seizure propagation in humans (la Fougère et al., 2009). Elucidating 
the neurobiology of canine epilepsy is essential to obtain a species specific, detailed 
classification system and an expansion of treatment options.  
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Following this rationale, regional brain perfusion changes in dogs with idiopathic 
epilepsy were investigated in the first chapter of this research project. We concluded that 
regional brain perfusion in the subcortical region was suppressed interictally in dogs with 
idiopathic epilepsy (n = 12). However, it was impossible to visualize more detailed 
structures within this subcortical volume of interest (VOI) due to resolution limits of 
conventional SPECT. A considerable part of this subcortical area consists of the 
thalamus, a structure that may play an important role in the pathophysiology of canine 
idiopathic epilepsy. The thalamus can be involved in the origin of seizures, according to 
the centrencephalic theory, which proposes that most generalized seizure activity 
originates in deep structures of the thalamus and brainstem and is projected to the cortex 
thereafter (Russo, 1981). Also in humans, the thalamus has a primary role in the initiation 
and propagation of seizures in several types of epilepsy (Spiegel and Wycis, 1950; 
Williams, 1953; Henry et al., 1990; Prevett et al., 1995; Yune et al., 1998). The 
hypoperfusion in the thalamic region found in the dogs of our study could have been a 
consequence of seizures through the corticothalamic diaschisis phenomenon, meaning 
that the subcortical hypoperfusion results from an interrupted afferent axonal supply from 
the epileptogenic cortex (Yune et al., 1998).  
Interestingly, the thalamus is also involved in the mechanism of action (MOA) of 
different neurostimulation treatments for human refractory epilepsy. It is an important 
target of deep brain stimulation in humans where electrical stimulation of the anterior 
nucleus of the thalamus has beneficial seizure suppressing effects (Fisher, 2013). 
Furthermore, the thalamus is involved in the antiepileptic MOA of VNS in humans 
(Henry et al., 1999; Vonck et al., 2008). In the fourth chapter of this PhD thesis, rCBF 
in the thalamus was not altered by a short period of VNS in healthy Beagle dogs, so the 
role of the thalamus in the MOA of VNS in dogs remains uncertain.   
In humans, interictal SPECT can be useful for localization of the epileptogenic focus 
(Yune et al., 1998), but is often part of a multimodality work-up. The epileptogenic focus 
usually appears as an area of hypoperfusion on interictal SPECT, as an area of 
hyperperfusion on ictal SPECT and as an area of hypometabolization on interictal PET, 
but the sensitivity between these modalities differs. Ictal SPECT clearly has a higher 
sensitivity than interictal SPECT (Devous et al., 1998; Spanaki et al., 1999; Weil et al., 
2001) and the sensitivity of interictal PET is higher than that of interictal SPECT 
(Spencer, 1994). As part of a multimodality work-up, it would have been useful to 
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investigate ictal SPECT changes in dogs with idiopathic epilepsy. However, ictal SPECT 
studies are difficult to perform as they require the injection of the tracer immediately at 
the start of a seizure (Menzel et al., 1997; Van Paesschen et al., 2007). As seizures in 
dogs tend to generalize rapidly (Berendt and Gram, 1999), a true image from the start of 
the seizure would be difficult to obtain. Furthermore, a specialized monitoring unit with 
nuclear tracer available onsite is often difficult to achieve in veterinary medicine.   
In the second chapter we demonstrated that micro-SPECT (µ-SPECT) is a feasible 
technique to investigate the regional brain perfusion of healthy Beagle dogs and that a 
substantial improvement of resolution could be obtained using this technique compared to 
conventional SPECT (2.3 mm instead of 8 mm) (Peremans et al., 2001). Also, a new 
detailed VOI map based on Magnetic Resonance Imaging (MRI) was created and allowed 
the evaluation of regional cerebral blood flow (rCBF) in 19 different regions, including 
important subcortical structures. Interestingly, a general hemispherical and regional 
asymmetry in brain perfusion towards the left was demonstrated in the temporal, parietal 
and frontal cortex of our healthy Beagle dogs. These changes have not been demonstrated 
previously in adult dogs using conventional SPECT (Peremans et al., 2001; Waelbers et 
al., 2011). Asymmetries in hemispheric perfusion have also been detected in healthy 
people using conventional SPECT and in cats using µ-SPECT (Catafau et al., 1996; 
Krausz et al., 1998; Lobaugh et al., 2000; Van Laere et al., 2001; Waelbers et al., 2013). 
In humans, they have been attributed to volumetric and possibly also functional 
differences (Catafau et al., 1996). It is important for future µ-SPECT studies to 
acknowledge the fact that asymmetries in the canine brain can be normal, because in 
cerebral diseases (e.g. epilepsy), the identification of rCBF abnormalities has been based 
on the detection of interhemispheric asymmetries (Catafau, 2001; Aubert-Broche et al., 
2003; Vermeire et al., 2009a; McArthur et al., 2011).  
 
Methodological considerations and future perspectives 
 
The number of dogs with idiopathic epilepsy investigated in the first chapter was rather 
small, especially since their demographics and clinical variables were heterogeneous. 
Most dogs received antiepileptic drugs (AEDs) at the moment of the SPECT study, which 
is inevitably a possible confounding factor in many human SPECT studies as well. 
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Unfortunately, the exact influence of different AEDs on brain perfusion and metabolism 
remains largely unknown. Phenobarbital (PB) and phenytoin can cause diffuse cerebral 
hypoperfusion in humans (Jibiki et al., 1993). Therefore, in our study, a semiquantitative 
analysis of the SPECT data was performed by normalizing the regional brain perfusion to 
the total counts of the brain. Hence, the possible confounding effects of AEDs on global 
brain perfusion should be minimized. There is a need for further studies to evaluate the 
influence of AEDs on regional brain perfusion in dogs and humans. 
Concerning the multi-modality work-up, it would have been useful to include interictal 
EEG in our dogs with idiopathic epilepsy (chapter 1), as EEG can investigate the 
epileptic nature of detected SPECT abnormalities. Recently, interictal scalp EEG was 
used to investigate the epileptic nature of PET abnormalities in epileptic Lagotto 
Romagnolo and Finnish Spitz dogs (Jokinen et al., 2013; Viitmaa et al., 2014). However, 
the use of scalp EEG in dogs is associated with serious limitations such as muscle 
artifacts and the need for sedation (Russo, 1981). Furthermore, interictal scalp EEG 
seems to have a low sensitivity to detect seizure activity in dogs with epilepsy and is not 
considered a useful screening method (Brauer et al., 2012; Pakozdy et al., 2012). 
Intracranial EEG recording remains the gold standard in humans for localization of the 
epileptogenic focus, but requires the surgical implantation of electrodes. Recently, some 
progress has been made by investigating the use of wireless implantable EEG devices in 
dogs, but further research will be needed (Davis et al., 2011). For the aforementioned 
reasons and due to the lack of technical equipment and expertise, EEG was not performed 
in the present PhD thesis. 
SPECT was used in this research project as it offers numerous advantages. It is less 
expensive and more widely available than PET. Furthermore, 
99m
Tc-ECD SPECT has the 
unique “frozen image” capacity (Peremans et al., 2001), which is certainly of value in 
veterinary medicine as it allows the tracer to be injected in the awake animal while the 
acquisition can be postponed until general anesthesia is induced (Waelbers et al., 2010). 
Furthermore, this capacity creates the opportunity to obtain SPECT images from the ictal 
period, as the start of the acquisition can be delayed until the seizure has been controlled 
(Ichise et al., 1997; la Fougère et al., 2009). Despite the benefits of SPECT, spatial 
resolution limits - mainly due to attenuation, scatter and partial volume effects - remain a 
major concern (Catafau, 2001). Consequently, not all registered photons are with 
certainty derived from the actual VOI, which can lead to an under- or overestimation of 
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rCBF in certain regions. The limited spatial resolution (7-8 mm) of the conventional 
SPECT system used in the first chapter precluded a detailed assessment of the 
suppressed rCBF in the subcortical region. The use of a µ-SPECT system with multi-
pinhole collimators in chapter 2 and 4 led to a clear improvement of spatial resolution 
(2.3 mm), and this technique offers future possibilities to investigate the canine brain into 
detail. The currently available µ-SPECT system is feasible to use in Beagle dogs, but the 
field of view is limited (Peremans et al., 2005b), which hampers its use in the evaluation 
of the brain of larger dog breeds. Since many dogs with idiopathic epilepsy are large 
breed dogs, µ-SPECT might not be the optimal technique to use. Recently, new 
“resolution recovery” software (e.g. Hybrid, Hermes, NUD, Sweden) has become 
available to process conventional SPECT data. This software corrects for attenuation 
based on CT images, for scatter based on Monte Carlo methods and for collimator 
response. In this way, resolution may improve from 8 to 5 mm according to the producers 
(Waelbers, 2012a; LeBlanc and Peremans, 2014). The detailed VOI map created in 
chapter 2 can also be used with this software. Therefore, future studies evaluating rCBF 
in epileptic dogs, can use this software for data analysis. 
The µ-SPECT study was performed in a homogenous group of healthy young adult male 
Beagle dogs, which precludes the evaluation of gender and age differences on the rCBF 
in dogs. Age and gender differences in brain perfusion exist in healthy people (Van Laere 
et al., 2001). Significant rCBF differences have also been detected in dogs older than 8 
years with conventional SPECT (Peremans et al., 2002). Future studies investigating age 
and gender differences with µ-SPECT are warranted. 
As immobilization of the animal is essential, general anesthesia is required to perform 
brain SPECT in veterinary medicine. Certain anesthetics definitely influence 
99m
Tc-ECD 
SPECT images in dogs (Waelbers et al., 2011; Waelbers et al., 2012b). However, in the 
SPECT studies of this PhD thesis (chapter 1, 2 and 4), influence of anesthesia was 
avoided by injecting the tracer prior to sedation or anesthesia, hence allowing an 
undisturbed tracer distribution and creating a “frozen image” in the awake dog. In 
humans, this fixed image is obtained within a couple of minutes after tracer injection 
(Walovitch et al., 1994). In dogs a stable image, representing rCBF at the moment of 
tracer injection, is obtained as long as the acquisition starts between 15 and 40 min after 
tracer administration (Waelbers et al., 2012c), which was respected in the present work.  
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Evaluation of SPECT images was consistently performed by semiquantification (chapter 
1, 2 and 4), which is more objective than visual analysis. Automated registration of the 
perfusion data to a template, combined with an automatically applied VOI map, results in 
a more reliable analysis compared to manual registration and visual interpretation 
(Slomka et al., 1997). On the other hand, visual analysis, in comparison with 
semiquantitative analysis, had a higher sensitivity in the detection of areas of 
hypometabolism with PET in epileptic dogs (Jokinen et al., 2013). Therefore, it might 
still be rewarding to compare both in further studies. 
In the 3 SPECT studies of this thesis (chapter 1, 2 and 4), brain perfusion was evaluated 
using the tracer 
99m
Tc-ECD, which revealed interesting information as rCBF is strongly 
related to regional brain metabolism and neuronal activity (Leonard et al., 1986; 
Warwick, 2004). However, in addition to the evaluation of rCBF, SPECT can also be 
used to evaluate certain neurotransmitter systems and their receptors using specific tracers 
(LeBlanc and Peremans, 2014). Several receptor ligands have been used to investigate the 
neurochemical basis of epilepsy in humans with PET or SPECT (la Fougère et al., 2009). 
Benzodiazepine/GABA receptor, serotonin receptor and dopamine receptor brain imaging 
have been investigated in humans with epilepsy, but results remain controversial (la 
Fougère et al., 2009). Neurotransmitter systems in epileptic dogs have not yet been 
investigated with SPECT, although similar research has been performed in dogs with 
behavioral disorders at our SPECT department (Peremans et al., 2003, 2005a, 2006; 
Vermeire et al., 2009b, 2011, 2012). Neuroreceptor brain imaging studies in dogs with 
idiopathic epilepsy might aid in the localization of epileptogenic foci and in the 
understanding of the neurobiology of epilepsy. Also, this type of functional brain imaging 
could be applied to investigate the effects of VNS on certain neurotransmitter systems in 
dogs.  
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2. The mechanism of action of vagus nerve stimulation in the Beagle 
dog 
 
Since almost two decades, VNS is an established treatment for refractory epilepsy in 
humans (Ben-Menachem, 2002). However, approximately one third of treated patients do 
not respond even to long-term treatment (DeGiorgio et al., 2000). Since the antiepileptic 
MOA of VNS is not fully understood, no rational hypotheses have been derived to help 
identify predictive factors for clinical response. Also, the currently applied stimulation 
parameters are not evidence-based. Further elucidation of the MOA could lead to an 
improvement of VNS efficacy by identifying early biomarkers of response to treatment or 
biomarkers for optimized stimulation paradigms.  
The second part of this PhD thesis was dedicated to the investigation of the influence of 
VNS on the canine brain. The use of this animal model for translational research has 
certain advantages. First of all, naturally occurring canine epilepsy is comparable to 
human epilepsy, particularly regarding its prevalence and semiology (Chandler, 2006). 
This renders translational research in a canine model justified. Secondly, the canine brain 
shares more similarities with the human brain regarding its size and function than with the 
rodent brain. The collection of cerebrospinal fluid (CSF) in dogs is a routine procedure 
with only few complications. Also, a larger sample than in rodents can be collected (Cook 
and DeNicola, 1988; Pegg et al., 2010). Finally, canine seizure models, such as the PTZ 
model, have been well described previously (Löscher et al., 2004; Löscher et al., 2013) 
and a similar protocol was used in chapter 5. 
Functional brain imaging is able to identify brain structures altered by VNS in humans 
and rodents (Chae et al., 2003), but this was not yet investigated in dogs. Micro-SPECT, a 
feasible technique to assess regional brain perfusion in Beagle dogs (see chapter 2), was 
used in chapter 4 to investigate rCBF changes induced by a short period of standard and 
microburst VNS in healthy Beagle dogs. A hypoperfusion in the left frontal and right 
parietal cortex was induced by microburst VNS, whereas standard VNS did not elicit 
changes in canine rCBF. Several human PET or SPECT studies, investigating the effect 
of acute VNS on the rCBF in people with epilepsy or depression, detected a similar 
involvement of the frontal and parietal lobes (Henry et al., 1998; Ko et al., 1999; Barnes 
et al., 2003; Conway et al., 2006). Moreover, functional MRI performed during VNS in a 
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small group of human patients with intractable focal seizures described an activation of 
the frontal and parietal structures (Sucholeiki et al., 2002). From our study, it cannot be 
concluded that the cortical rCBF alterations are involved in the antiepileptic MOA of 
VNS, but it seems reasonable that suppression of rCBF, coupled indirectly to neuronal 
activity (Roy and Sherrington, 1890), in certain cortical regions could be associated with 
a seizure suppressing effect. Epileptiform activity has also been detected in the frontal 
lobe of dogs with idiopathic epilepsy using EEG (Brauer et al., 2012). Furthermore, 
structural lesions in the frontal lobe in dogs are often associated with seizures (Schwartz 
et al., 2011). 
On the neurochemical level, a significant increase of NE was detected in the canine CSF 
after one hour of VNS (chapter 5). The influence of VNS on the LC/NE system has been 
previously demonstrated in rodents (Hassert et al., 2004; Dorr and Debonnel, 2006; 
Roosevelt et al., 2006; Follesa et al., 2007; Manta et al., 2009; Raedt et al., 2011; Manta 
et al., 2013). Moreover, it was found that activation of the LC, associated with a focal NE 
increase, was correlated to the antiepileptic efficacy of VNS (Krahl et al., 1998; Raedt et 
al., 2011). These studies used invasive techniques (e.g. microdialysis), which are not 
practical to use in patients as a screening tool for responsiveness to VNS. On the other 
hand, collection of CSF is a minimally invasive, well known procedure. Importantly, our 
study (chapter 5) is the first to demonstrate an increase of NE, induced by VNS, 
measurable in the CSF. This finding supports also further research into non-invasive 
biomarkers of NE increase, such as the P300 amplitude, whose increase has been 
correlated with a positive antiepileptic effect of VNS in humans (De Taeye et al., 2014). 
An important aim of the second part of this PhD thesis was to compare the influence of a 
novel and promising stimulation paradigm (microburst VNS) with standard VNS. The 
rationale of microburst stimulation is primarily based on the phenomenon of paired-pulse 
facilitation, meaning that two stimulations of a presynaptic terminal within a short period 
of time result in a larger evoked synaptic response to the second stimulation (Zucker and 
Regehr, 2002). Hence, it has been shown in primates that multiple stimulations of the 
vagus nerve within a short period of time evoked a larger response at central vagal targets 
(Hallowitz and MacLean, 1977; Ito and Craig, 2005, 2008). Therefore, it can be expected 
that short bursts of stimulation (“microbursts”) of the vagus nerve are more potent in 
affecting central mediators of VNS and could possibly be associated with a stronger 
antiepileptic effect compared to standard VNS. In the rat kindling model, it was suggested 
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recently that microburst VNS may indeed represent an improved stimulation paradigm 
(Alexander and McNamara, 2012). Interestingly, we demonstrated that microburst VNS 
seems to have more potency than standard VNS to induce µ-SPECT changes in the brain 
of healthy dogs (chapter 4), which reflects the higher potency of affecting central targets. 
On the neurochemical level, microburst VNS is thought to be as potent as standard VNS 
to induce an increase of NE levels in the canine CSF (chapter 5). Despite these 
promising effects of microburst VNS on the canine brain, no antiepileptic effect could be 
demonstrated in the canine PTZ model (chapter 5). Still, further research is warranted to 
investigate the antiepileptic effect of microburst VNS, since the effectiveness of VNS 
improves over time in humans (Morris and Mueller, 1999; Vonck et al., 1999) and only 
the effects of one hour of stimulation in one particular canine seizure model were 
investigated in the present work.  
Also from a veterinary point of view, research towards non-pharmacological treatments 
for refractory canine epilepsy is needed (Muñana, 2013), as currently, many dogs with 
refractory epilepsy are eventually euthanized or die due to uncontrollable seizures (Arrol 
et al., 2012; Monteiro et al., 2012). VNS has the advantage of being independent of the 
localization of the epileptogenic focus and of owner compliance. Earlier studies 
investigating the antiepileptic effect of VNS in dogs seemed promising, but the number of 
studies are limited. An experimental study in dogs demonstrated that chemically induced 
seizures could be aborted by stimulation of the cervical vagus nerve (Zabara, 1992). 
Furthermore, ocular compression, which is an indirect way of stimulating the vagus 
nerve, has been shown to be beneficial for controlling seizures in a few dogs (Speciale 
and Stahlbrodt, 1999). Only one placebo controlled, double-blinded cross-over study 
evaluated the safety and efficacy of VNS in 10 dogs with refractory epilepsy using a 
similar implantable device as in humans (Muñana et al., 2002). No significant difference 
in seizure frequency, duration and severity was detected between the treatment and 
control period of 13 weeks, but when the final 4 weeks of both periods were compared, a 
significant decrease in seizure frequency was found during the treatment period. In our 
study, no antiepileptic effect of a short period of VNS could be demonstrated in the 
canine PTZ model (chapter 5).  
 
VNS, as a tool to treat refractory epilepsy, aims to mainly activate the afferent fibers of 
the vagus nerve, but co-activation of the efferent fibers is inevitable (Banzett et al., 1999). 
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Given the influence of the efferent fibers of the vagus nerve on the heart, the potential 
occurrence of cardiac side effects was a serious initial concern when VNS was introduced 
as a treatment for refractory epilepsy in humans (Asconape et al., 1999). Despite this 
concern, clinically relevant cardiac side effects of VNS are rarely noticed in humans. 
Bradycardia and asystole have occasionally been reported, mainly during intraoperative 
testing of the device, which is probably due to the simultaneous influence of anesthesia 
and VNS (Asconape et al., 1999; Schwartz, 2011). To avoid cardiac complications, the 
left vagus nerve is usually chosen as it has less cardiac influence than the right nerve, 
both in humans and dogs (Kamath et al., 1992; Muñana et al., 2002; Spuck et al., 2008; 
Kahlow and Olivecrona, 2013). Furthermore, the helices are placed distally from the 
vagal cervical cardiac branches in humans to avoid stimulation of these fibers during 
VNS. This is impossible in dogs due to anatomical differences and therefore, dogs might 
be more sensitive to cardiac effects of VNS than humans (Muñana et al., 2002). For this 
reason and because the cardiac side effects of microburst VNS had not yet been 
evaluated, the influence of standard and microburst VNS on heart rate variability was 
examined in healthy Beagle dogs using Holter monitoring (chapter 6). No effects of 
neither standard nor microburst VNS on the different Holter parameters were noticed, but 
long-term studies in a larger number of animals are recommended before definitive 
conclusions can be drawn.  
 
VNS is usually well tolerated in humans with a low incidence of side effects (Ramsay et 
al., 1994). No obvious side effects of the stimulation were noticed in our Beagle dogs, but 
it is important to acknowledge that only short periods of stimulation were delivered. 
Effects of chronic VNS cannot be evaluated in the present work. Furthermore, the 
occurrence of paresthesia and hoarseness, which are common, but often transient 
stimulation-related side effects of VNS in humans (Ben-Menachem, 2002), is difficult to 
evaluate in dogs. Surgical complications did not occur, but postoperative or technical 
problems were frequently encountered in our Beagle dogs and needed surgical 
exploration in 2 dogs. These complications are reported in chapter 3 and suggestions 
have been made to refine the surgical technique.  
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Methodological considerations and future perspectives 
 
The studies in the second part of this PhD thesis were performed in healthy Beagle dogs. 
We considered it useful to get experienced with the VNS Therapy
®
 system and to assess 
the antiepileptic effect in a canine model, before implanting these VNS devices in canine 
epileptic patients. Also, by investigating regional brain perfusion and CSF changes 
induced by VNS in healthy dogs, epilepsy related confounding factors have been 
excluded both on the neuroimaging and neurochemical level. However, it may be possible 
that the healthy and epileptic brain respond differently to VNS. Therefore, the MOA of 
VNS should be investigated in dogs with spontaneous epilepsy as well.   
Only the effects of a short period of VNS were assessed. To increase the number of 
pulses delivered to the nerve during this short period of stimulation, a rapid-cycling 
stimulation protocol (7s on – 18s off) was used instead of the classic intermittent 
stimulation protocol (30s on – 5min off) most often used in a clinical setting (Ben-
Menachem, 2002). In humans, the effectiveness of VNS clearly improves over time 
(Morris and Mueller, 1999; Vonck et al., 1999). Also, the Holter monitoring, performed 
in chapter 6, was short, which precludes the evaluation of naturally occurring circadian 
variations. Therefore, a challenge would be to investigate the effects of chronic VNS on 
functional brain imaging, neurochemical, antiepileptic and cardiac parameters. 
In the neurotransmitter study (chapter 5) we focused on the evaluation of monoamines 
based on the biomarker role of NE in rodents (Raedt et al., 2011). However, other 
neurotransmitters (e.g. glutamate, GABA) can be involved in the MOA of VNS as well. 
Future studies should expand the research towards other neurotransmitter systems. Also, 
the site of CSF collection (lumbar vs. cervical) could have an influence on 
neurotransmitter results, and this should be taken into account. In our Beagle dogs, CSF 
was obtained from the cerebellomedullary cistern, but in humans a lumbar puncture is 
usually the method of choice to collect CSF. 
Neither standard nor microburst VNS increased the PTZ seizure threshold in our Beagle 
dogs, whereas the positive control test with PB showed a significant increase of this 
threshold (chapter 5). As mentioned before, it cannot be excluded that the period of 
stimulation was too short to induce a significant change in PTZ seizure threshold. The 
possibility that VNS is not able to exert any antiepileptic effect against PTZ-induced 
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seizures seems unlikely, because an acute abortive effect of VNS on PTZ induced 
convulsions in dogs has been demonstrated (Zabara, 1992). Furthermore, a positive effect 
of VNS on seizure severity has been shown in the rat PTZ model (Takaya et al., 1996; 
Krahl et al., 2001, 2003; Zhang et al., 2008; Sahin et al., 2009). It is also possible that 
VNS could be less effective in dogs than in humans, with potentially anatomical 
differences in the cervical vagus nerve between dogs and humans playing a role. Previous 
studies investigating the antiepileptic effect of VNS in dogs are limited and were 
performed only on a small number of dogs. However, antiepileptic efficacy was 
demonstrated in these studies (Zabara, 1992; Speciale and Stahlbrodt, 1999; Muñana et 
al., 2002). Consequently, it remains unknown whether the µ-SPECT (chapter 4) and CSF 
changes (chapter 5), induced by VNS, have an antiepileptic significance. Future studies 
using VNS in dogs should prioritize the evaluation of its antiepileptic effect, before 
further translational research is performed in this species.  
The stimulation output current of VNS, used in the different chapters, was defined as the 
subcoughing threshold, according to Muñana et al. (2002). In analogy to that study, the 
strength of this current tolerated by our Beagle dogs was low compared to the current 
used in human clinical trials. Hence, it is possible that more significant effects of VNS 
could have been obtained if higher stimulation currents would have been used. However, 
the effectiveness of VNS has not been correlated to the degree of output current in 
humans (Muñana et al., 2002). Still, it could be warranted to compare the effects of 
different stimulation output currents on the canine brain.  
Postoperative complications after implantation of a VNS Therapy system were relatively 
common in this small group of healthy Beagle dogs (chapter 3). We assume that these 
complications will not have influenced our study results significantly, as dogs with 
serious complications were excluded from the study or surgically implanted with a new 
VNS device. Also, despite the fact that one helix (anchor tether) was dislodged in 4 dogs, 
the two stimulation electrodes remained correctly implanted in all dogs.  
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Conclusions 
Interictal conventional SPECT demonstrated a suppression of the subcortical brain 
perfusion, but was not able to reveal cortical rCBF alterations in dogs with idiopathic 
epilepsy. Whether this reflects an important role for the thalamus in the pathophysiology 
of canine idiopathic epilepsy is unclear. Future SPECT studies in dogs with idiopathic 
epilepsy should include larger patient numbers and could use the recently developed 
Hybrid software for data processing. Ideally, future studies should include ictal SPECT 
analysis.  
Micro-SPECT of the brain is a feasible technique to evaluate regional brain perfusion in 
healthy Beagle dogs. Furthermore, an improved resolution compared to conventional 
SPECT is obtained allowing the assessment of rCBF in 19 different VOIs. It is important 
to acknowledge the fact that hemispheric and regional asymmetries are present in healthy 
dogs. Despite the great potential of this technique for experimental research, the currently 
available µ-SPECT system cannot be used in large breed dogs due to the limited field of 
view.  
Microburst VNS appears to be more potent than standard VNS in the induction of 
regional brain perfusion changes in healthy Beagle dogs. A short period of microburst 
stimulation suppresses rCBF in the frontal and parietal cortex. Furthermore, this 
promising stimulation paradigm was as potent as standard VNS to induce a NE increase 
in the CSF of healthy Beagle dogs and was considered as safe as standard VNS when 
evaluating cardiovascular side effects. Unfortunately, no antiepileptic effect of either 
standard or microburst VNS could be demonstrated in our canine PTZ model. However, 
as only a short period of stimulation was evaluated, long-term VNS studies in dogs are 
required.  
This is the first time that a VNS induced increase of NE, measurable in the CSF, is 
described. Considering the important protective role of NE in seizures and the biomarker 
role of NE for VNS efficacy in rodents, further research towards this CSF NE increase 
and its potential biomarker role are recommended both in dogs and humans. 
VNS appeared to be a safe and well tolerated treatment in dogs. Ideally, this should be 
evaluated in a larger group of dogs receiving long-term VNS treatment. The surgical 
implantation of a VNS Therapy
®
 System in dogs is minimally invasive, feasible and safe. 
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However, refinements of the surgical technique are advised to reduce post-operative 
complications.  
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Epilepsy is one of the most common neurological disorders both in humans and dogs. The 
majority of dogs have idiopathic epilepsy and often they are managed successfully with 
antiepileptic drugs. However, up to 30% of dogs are refractory to treatment, which is 
comparable to the prevalence of refractory epilepsy in humans. A better understanding of 
the neurobiology of epilepsy could lead to the optimization and expansion of therapeutic 
options in dogs. This rationale was followed in the first part of this PhD thesis (chapter 
1 – 2), where the functional brain imaging technique SPECT was used to investigate the 
brain of dogs with idiopathic epilepsy. 
The past 2 decades there has been an enormous expansion of treatment options for human 
epilepsy, in contrast to canine epilepsy. However, a lot of these treatments still need to be 
optimized. Research in animal models may contribute. The second part of this PhD 
thesis (chapter 3 – 6) investigated the mechanism of action (MOA) of Vagus Nerve 
Stimulation (VNS) in a canine model. VNS is an established effective add-on treatment 
for refractory epilepsy in humans, but the biomarkers for response and optimal 
stimulation parameters remain unknown. Also in this second part, a novel stimulation 
paradigm, microburst VNS, was compared with standard VNS. 
As a general introduction, a brief review is given on the basic principles of canine 
epilepsy with a focus on classification, diagnostic work-up, standard treatment and 
pharmacoresistance. Additionally, the working mechanism of SPECT, a comparison 
between conventional and high-resolution micro-SPECT (µ-SPECT) and the use of 
SPECT in human epilepsy are described. Finally, VNS is explained and its effectiveness 
and safety in human epilepsy is summarized. Also, the limited available information on 
VNS in dogs is provided. 
In the first chapter, conventional SPECT was used to investigate if regional brain 
perfusion alterations occurred during the interictal period of dogs with idiopathic epilepsy 
(1
st
 research aim). The regional brain perfusion was evaluated in 11 regions and 
compared between the epileptic and control group. A significant hypoperfusion was 
demonstrated in the subcortical region of the epileptic dogs. No cortical or cerebellar 
perfusion changes were noticed. So, SPECT is a feasible technique to detect regional 
brain perfusion changes in dogs with idiopathic epilepsy and the subcortical area, more 
specifically the thalamus, may have an interesting role in the pathophysiology of canine 
idiopathic epilepsy. 
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The second chapter aimed at improving the limited resolution of the conventional 
SPECT system to evaluate canine brain perfusion. The feasibility of a high-resolution µ-
SPECT system to evaluate regional brain perfusion was evaluated in healthy Beagle dogs 
(2
nd
 research aim). Furthermore, a new, more detailed Volume of Interest (VOI) map was 
created based on Magnetic Resonance (MR) images. Functional imaging of the canine 
brain is possible using µ-SPECT, however, the currently available µ-SPECT system 
cannot be used in large breed dogs. Another aim of this study was to describe the normal 
regional brain perfusion pattern in adult healthy Beagle dogs. The highest and lowest 
regional brain perfusion was found in the parietal and piriform cortex respectively. 
Importantly, hemispherical and regional asymmetry in regional brain perfusion was 
demonstrated in the brain of healthy Beagle dogs. 
In the third chapter of this PhD thesis, we provide a detailed description of the surgical 
implantation technique of a VNS Therapy
®
 System in dogs (3
rd
 research aim). Moreover, 
short- and long-term complications are reported. The implantation procedure succeeded 
safely in all dogs, but postoperative complications were common. Practical considerations 
to improve the surgical technique in the future are summarized. A regular impedance 
evaluation of the system seems important in dogs. 
In the fourth chapter, the effect of a short period of standard and microburst VNS on the 
regional brain perfusion of healthy Beagle dogs was examined using µ-SPECT (4
th
 
research aim). Acute microburst VNS suppressed the perfusion in the frontal and parietal 
lobes, but acute standard VNS did not cause perfusion alterations. In conclusion, 
microburst VNS is more potent than standard VNS to modulate regional brain perfusion 
in dogs.  
In the fifth chapter, the effect of a short period of standard and microburst VNS on 
monoamine levels in the cerebrospinal fluid (CSF) of healthy Beagle dogs was 
investigated (5
th
 research aim). Furthermore, the antiepileptic effect of a short period of 
VNS was investigated, using the canine pentylenetetrazole (PTZ) model (6
th
 research 
aim). Both standard and microburst VNS caused a significant increase of norepinephrine 
(NE) levels in the CSF. However, neither standard nor microburst VNS caused an 
increase of the PTZ seizure threshold. So, VNS induces an increase of NE in the canine 
brain that is measurable in the CSF. Nevertheless, this could not be linked to an 
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antiepileptic effect of VNS using the PTZ model in our dogs. Our results encourage 
further investigation of the biomarker role of NE in VNS efficacy.  
The last chapter assessed cardiovascular safety of acute standard and microburst VNS in 
healthy Beagle dogs, using Holter monitoring (7
th
 research aim). Heart rate variability 
parameters were compared and no significant changes in any of the Holter parameters 
were demonstrated. Short-term, left-sided standard and microburst VNS have no effect on 
heart rhythm in healthy dogs, although larger and long-term VNS studies are 
recommended. 
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Epilepsie is één van de meest voorkomende neurologische aandoeningen bij de mens en 
de hond. Het grootste deel van de honden heeft idiopathische epilepsie en reageert goed 
op medicamenteuze behandeling. Toch is tot 30 % van de behandelde honden 
farmacoresistent, wat goed overeenkomt met de prevalentie van refractaire epilepsie bij 
de mens. Het beter begrijpen van de neurobiologische achtergrond van epilepsie zou 
kunnen leiden tot optimalisering en uitbreiding van de behandelingsmogelijkheden. Deze 
redenering werd gevolgd in het eerste deel van deze doctoraatsthesis (hoofdstuk 1 - 2) 
waar de functionele beeldvormingstechniek Single Photon Emission Computed 
Tomography (SPECT) gebruikt werd om de hersenen van de hond met idiopathische 
epilepsie te onderzoeken. 
De laatste 2 decennia heeft er een enorme uitbreiding plaatsgevonden van de 
behandelingsmogelijkheden van epilepsie bij de mens, dit in tegenstelling tot de hond. 
Vele van deze behandelingen moeten echter nog geoptimaliseerd worden. Onderzoek 
door middel van diermodellen kan hierbij van nut zijn. In het tweede deel van deze 
doctoraatsthesis (hoofdstuk 3 - 6) werd het werkingsmechanisme van nervus vagus 
stimulatie (NVS) onderzocht bij de hond als diermodel. NVS is een effectieve 
behandeling voor refractaire epilepsie bij de mens, maar het is nog niet gekend welke 
factoren de respons op behandeling kunnen voorspellen en welke stimulatieparameters 
optimaal zijn. In dit tweede deel werd tevens een nieuw stimulatie type, microburst 
stimulatie genaamd, vergeleken met standaard NVS. 
In de algemene inleiding wordt een kort overzicht gegeven van de basis principes van 
epilepsie bij de hond, waarbij de nadruk wordt gelegd op de classificatie, diagnostiek, 
standaard behandeling en farmacoresistentie. Tevens wordt het werkingsmechanisme van 
SPECT toegelicht, wordt conventionele met micro-SPECT (µ-SPECT) vergeleken en 
wordt de rol van SPECT in de diagnostiek van humane epilepsie beschreven. Tenslotte 
wordt er uitgelegd wat NVS is en wordt er een kort overzicht gegeven van de effectiviteit 
en veiligheid van NVS bij de mens met epilepsie aangevuld met de beknopte informatie 
die beschikbaar is over NVS bij de hond. 
In het eerste hoofdstuk werd conventionele SPECT gebruikt om na te gaan of er 
veranderingen in hersendoorbloeding kunnen vastgesteld worden bij honden met 
idiopathische epilepsie tijdens de interictale fase (1
e
 onderzoeksdoelstelling). De 
regionale hersendoorbloeding werd beoordeeld in 11 regio’s en de bevindingen van de 
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groep honden met epilepsie werden vergeleken met een controle groep. Een significant 
lagere doorbloeding werd aangetoond in de subcorticale regio van de honden met 
epilepsie. Er werden geen veranderingen gevonden in de corticale of cerebellaire regio’s. 
SPECT is dus een nuttige techniek om veranderingen in hersendoorbloeding aan te tonen 
bij honden met idiopathische epilepsie en de subcorticale regio, meer specifiek de 
thalamus, vervult mogelijk een interessante rol in de pathofysiologie van epilepsie bij de 
hond.  
Het doel van het tweede hoofdstuk was de beperkte resolutie van het conventionele 
SPECT systeem, gebruikt om de hersendoorbloeding bij de hond te beoordelen, te 
verbeteren. De mogelijkheid om de hersendoorbloeding te beoordelen met een µ-SPECT 
systeem met hogere resolutie werd nagegaan bij gezonde Beagles (2
e
 
onderzoeksdoelstelling). Bovendien werd een nieuwe, meer gedetailleerde kaart 
ontwikkeld waarop 19 verschillende hersengebieden werden afgelijnd, gebaseerd op 
Magnetische Resonantie. Uit deze studie blijkt dat µ-SPECT een geschikte techniek is om 
de regionale hersendoorbloeding bij de hond te beoordelen, maar dat het huidig 
beschikbare µ-SPECT systeem niet kan gebruikt worden bij grote hondenrassen. Een 
volgende doelstelling  in dit hoofdstuk was om de regionale hersendoorbloeding bij de 
normale volwassen hond te beschrijven. De hoogste en laagste regionale 
hersendoorbloeding werd respectievelijk vastgesteld in de pariëtale en piriforme cortex. 
Tevens werd er een algemene en regionale asymmetrie in de hersendoorbloeding 
aangetoond in de hersenen van gezonde Beagles. 
In het derde hoofdstuk van deze doctoraatsthesis wordt een gedetailleerde beschrijving 
gegeven van de chirurgische implantatie techniek van een vagale zenuwstimulator bij de 
hond (3
e
 onderzoeksdoelstelling). Vervolgens worden ook de complicaties na chirurgie 
beschreven op korte en lange termijn. De chirurgische implantatie lukte goed en bleek 
veilig bij alle honden, maar postoperatieve complicaties kwamen regelmatig voor. 
Praktische aanbevelingen om de chirurgische techniek te verbeteren worden opgesomd. 
Zo is het bij de hond belangrijk om de impedantie van het geïmplanteerde systeem 
regelmatig te controleren.  
In het vierde hoofdstuk werd door middel van µ-SPECT het effect van een korte periode 
van standaard en microburst NVS op de regionale hersendoorbloeding van Beagles 
nagegaan (4
e
 onderzoeksdoelstelling). Acute microburst NVS onderdrukte de 
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hersendoorbloeding in de frontale en pariëtale hersenkwabben. Standaard NVS 
veroorzaakte geen veranderingen in hersendoorbloeding. Microburst NVS beïnvloedt de 
regionale hersendoorbloeding dus meer dan standaard NVS bij de hond. 
In het vijfde hoofdstuk werd de invloed van een korte periode van standaard en 
microburst NVS onderzocht op het gehalte aan monoamines in het cerebrospinaal vocht 
(CSV) (5
e
 onderzoeksdoelstelling). Daarnaast werd het anti-epileptisch effect van een 
korte periode van NVS nagegaan gebruik makend van het pentylenetetrazole (PTZ) 
model bij de hond (6
e
 onderzoeksdoelstelling). Zowel standaard als microburst NVS 
veroorzaakte een stijging van het noradrenaline (NA) gehalte in het CSV. Geen van beide 
stimulatie types veroorzaakten echter een stijging van de PTZ aanvalsdrempel. NVS 
veroorzaakt dus een stijging van NA in de hersenen, welke meetbaar is in het CSV bij de 
hond. Dit kon echter niet gelinkt worden aan een anti-epileptisch effect van NVS gebruik 
makend van het PTZ model bij onze honden. Verder onderzoek naar een mogelijke rol 
van NA als biomarker voor de doeltreffendheid van NVS is dus aangewezen.  
In hoofdstuk 6 werden mogelijke cardiovasculaire neveneffecten van een korte periode 
van standaard en microburst NVS geëvalueerd door middel van Holter monitoring bij 
gezonde Beagles (7
e
 onderzoeksdoelstelling). Parameters die de variabiliteit in hartslag 
weergeven werden vergeleken en voor geen enkele parameter werden significante 
verschillen aangetoond. Een korte periode van standaard of microburst stimulatie van de 
linker vagale zenuw veroorzaakt dus geen veranderingen in hartritme bij gezonde 
Beagles. Het is echter aangewezen dit te revalueren bij een groter aantal honden en 
gedurende een langere periode van NVS.  
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Mijn grootste dank gaat uit naar  
diegenen die de essentie vormen van dit werk! 
 
Lieve maatjes, 
Samen legden we een hele weg af, 
Een weg die begon met socialiseren en leren omgaan met elkaar, 
Een weg waarop leuke verwendagen afwisselden met minder leuke proefdagen, 
gelukkig waren die eerste dagen toch wel in de meerderheid. 
Toch bleven jullie me altijd trouw en vol enthousiasme  
met een kwispelende staart begroeten. 
 
Tijdens de uurtjes die we samen doorbrachten, leerde ik jullie nog beter kennen: 
 Kamiel, olijke Kamiel, altijd in voor een spelletje, tot een wildvreemde de 
stal betreedt! 
 Cézar, beetje eigenzinnige, schattige rimpelkop, een echte durver! 
 Jef, de gelukzak met je speciale ogen die een beetje uit mijn proeven viel, 
maar die ik toch evenveel aandacht en knuffels probeerde te geven… 
 Richard, onze steltloper, eigenzinnig en de complicatie kampioen, kom 
maar verder goed overeen met je maatje Jef! 
 Hugo, de grootste en vrolijkste van de bende! 
 Ernest, onze eeuwige stresskip met je fronskop en je prangende blik in je 
ogen, een echte bergbeklimmer, maar ondanks dit, toch oh zo veel 
geduld. Ik hoop dat je snel een goede thuis mag vinden! 
 Victor, kleine en magere vriend met je hoog metabolisme. Een echt 
energiebommetje! Jammer dat je recent bent ziek geworden… Slaap zacht 
mijn lieve vriend! 
 Louis, leuke sociale kerel, maar laat vriend Jules eens gerust op de wei aub. 
 Jules, soms beetje geterroriseerd door je broertjes Henry en Lukas in het 
verleden, maar nu lijk je toch open gebloeid. 
 Lukas, stresskip nummer 2, maar oh zo schattig en mooi. Je moest even 
wennen aan het vertrek van je grote voorbeeld Henry, maar je hebt 
ondertussen samen met Jules je draai weer gevonden. 
 Henry,  ster op de cover van dit boekje! Je schildklier gaf je het excuus om 
de dikste van kennel 4 te zijn, maar ook het geluk om al een nieuwe thuis 
te mogen vinden… Je herkenbare “subtiele” blaf hoor ik nog steeds in m’n 
gedachten… 
Nu dit werk is afgerond, laat ik jullie met rust en scheiden onze wegen jammer 
genoeg. Het ga jullie goed en laat jullie maar nog goed verwennen in de 
toekomst door mijn opvolger(s), door Ine, door Anne en Nina en door alle andere 
mensen met een hart voor proefdieren! Geniet in de nabije toekomst van jullie 
nieuw etablissement en in de latere toekomst hopelijk van een warme thuis!  
Dubbel en oh zo dik verdiend! 
BEDANKT!!!!!!!!!!!!!!!!!!!  Ik vergeet jullie nooit! 
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Dankwoord wordt vervolgd… 
 
Een doctoraat vergelijk ik graag met een puzzel die beetje bij beetje, stukje voor 
stukje uiteindelijk een geheel gaat vormen. Aan mijn puzzel werkten ongelooflijk 
veel mensen mee, die ik dan ook heel oprecht wil bedanken!  
Sofie, wat begon als een poging om jouw enthousiasme voor stamcellen over te 
brengen naar mij, is geëindigd in een gemeenschappelijk epilepsie-avontuur (oef, 
veel meer mijn dada). Ik denk dat weinig doctoraatsstudenten op zo’n 
begeleiding kunnen rekenen zoals ik van jou heb gehad. Ongelooflijk hoe je 
steeds voor me klaar stond met raad en daad, met concreet gericht advies, met 
peptalk, met wegnemen van bepaalde twijfels, met helpen beslissingen nemen, 
met brainstormen,… Op die manier had ik altijd het gevoel dat we er samen 
tegenaan gingen en voelde ik mij enorm ondersteund. BEDANKT hiervoor! 
Bovendien ben ik je enorm dankbaar dat je je ook effectief hebt geëngageerd om 
bepaalde proeven mee te doen. Tijdens het allerlaatste deeltje van de proeven 
(dat er onverwacht nog bijkwam tijdens mijn zwangerschap) nam je zonder 
enige twijfel mijn taak over ondanks je anders ook al volle agenda. Ongelooflijk 
chapeau! Natuurlijk hebben we ook al langer een gemeenschappelijk verleden 
voor het doctoraat en ik vond het altijd heel fijn om met jou samen op kliniek te 
staan. Merci ook om mij in het begin van mijn neuro-avontuur veel van je 
ervaring bij te brengen. Ik hoop dat je een toekomst mag tegemoet gaan vol met 
interessante, uitdagende onderzoeken, aangezien dat echt jouw ding is en je er 
bovendien ook nog ongelooflijk goed in bent! Merci ook voor de leuke babbels, 
etentjes,… buiten het werk om! Dikke knuffel voor Tuur en Juul en hopelijk komen 
ze nog eens spelen en wat mij betreft houden we zeker contact in de toekomst! 
Luc, mijn neuro-avontuur zou nooit zijn gestart zonder u. Bedankt voor het 
vertrouwen! Al van in het begin, na mijn internship, gaf u mij de kans om te doen 
wat ik het liefste wou, nl. neurologie! Joepie! Tijdens mijn residency en ook erna 
kon ik altijd terugvallen op uw kennis en ervaring. Ongelooflijk hoe u soms 1 blik 
op een patiënt kon werpen en al direct wist wat er aan de hand was. Dit noemt 
men ervaring, geloof ik… Ook bedankt om mij mee te begeleiden in dit epilepsie-
avontuur en de tijd te nemen om over alles kritisch mee na te denken en alles na 
te lezen. Ondanks de recente moeilijke periode voor u op persoonlijk vlak, bent u 
er toch altijd voor mij geweest. Chapeau! Bedankt ook dat ik mijn persoonlijk 
leven niet “on hold” moest zetten tijdens de residency en het doctoraat. 
“Kinderen komen op de eerste plaats” was iets wat u ooit antwoordde op een 
mailtje… Daarover ben ik het grondig met u eens, maar niet elke promotor is daar 
zo begripvol voor als u, denk ik. Jammer genoeg scheiden onze wegen hier, aan 
ons gemeenschappelijk neuro-avontuur komt een einde, maar zoals u altijd zegt: 
je weet nooit wat de toekomst brengt… Ik heb ongelooflijk graag deel uitgemaakt 
van uw neuro-team! Bedankt! 
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Professor Boon, beste Paul, groot is mijn bewondering voor alles wat u hebt 
bereikt zowel op klinisch als op onderzoeksgebied. U bent echt een pionier in de 
humane epilepsie en wij in de diergeneeskunde kunnen hier alleen maar van 
leren!  Bedankt om al uw ervaring, kennis en connecties met ons te willen delen. 
Ik hoop dat de samenwerking tussen humane en diergeneeskundige neurologie 
hier niet eindigt. Ook al heb ik een heel klein stukje proberen bijdragen, er blijven 
nog heel wat stukjes van de grote epilepsie-puzzel onopgelost. 
Beste Kathelijne, de SPECT wereld was voor mij bij het begin van mijn onderzoek 
even onbekend en ingewikkeld als de Chinese taal. Gelukkig heb jij me onder je 
vleugels genomen en snel ingewijd. Sorry voor mijn soms kritische en lastige 
vragen, maar als neurologe, die gewoon was om structurele beelden van de 
hersenen te zien, moest ik even wennen aan die vage, onduidelijke functionele 
beeldvormingstechniek. Ondertussen is de onduidelijkheid gelukkig heel wat 
duidelijker geworden en heb ik veel van u opgestoken, bedankt hiervoor!  Het 
was altijd fijn en gezellig op de scintigrafie! Bedankt dat ik mocht deel uitmaken 
van het scinti-clubje en bedankt voor de gezellige etentjes! Ik ben er zeker van dat 
er naar de toekomst toe nog heel veel interessant onderzoek op uw dienst zal 
plaats vinden, ideetjes genoeg! Chapeau! Bedankt om ook deel te willen 
uitmaken van mijn examencommissie. 
Beste Professor Vonck, beste Kristl, heel erg bedankt voor al uw hulp bij dit 
doctoraatsonderzoek! Bedankt om tijd te maken om te brainstormen, artikels na 
te lezen, contacten te onderhouden met Cyberonics,… Ook al was dit “maar” een 
onderzoekje bij honden, veel minder belangrijk dan allerlei humane onderzoeken 
volgens mij, toch bleef u altijd enorm enthousiast!!!! Zonder u en Prof. Boon zijn 
inbreng hadden we nooit de support van Cyberonics verkregen. Ook bedankt 
om deel te willen uitmaken van mijn examencommissie.  
Beste Professor Raedt, beste Robrecht, wat begon als een brainstorm sessie over 
stamcellen met Sofie en mezelf op uw bureau, heeft al snel een wending 
genomen richting de epilepsie (oef nogmaals). Dankzij uw kritische kijk op 
realiseerbaarheid van stamcelonderzoek en uw interessante ideeën over vagale 
zenuwstimulatie kwamen we tot de plannen voor een belangrijk deel van dit 
doctoraatsonderzoek. Ik wil je vooral bedanken voor al je tijd en werk dat je mee 
in dit onderzoek hebt gestoken. Bedankt om zelf actief aan allerlei proeven deel 
te nemen! Je aanwezigheid, nuchtere kijk en hulp was onmisbaar! Ondanks je 
allergie, trotseerde je de Beagles en ook al vond je mijn affectie voor mijn hondjes 
waarschijnlijk overdreven, toch toonde je alle begrip. Ook met allerlei stomme, 
kleine vragen kon ik altijd bij jou terecht. Jij bekijkt de dingen ietwat anders dan 
Kristl, minder vanuit een klinisch standpunt, maar net die andere kijk was hier en 
daar heel  belangrijk en leerrijk! Bedankt ook om deel te willen uitmaken van mijn 
examencommissie en ik wens je een heel mooie toekomst! 
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Dear Professor Mette Berendt, it really means a lot to me that you could take the 
time to evaluate my work and be a part of the examination committee. To me, 
you are one of the pioneers examining canine epilepsy. I believe we share a 
fascination for this mysterious disease. Keep up the interesting work!!!  
Beste Professor Smolders, beste Ilse, heel erg bedankt voor alle analyses van mijn 
hersenvocht stalen. Het was zeer fijn en praktisch om op jullie grote expertise een 
beroep te kunnen doen. Ook wil ik u heel erg bedanken om de tijd te willen 
nemen om in mijn examencommissie te zetelen. Bovendien wil ik hier ook nog 
eens van de gelegenheid gebruik maken om Ria te bedanken voor al haar uurtjes 
werk in het labo om mijn stalen verwerkt te krijgen!  
Tim Waelbers, beste Tim (sorry, maar er komen nog Timmen aan bod, vandaar 
familienaam), merci voor al je hulp bij de proeven en je belangeloze inzet voor de 
proefhondjes jarenlang! Ik zie ons nog de scinti-stal samen poetsen nadat een 
aantal Beagles hadden besloten om de vloerbekleding te lijf te gaan… . Ook 
was je altijd heel snel paraat op moment dat “de chronometer” riep ondanks het 
feit dat je vaak ook op kliniek stond of zelf je doctoraat aan het afwerken was. Ik 
ben blij dat je nu een job hebt gevonden die je volledig ligt en wens je daar alle 
succes bij! Zo zie je maar dat de aanhouder wint. Ik wens je een mooie toekomst 
samen met Bram en hopelijk houden we contact! Bedankt ook om deel uit te 
willen maken van mijn examencommissie. 
Iris, ook al heb jij rechtstreeks iets minder met dit doctoraatsonderzoek te maken, 
sowieso ben jij voor mij een superfijne collega al zoveel jaren lang en verdien je 
dus ook een zeer grote DANK u WEL! Merci om mij mee te helpen opleiden 
tijdens mijn residency!!! Merci ook voor alle gedeelde studeer- en examenleed. Ik 
zie ons nog samen op de hotelkamer in dat leuke hotelletje in Bologna…. 
Samen stressen is toch zoveel fijner! Binnenkort zit jij er terug, maar dan aan de 
goede kant. Chapeau voor alles wat je al verwezenlijkte, je bent een 
topneurologe die ook in het Frans haar mannetje kan staan! Je aanleg voor 
elektrofysiologisch OZ kan ik alleen maar bewonderen. Merci ook voor alle 
peptalk over van alles en nog wat, alle wandelingetjes, alle etentjes, EIP 
opleidingen, gemeenschappelijke presentaties en congresbezoekjes. Met jou erbij 
was het des te fijner!!! Merci om de organisatie van de journal club en 
bookreading van mij over te nemen in tijden van bevallingsverlof, schrijven van 
een doctoraat,… Dikke knuffel voor Ina en Darko en hopelijk komen ze ook nog 
eens spelen! Keep in touch!!!!  
Ine, bureaumaatje. Ik ben je dankbaar om zo complementair te zijn met mij op 
gebied van agenda’s bij te houden en sleutels niet kwijt te spelen. De ene zijn 
zwakte is de andere zijn sterkte… ! Merci om mij in van alles en nog wat te 
ondersteunen en ook vaak mijn geleuter en gezaag te aanhoren. We weten 
allebei dat een doctoraat schrijven niet te onderschatten valt, maar je bent goed 
bezig en je komt er wel (kijk maar naar mij)… alles komt uiteindelijk goed! Ik wil je 
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vooral heel erg bedanken voor je belangeloze inzet dag na dag voor de 
proefhondjes! Ongelooflijk chapeau!!!!! Ik heb je er hier en daar minimaal 
proberen in ondersteunen, maar dat is nog niks vergeleken met wat jij allemaal 
doet. Het was je ook nooit teveel als ik vroeg om eens een hond te helpen 
vasthouden ofzo! Thx!!!! Ik wens je een mooie toekomst samen met Rik en ik vind, 
aangezien deze mama het bureau gaat verlaten, dat het toch langzaamaan tijd 
wordt dat er een nieuwe mama op het bureau komt… Heel veel succes in alles 
wat je doet en we houden zeker contact! Veel succes met je ECVN examen!!! 
Daniela, ex-bureaumaatje, bijna ex-resident. Bedankt om er te zijn op momenten 
dat er nood was aan een babbel. Je bent nu al een tijdje je droom achterna in the 
USA en ik ben er zeker van dat de ECVN er binnenkort een Diplomate zal 
bijhebben (en wat voor eentje )! Ik wou dat ik voor mijn carrière even 
avontuurlijk was ingesteld als jij, aangezien ze onder de kerktoren van Ursel niet 
veel neurologen nodig hebben…. Maar goed, gelukkig ben ik ondertussen een 
nieuwe, eveneens interessante weg kunnen inslaan. Dikke kus voor Finnja en de 
katjes! Misschien moet ik toch maar eens beginnen Facebook’en… je weet 
nooit…als ik eens veel tijd over heb… 
Antita, ex-bureaumaatje, ik ben de volgende na jou die het bureau zal verlaten… 
Onze babbels waren onvergetelijk, de ene al wat productiever of oppeppender 
dan de andere, maar het was fijn om een lotgenoot te hebben! Jij was mijn 
maatje op het bureau-eiland… Ik wens je een supermooie toekomst met Tony en 
de beestjes in jullie mooie knusse huis. Ik wens je alle geluk in je job en succes in 
alles wat je onderneemt! Volg je dromen, volg je hart en je komt er wel! Keep in 
touch! 
Kenny, één van de jongste collega’s die het bureau vervoegden. Het was toch 
hoogdringend tijd voor opnieuw een mannelijke inbreng! Bedankt voor je 
positivisme en leuke babbels! Ik hoop dat ik je in het kader van je residency toch 
het één en het ander heb kunnen bijbrengen, ook al had ik er niet zoveel tijd 
voor als ik zelf zou willen. Ik wens je alle succes met het afronden van je residency 
en ik blijf bereikbaar he! Ik wens je een mooie toekomst met Alix! PS: mijn 
bureauke aan het raam is terug beschikbaar… go for it. Zorg goed voor de 
Beagles!!! 
Emilie, onze jongste collega. Wat een verademing en wat een uitzondering op de 
neurologie regel dat zo’n stil en rustig persoon ons bureau heeft vervoegd. Ik 
wens je heel veel succes met je residency en in alles wat je onderneemt! Je 
enthousiasme, inzet en motivatie zijn in ieder geval super! Dikke knuffel voor 
Igortje! 
Sofie VM, An en Steven, bureau-genootjes uit reeds “lang vervlogen” - maar niet 
vergeten - tijden. Alle 3 zochten jullie het geluk in het buitenland (de ene al wat 
kouder dan de andere). Ik wens jullie op persoonlijk en professioneel vlak het 
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allerbeste toe en keep in touch! An, bedankt om hier en daar wat Engels bij te 
schaven… 
Simon, ondertussen ben je al even in het koude Zweden en heb je het heel druk 
met allerlei andere projecten en met het opvoeden van je dochter… Maar ik  ben 
zeker niet vergeten hoe je mij altijd hebt bijgestaan voor al m’n SPECT proeven! 
Fun verzekerd. Bedankt en nog heel veel geluk daar in het Noorden! 
Valérie, jij maakte me wegwijs in de wereld van Holter monitoring (wat ook wel 
echt nodig was). Bedankt voor al je hulp en je urenlang werk bij de interpretatie! 
Dat een Beagle nu eenmaal niet het ideaalste ras is voor Holter monitoring, is 
hierbij denk ik ook wel gebleken . Ik wens je een fijne toekomst, op alle gebied! 
Knuffel voor je rakkers! 
Professor Luc Duchateau, Professor Stanislas Sys en Professor Kurt Audenaert, 
bedankt voor jullie hulp bij de verwerking van mijn data. Dat statistiek een ver 
van mijn bed show is, zal jullie wel al zijn opgevallen. Dus het was fijn (en ook wel 
essentieel) om dit aan experts zoals jullie te kunnen overlaten. 
Ook alle andere (ex) anesthesie collega’s (naast Tim Waelbers) wil ik hier graag 
bedanken: Ingeborgh, Bossie, Koen, Sanne, Inge, Barbara, Annika,.. ! Bedankt 
voor jullie hulp en sorry dat ik af en toe de Waelbers of de Koen heb ingepalmd 
op bepaalde dagen voor mijn proeven… Bossie, bedankt voor de babbels de 
voorbije jaren en keep in touch! 
Dr. Tshamala, Clément, bedankt voor al uw hulp met het plaatsen en terug 
verwijderen van de stimulatoren! Ook bedankt om mee in te staan voor mijn 
neurochirurgie opleiding! Un grand merci!!!! Ik wens u en uw familie nog veel 
geluk en een goede gezondheid!  
Prof. Caemaert, beste Jacques, ongelooflijk hoe u zich telkens weer belangeloos 
inzet voor de diergeneeskunde bovenop uw overvolle agenda!!!!! Bedankt om 
ons te helpen met de eerste implantaties en de revisies. Ook bedankt voor uw 
neurochirurgische hulp in het verleden bij een aantal van mijn patiënten. 
Chapeau!!!! Als ik ooit een neurochirurg nodig hebt (laat ons hopen van niet) dan 
weet ik tot wie mij te wenden. 
Ingrid, Kaatje en Annemie, bedankt om de MRI’s van mijn hondjes te nemen en 
interpreteren! Ook bedankt voor de fijne samenwerking in het verleden wat 
betreft neurologie patiënten.  
Ook alle andere mensen van de beeldvorming die ooit een RX of echo hebben 
gedaan bij één van mijn Beagles: dank je wel (Elke, Yseult, Pascaline, Anaïs, 
Veerle, Olga …) en het ga jullie goed. 
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Professor Deblaere en de mensen van Infinity: bedankt om “Henry Beagle” te 
scannen! Wat een avontuur! Ik vergeet nooit die knalroze SPECT scan in een 
smetteloos bureau en die fantastisch mooie 3 Tesla MRI beeldjes. 
Alle mensen van LKEN: bedankt voor jullie hulp af en toe met het heen en weer 
brengen van stalen en nog veel plezier met de ratjes! 
Aan alle dierenverzorgers van onze Beagles ooit: BEDANKT! Jullie zijn heel 
belangrijke personen in het leven van onze Beagles en ook heel belangrijk om 
bepaalde proeven te doen slagen. De samenwerking met jullie is dan ook 
essentieel geweest en jullie inzet heb ik enorm gewaardeerd.  
Aan alle chirurgen, bedankt voor de hulp en goede zorgen bij bepaalde 
complicaties. Dat Beagles en seroma’s blijkbaar goed samengaan is ook iets wat ik 
via dit werk heb bijgeleerd.  
Filip, bedankt voor al je ondersteuning bij de opmaak van de figuren en lay-out 
van dit boekje en van publicaties. Ook bedankt om hier vanavond aanwezig te 
zijn. 
Nathalie, bedankt voor de gezellige lunchmomenten en babbels. Ik ben er zeker 
van dat jij het maandag fantastisch gaat doen en wens je heel veel geluk op alle 
vlak! Keep in touch! 
Alle andere collega’s van de vakgroep: bedankt voor de fijne jaren van 
samenwerking, de gezellige babbels in de gang/keuken en zoveel meer! Ik  
voelde mij altijd heel goed thuis in het team van de kleine huisdieren en zal jullie 
dan ook missen, maar ik spring zeker nog af en toe eens binnen! Keep up the 
good work! 
Ook alle hondjes met idiopathische epilepsie die deelnamen aan mijn eerste 
studie en hun eigenaars zou ik van harte willen bedanken. Jullie vormen de 
essentie van hoofdstuk 1 van dit werk. 
 
Friends! Een groep van oh zo belangrijke mensen in mijn leven. Ik zal hier zeker 
een aantal mensen vergeten en ook heel wat collega’s vallen eigenlijk onder deze 
noemer, dus bij deze mijn excuses ik noem er slechts een aantal bij naam… Hilde, 
Andy, Diederika, Kim, Nele, Robby,…: bedankt voor alle leuke momenten, babbels, 
etentjes, feestjes, weekendjes… Dankzij die leuke momenten kon ik telkens weer 
mijn batterijtjes opladen! Dat er nog vele van die leuke momenten mogen 
volgen! Friends forever! Dikke kus voor Léonie, Thibault, Mauro, Nand en Esmée! 
Diedie, nog eens extra bedankt om de kids op te vangen vanavond! Onmisbare, 
essentiële hulp! Weet dat ook jij altijd op mijn hulp kan rekenen! 
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Family! Een andere groep van superbelangrijke mensen in mijn leven. Iedereen 
enorm bedankt om mij te ondersteunen en aan te moedigen. Mama en papa, 
bedankt om mij in het verleden alle kansen te geven om verder te studeren en 
maar te blijven specialiseren,… Zonder jullie ondersteuning was dit nooit mogelijk 
geweest! Bedankt ook om er altijd te zijn voor ons en voor de kindjes, wat de 
laatste tijd nogal veel nodig was (gezien de eindspurt van dit boekje nogal vaak 
samenging met een zieke Arno). Mijn schoonouders, Rita en Willy, ook heel erg 
bedankt, jullie zijn altijd al een hele grote hulp geweest op allerlei gebied. Ik weet 
dat jullie de laatste tijd meer hadden willen doen, maar Willy, je gezondheid komt 
ook voor mij op de allereerste plaats! Zusje, Stéphanie, hoever onze professionele 
werelden uit elkaar liggen, zo dicht liggen onze persoonlijke werelden en 
interesses bij elkaar! Bedankt om er altijd voor mij en de kindjes te zijn (ook 
bedankt aan Mario natuurlijk)! Ik weet dat Tim niet altijd snapt waarom we elkaar 
nu weeral moeten bellen, ook al hebben we elkaar net gezien, maar daar trek ik 
mij nu eens niks van aan. Dat we nog veel mooie familie momenten mogen 
meemaken! Dikke kus aan Bram en Elien! Nadia, Bart en de kids, merci voor de 
leuke momenten en fijn dat Daan (en binnenkort ook Arno) altijd eens kan 
komen spelen. Neven, nichten, tantes en nonkels, merci voor jullie aanwezigheid 
(in gedachten of in levende lijve) en steun! Lieve tante Alice, bedankt voor je 
interesse en bemoedigende woorden.  
Last but not least… ons fantastisch gezinnetje 
Lieve Eros, trouwe vriend. Negen jaar geleden kwam je als “fluffy beerachtige” 
pup in ons leven en zoveel jaren later heb ik daar nog geen seconde spijt van 
gehad. Je bent een belangrijk deel van ons gezin en ook de kids vinden je 
fantastisch. Hilarisch hoe Arno “woewoe” zegt op het moment dat hij je ziet. 
Bedankt om mij gezelschap te houden tijdens het thuis werken. Toen ik zwoegde 
op het schrijven van dit werk, vond jij het, denk ik, niet erg om lekker warm in je 
mandje of aan mijn voeten te liggen. Hopelijk ben je nog vele gezonde jaartjes 
onder ons! 
Allerliefste schat, liefste Tim, zonder jouw steun en kracht had ik dit werk nooit tot 
een goed einde kunnen brengen! Dit geldt eigenlijk voor alles wat ik tot nu toe 
heb bereikt. Je ondersteunt me niet alleen emotioneel, maar ook praktisch help je 
ons op allerlei vlak. Bedankt om er altijd voor ons te zijn! Love you!!!!  
Allerliefste Daan en Arno, jullie vormen de essentie van mijn leven! Een mindere 
dag wordt zo weer goed gemaakt door jullie glimlach! Het tot een goed einde 
brengen van dit doctoraat is het bewijs dat een doctoraat en kindjes wel 
samengaan en ik ben van het principe dat het juist motiverend en stimulerend 
werkt. Ook al bracht de combinatie soms wel wat praktische rompslomp met zich 
mee... ik zou het niet anders gewild hebben! Het allermooiste wat mij ooit 
overkwam is mama worden. Het plaatst alles in een ander perspectief. Ik ben fier 
om jullie mama te zijn!!!! 
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